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Multiple Sclerosis is an immune mediated disease of the central nervous 
system associated with a wide range of mainly irreversible psychological and 
physical disabilities in young adults. Despite the invaluable knowledge gained 
from the research into the disease, its aetiology and mechanism of progression 
are poorly understood. The natural history of multiple sclerosis is complex and 
there are still many unanswered questions in respect to the risk factors 
associated with its development and the way that the disease evolves with age. 
Over the years numerous theories about the disease aetiology have been 
postulated, but the one that best describe the disease, on the basis of our 
current understanding, both in terms of susceptibility and progression is the 
gene-environment hypothesis. According to this hypothesis, multiple sclerosis 
occurs as the result of an exposure(s) to some unknown environmental 
factor(s) in genetically susceptible individuals. In multiple sclerosis, it has 
been hypothesised that tobacco smoking is associated with an increased risk of 
the disease occurrence and adverse effects on the progression of disabilities. 
Despite the relatively large amount of data on the adverse effect of smoking on 
multiple sclerosis risk and clinical course, data from a large population based 
cohort was lacking. The aim of the current work was to investigate the 
influence of tobacco smoking on the natural history of the disease from the risk 
of occurrence to mortality.  
In the first part of the investigation, our age- and sex-matched case-control 
study showed that tobacco smoking is associated with higher risk of disease 
occurrence. However, we did not observe any association between parental 
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VPRNLQJ GXULQJ SDWLHQWV¶ FKLOGKRRG DQG WKH ULVN RI multiple sclerosis. When 
investigating the impact of tobacco smoking on the clinical course and 
prognosis of the disease, our cohort study failed to show any evidence of the 
influence of tobacco smoking on the risk of progressive onset multiple 
sclerosis. However, tobacco smoking was associated with more severe disease 
and significantly higher levels of psychological and physical disability in 
current smokers. Moreover, tobacco smoking in current smokers was 
associated with faster disability progression and shorter time to the progressive 
stage of the disease in patients with relapse onset multiple sclerosis. A 
significant impact of tobacco smoking on the risk of premature death and 
SDWLHQWV¶OLIHH[SHFWDQF\ZDVDOVRHYLGHQWLQRXUGDWDZKHUHWREDFFRVPRNLQJ
in our cohort was associated with more than 2.5-fold increase in the risk of 
SUHPDWXUHGHDWKDQGDOPRVW\HDUVUHGXFWLRQLQWKHSDWLHQWV¶OLIHexpectancy. 
Our data also showed that tobacco smoking can account for some of the excess 
mortality seen in multiple sclerosis patients. A novel finding of our research 
was that smoking cessation significantly UHGXFHG SDWLHQWV¶ ULVN of disease 
progression and premature death. Although the benefits of smoking cessation 
were greater for patients who stopped at earlier ages, cessation was found to be 
beneficial at all ages. To our knowledge, this is the first study that showed 
smoking cessation could potentially be beneficial in reducing the risk of 
disability progression and premature mortality in patients with multiple 
sclerosis.  
Overall, our findings point toward adverse health impact of tobacco smoking 
on the clinical course of multiple sclerosis from the occurrence to mortality. 
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1.1  Summary of the chapter 
The aim of this chapter is to provide a basic introduction on the key ideas, 
issues and important findings of studies of multiple sclerosis with particular 
emphasis on its epidemiology. I kept this chapter as short as possible due to the 
high volume of the original data in the following chapters. The detailed review 
of all aspects of the disease is beyond the scope of this thesis.  Hence, my 
summary views here are short and tried to be most relevant to the aim of the 
thesis. The structure of the chapter is as follows: 
The next section 1.2 will offer some key ideas on some of the well-known 
theories of multiple sclerosis. Section 1.3 will very briefly cover some key 
findings and idea in MS immunology.  
Section 1.4 gives a background on studies of multiple sclerosis epidemiology 
and discuses in a general way some of the key challenges and findings 
suggested by these studies. 
Section 1.5 identifies the key stages in the natural history of the disease and 
discusses some of the theories behind the multiple sclerosis onset, progression 
and mortality with particular emphasis on epidemiological findings.  
Section 1.6 reviews the disease burden in terms of direct costs of treatment and 
their cost-effectiveness 
Section 1.7 discusses some important features of tobacco smoking in the UK 
and Nottingham based on findings from national surveys. 
Section 1.8 states our aims and hypothesis of the study.   
Chapter one: introduction and our hypothesis 
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1.2  Multiple Sclerosis (MS): 
MS is one of the major health problems in the UK. It is associated with 
numerous long term complications including difficulty with mobilisation, 
bowel and bladder problems, cognitive impairments, sexual dysfunction, 
depression, severe chronic pains, etc. MS has enormous impact on individuals¶ 
quality of life and wellbeing. Despite the relatively high prevalence of MS, 
highly effective interventions for the treatment of MS are lacking. The 
development of such interventions requires a greater understanding of 
underlying aetiological mechanisms of the disease.  
MS, as it is currently understood, is an immune mediated disorder of the 
central nervous system (CNS). The most well-known feature of MS pathology 
is the demyelinated plaques in the white matter of the brain and spinal cord. 
Clinically, MS is a very variable condition and disease manifestation can range 
from asymptomatic (subclinical) and relatively benign to somewhat disabling 
and devastating. Most people with MS experience their first symptoms 
between the ages of 20 and 40 years and like many of the autoimmune 
diseases, MS disproportionately affects women more than men. There are three 
main phenotypes of MS, namely Relapsing Remitting (RR MS), Primary 
Progressive (PP MS) and Secondary Progressive (SP MS). RR MS accounts 
for around 85 to 90% of MS cases diagnoses at the disease onset. Studies of 
the natural history of the disease have shown that of the RR patients, a 
majority would eventually transit to SP MS characterised by gradual but steady 
deterioration (Weinshenker, Bass et al. 1989; Lublin and Reingold 1996).  
Chapter one: introduction and our hypothesis 
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MS epidemiologic studies in migrating populations and recently industrialised 
populations have shown that there is an increased incidence of MS as 
individuals adopt a more westernised lifestyle. It may be the pronounced 
changes in environment, behaviour and lifestyle accompanying globalisation 
that have resulted in the escalation of MS both in developed and developing 
nations. Despite the high volume of research investigating the influence of 
environment on the development and progression of MS, epidemiologic 
studies of the natural history of the disease are still needed to systematically 
evaluate the role of environment and life style in MS physiopathology. 
 
1.3 Immunology  
The active role of immune system in the pathogenesis of MS is undisputable. 
Based on our current understanding of the disease, MS is an autoimmune 
disease inducing organ-specific inflammation (Pouly and Antel 1999; 
McFarland and Martin 2007). In MS, myelin damage occurs in response to a 
series of pathological changes initiated by activated peripheral T cells (Pouly 
and Antel 1999; Huizinga, Linington et al. 2008; Henderson, Barnett et al. 
2009). MS shares many similarities with other autoimmune diseases and is one 
of the most common autoimmune diseases in the world. It has been estimated 
that approximately  5% of the world population suffer from some sort of 
autoimmune diseases (Shoenfeld, Selmi et al. 2008). Over the past decade 
several new developments and technological advances have clarified some of 
the mechanisms underlying autoimmune diseases. Despite this and some well-
known genetic factors, (mainly in HLA region) (Zanelli, Breedveld et al. 2000; 
Chapter one: introduction and our hypothesis 
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Thorsby and Lie 2005; 2006) most of the causal mechanisms remain to be 
identified.  
Thanks to the pioneer work of Rivers in 1933 (Rivers, Sprunt et al. 1933) 
many of our current understanding of MS from immunology to therapy are 
based on data gained from animal models of the disease; experimental 
autoimmune encephalomyelitis (EAE) (Zamvil and Steinman 1990). EAE is 
established in numerous species and is developed by immunisation with CNS-
derived myelin antigens, such as myelin basic protein (MBP), proteolipid 
protein (PLP) and oligodendrocyte glycoprotein (MOG), usually with the 
addition of an immunologic adjuvant, into susceptible animals which 
ultimately leads to either an acute, chronic, or relapsing-remitting 
encephalomyelitis that has clinical and pathological similarities with MS. The 
observation that EAE cannot be transferred by antibodies indicated that MS is 
likely to be an autoimmune disease mediated by T cells (encephalitogenic T 
cells) with potential ability to migrate to the CNS and attack the myelin sheath 
(Crawford, Yan et al. 2004).  However, data during the past decades has shown 
that possibly more factors than originally proposed CD4+ T cells, including B 
cells, antibodies, and complement, are involved in the development of MS and 
shaping the disease. In addition to the well-known originally proposed role of 
CD4+ T cells, there is little doubt that CD8+ T cells also mediate CNS 
damage. Two closely related cytokines, Interleukin-12 (IL-12) and IL-23 are 
suggested to play important roles in the mechanisms underlying the 
differentiations of these T cells (Segal and Shevach 1996; Langrish, Chen et al. 
2005).  During the past decade several new immunomodulatory treatments, 
some of which specifically target T cells have emerged. These 
Chapter one: introduction and our hypothesis 
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immunomodulatory treatments vary in their effectiveness and side-effects. 
While the result from the clinical trial of anti-interleukin (IL) 12p40 was not 
successful (Segal, Constantinescu et al. 2008), Alemtuzumab, a monoclonal 
antibody against CD52, a molecule expressed on many immune cells, has 
shown high efficacy in reducing relapse rate in MS patients (Investigators, 
Coles et al. 2008). The proposed mechanism of action of Alemtuzumab in RR 
MS includes robust depletion of both peripheral lymphocytes and monocytes 
(Cox, Thompson et al. 2005). 
It is clear that activation of T cells with potential for autoreactivity can lead to 
autoimmunity, but autoimmunity can also occur when the T regulatory (Treg) 
cells fail to suppress autoreactive T cells. Studies have shown defects in the 
number and function of Tregs in the peripheral blood of individuals with MS 
compared with healthy controls (Haas, Fritzsching et al. 2007; Venken, 
Hellings et al. 2008). No Tregs have also been found at any stage of MS 
lesions, indicating absence of regulatory mechanism in MS brain (Tzartos, 
Friese et al. 2008). The CD4+CD25+ regulatory T cell population 
characterised by the expression of forkhead family transcriptional factor 
(Foxp3) is shown to be reduced in autoimmune and inflammatory conditions 
and MS patients (Hori, Nomura et al. 2003; Viglietta, Baecher-Allan et al. 
2004; Zhang, Koldzic et al. 2004).   
T cells are not the only major players of the MS immunopathology. The 
elevated level of immunoglobulins (IGs) in the Cerebrospinal fluid (CSF) and 
presence of B cells in the lesions of MS suggest that B cells are involved in the 
pathology of the disease (Kabat, Freedman et al. 1950; Biddison, Cruikshank 
et al. 1998). The role of B cells in the pathogenesis of MS is diverse and B 
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cells are possibly involve in the disease in many ways (Disanto, Morahan et al. 
2012). One likely pathway is throughout local production of pathogenic 
antibodies leading to demyelination (O'Connor, Appel et al. 2005). In addition, 
the antigen presentation and cytokine secretion properties of B cells can 
potentially contribute to the progression of the disease (Bar-Or, Fawaz et al. 
2010). Drugs such as Rituximab (an anti-CD20 monoclonal antibody) which 
specifically target B cells has shown to decrease inflammation and reduced the 
number of relapses in patients with MS suggesting contributory role of B cells 
in the progression of MS (Hauser, Waubant et al. 2008). 
 
1.4  Epidemiology 
The first published epidemiologic observation of the disease by Davenport in 
1922 (Davenport 1922) revealed that the frequency varies across geographical 
regions. Further research in the epidemiology of the disease in the following 
years consistently indicated that the incidence and prevalence of MS not only 
vary in different parts of the world but can also vary within different regions of 
a country.  The difference in geographical distribution may suggest that 
environmental factor(s) play roles in aetiology of the disease. Epidemiological 
studies of MS and in particular those investigating the incidence and 
prevalence of the disease encounter many difficulties, as there are still many 
ambiguities about the disease physiopathology. A recent survey of MS 
incidence and prevalence in the UK have found that the incidence of MS has 
decreased in the UK by 1.5% (95%CI: 0.99% to 2.07%) per year from 1990 to 
2010 time period (Investigators, Coles et al. 2008). These findings contradict 
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the results from majority of the surveys which have shown an increase in the 
incidence and consequently prevalence of the disease (Kingwell, Marriott et al. 
2013). There are several explanations for this discrepancy. First, authors have 
mainly used data from the general practice research database which can 
potentially increase selection bias by excluding patients with benign disease 
and also introduce misdiagnosis/miscoding of MS. Relatively low positive 
predictive value (or precision rate of the diagnosis) of around 60% for MS 
using GPRD has been reported (Jadidi, Mohammadi et al. 2013). Second, the 
influences of changes in population demographics have not been evaluated by 
authors. For example, 39% of the population growth of the UK in the year 
2012 compared with 2011 was as a result of international migrants (Tzartos, 
Friese et al. 2008). 
It is still unclear whether the incidence of MS is actually increasing or other 
factors such as increase in MS global awareness (e.g. better and more accurate 
diagnosis) are responsible for what appears to be an increase of the disease. 
One possibility which should be noted is that the increase in MS cases from the 
1970s onwards can be due to improved diagnosis of MS facilitated by the 
introduction of magnetic resonance imaging (MRI).  
In 1922, Davenport pointed out that the disease affected persons of northern 
states relatively more common than southern states. This was confirmed in a 
study of American troops in World War I by Bailey (Bailey 1922). However, 
only in 1938 did Steiner first proposed that prevalence was associated with 
regional geographical factors (Steiner 1938). Nearly 30 years later, Ulett 
related the high disease frequency to northern latitude and  cold climate (Ulett 
1948) and in 1950, Limburg confirmed the north-south trend using mortality 
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data (Limburg 1950). In the UK, the number of patients diagnosed with the 
disease is increased by latitude from 80 in the southern parts to almost 150 per 
100,000 in Scotland (Investigators, Coles et al. 2008).  
Genetics is a major player of MS aetiology which can also, in part, describe 
some of the regional variations of MS. A study by Lonergan and colleagues 
has shown that the HLA DRB1*15 allele associated with MS susceptibility is 
more common in areas of higher MS prevalence (Cox, Thompson et al. 2005). 
Overall, the white peoples of north and central Europe are clearly generally 
more susceptible to the disease. MS is rare among African Caribbean and 
judging by the prevalence in immigrants and by local experience it is rare in 
the West Indies (Cabre, Signate et al. 2005). The majority of the data about the 
prevalence of the disease in African Caribbean comes from studies of USA 
army veterans (although subject to some biases such as healthy soldier bias) in 
which identical standards of diagnosis were applied to all races. These studies 
have shown that the disease is less frequent in African Caribbean than in 
American Whites (Venken, Hellings et al. 2008) and that in African Caribbean, 
as in Whites, the disease is less common in the south than in the north. Data 
from other sources fit this conclusion (O'Connor, Appel et al. 2005). The 
difference in risk between Africans in Africa and America might be genetic, 
environmental, or both but an environmental factor similar to those affecting 
Whites would explain the gradient in the USA. Although studied frequently, 
the interaction between genetic and environment in MS requires further 
investigations.  
Accurate case ascertainment in surveys of MS is very much handicapped by 
two features of the disease: first, the lack of an easily carried out specific and 
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sensitive diagnostic test; second, a gap of several years commonly intervenes 
between the biological onset, first onset of symptoms and diagnosis. In a 
disease as chronic as MS there are also problems that are less well recognised, 
which are associated with the selection of an appropriate population for the 
computation of incidence and prevalence rates. The normal practice is to use 
the population of the defined area on a specific date (prevalence day) and to 
relate to this all patients with the disease living on that day. However, such a 
population may differ substantially in respect when the disease duration 
increases, for example, of urban-rural and socio-economic parameters from the 
population in existence when the same patients experienced the onset of the 
disease or the causative events preceding the onset.  
MS is a disease with an asymmetric distribution in term of the age-incidence, 
age-prevalence and gender ratio. The majority of surveys agree that MS attacks 
women more frequently than men and on average in their 30s. Likewise the 
discrepancy in the onset age, the difference between the genders is not also 
consistent in different age stratums, however, overall MS gender ratio is at 
around 2:1 and seems unlikely to provide an etiological clue. It is worth noting 
that recent surveys suggest an increase in female incidence (Orton, Herrera et 
al. 2006; Ascherio and Munger 2008). The substantially higher relative risk in 
women (> 2:1) has also been noted in Hawaii, South Africa and Western 
Australia, in all of which places the disease is relatively rare. 
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1.5  Natural history and disease modifiers 
Natural history of disease refers to the process of development and progression 
of a disease in an individual over time. The first phase or biological onset 
begins with the exposure to the risk factor(s) in a susceptible host. This 
biological onset would trigger series of asymptomatic pathological changes 
(during subclinical disease phase or latency period) which as time goes on 
would eventually lead to the onset of symptoms. At this stage disease would 
become clinical and symptomatic. Most diagnoses are made during the clinical 
stage of the disease; however some pathologic changes may be detectable with 
laboratory, imaging or other screening methods during the latency period such 
as radiologically isolated syndrome (RIS), incidental MRI findings suggestive 
of MS (Okuda, Mowry et al. 2009). The process of definite clinical diagnosis 
can also take years. In the case of MS it has been estimated to be in a range of 
0 to 3 years after symptoms onset (Tsai and Lee 2013). 
 
Figure 1-1: MS natural history diagram 
 
There are differences amongst diseases and individuals, in terms of the disease 
course and its natural history. Environmental factors, genetic and treatment 
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interventions are amongst the factors which can influence the disease natural 
history. In MS, many studies have evaluated these factors independently; but 
identifying and recognising the potential interactions amongst these factors 
seem crucial. Here, I will briefly discuss some of the important features of MS 
natural history and some of its modifiers. The effects of tobacco smoking will 
be discussed in details in later chapters. 
 
1.5.1 MS Occurrence  
It is widely accepted that MS susceptibility is mediated by a complex 
interaction between the unknown environmental and/or behavioural factors 
that exist in some specific regions of the world in genetically susceptible hosts 
(Ebers 2008; Handel, Handunnetthi et al. 2010). The complexity of the disease 
aetiology and natural history has given rise to numerous theories, supported to 
a higher or lesser degree by evidence, including infectious disease (Ascherio 
and Munger 2007), autoimmune condition (Hafler and Weiner 1989), vascular 
disease (Zamboni 2006), psychological abnormality, neurocristopathy (Behan 
and Chaudhuri 2010), etc. However, accumulated data over the years points 
toward the plausible theory of MS being an immune mediated disease with 
variable levels of immune activity in individuals over time and between 
individuels in a population. Several general mechanisms of autoimmunity have 
been suggested. These include primary failure of mechanisms of tolerance or 
secondary failure of the normal tolerance mechanism due to factor(s) such as 
viral or bacterial infection or abnormality of the target tissue (Anaya 2010).  
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MS has also been described as a primary neurodegenerative disease 
(Chaudhuri 2013). For a long time, the clinical course of MS in relapsing onset 
MS followed by a secondary progressive phase has been thought  to 
characterise the presence of two separate disease course of  inflammatory 
demyelination during RR MS and neuronal degeneration during SP MS. 
However, recent epidemiologic studies of the natural history of MS (Compston 
2006; Confavreux and Vukusic 2006) have found that regardless of the 
relapsing phase, almost all patients reach the progressive phase at same age. 
This may indicate that MS is primarily a neurodegenerative disease with 
variable inflammatory activity in different individuals.  
Factors influencing risk of MS are not yet known and can be demographic, 
environmental and/or genetic. Below, several well-known demographic and 
environmental factors influencing the risk of MS are discussed. 
1.5.1.1 Age and gender effect 
The role of gender in MS susceptibility is complex. Like many other 
autoimmune conditions MS disproportionally affect females almost twice more 
than males, possibly due to some immunologic differences such as stronger 
Th1-mediated immune response in females (Schwendimann and Alekseeva 
2007). There are also possible contributory roles of X chromosome for higher 
susceptibility of the disease among females (Bar-Or, Fawaz et al. 2010). Clear 
understanding of the gender differences in MS requires better understanding of 
the structural and neurochemical differences in healthy brains, which is yet to 
be known. Over the years studies have demonstrated that male and female 
brains are similar in many ways, although, major structural and biological 
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differences also exist. For example, males have shown to have a larger 
amygdala and hypothalamus, while women have a larger caudate and 
hippocampus. Global cerebral blood flow is reported to be consistently higher 
in females than in males, while global cerebral metabolism is similar. Estrogen 
and distribution of estrogen and androgen receptors have been suggested to 
contribute in these regional and biological differences (Cosgrove, Mazure et al. 
2007). These sex differences in the brain structure may increase vulnerability 
to MS which considerably differ in prevalence and symptoms between men 
and women. Gender ratio in MS varies in different phenotypes of the disease 
and progressive onset MS is shown to be indiscriminative of gender (Disanto, 
Morahan et al. 2012). Data has shown that the female:male ratio has increased 
over the 20th century. Based on the finding from Oslo MS registry from 1910 
to 1980, the female to male ratio increased significantly from 1.48:1 to 2.30:1 
(Celius and Smestad 2009). These data contradict a recent survey of the 
general practice research database in the UK which has shown no change in 
gender ratio over the past two decades in the UK (Investigators, Coles et al. 
2008).  
Age is another important factor in MS susceptibility and MS is primarily 
considered a disease of young adults. Studies have shown that the onset of MS 
to be age-related, dependent on the initial course of the disease. The mean 
onset age for RR MS has been demonstrated to be in range of 30 years, and of 
the progressive course in range of 38 to 40 years (Fog and Linnemann 1970; 
Poser 1978; Confavreux, Aimard et al. 1980; Minderhoud, van der Hoeven et 
al. 1988; Cottrell, Kremenchutzky et al. 1999). Age also has significant impact 
on the gender distribution of MS. The female:male ratio differs considerably in 
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different age groups from 1.4:1 in MS onset before puberty to 3.25:1 in 
patients with onset after age 11 (Ghezzi, Deplano et al. 1997; Ruggieri, Iannetti 
et al. 2004; Chitnis, Glanz et al. 2009). At the onset of MS in adulthood the 
female: male ratio is 2:1 (Rosati 2001; Pugliatti, Rosati et al. 2006). Late onset 
MS (onset age > 50) has been reported in 0 to 12 percent of the total MS 
population and unlike adulthood MS, is more frequent in male patients (Bove, 
Healy et al. 2012). Table 1-1 shows female percentage and onset age of some 
selected autoimmune diseases. 
Table 1-1: approximate female percentage and onset age of some selected 
autoimmune conditions are shown 
 ~ female percentage Onset age 
Multiple Sclerosis 65 20-40 (Ghezzi 2004) 
Type-1 diabetes DJH 
age >16: 40 
Childhood onset: 5-9 and 10-14 (2000) 
Adulthood onset: 25-61 (Nishimura, 
Obayashi et al. 2000) 
*UDYH¶VGLVHDVH >85 30-60 (Lantz, Abraham-Nordling et al. 
2009) 
Thyroiditis 95 20-40 (Furszyfer, Kurland et al. 1972) 
Systemic lupus 
erythematosus 
88 65% 16-55 (Ballou, Khan et al. 1982) 
20% <16 (Font, Cervera et al. 1998) 
15% >55 (Font, Cervera et al. 1998) 
Rheumatoid arthritis 75 30-55 (Deal, Meenan et al. 1985) 
&URKQ¶VGLVHDVH 53 (Montgomery, 
Wakefield et al. 2003) 
Bimodal onset age distribution. 
Peak at 20 and 50 (Rose, Roberts et al. 
1988; Haug, Schrumpf et al. 1989) 
Uveitis 50 45-65 male 
>65 female (Gritz and Wong 2004) 
Sjögren's Syndrome 94 40-75 (Pillemer, Matteson et al. 2001) 
except as referenced, female percentage from Jacobson et al. (Jacobson, Gange et al. 
1997) 
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1.5.1.2 Geography and ethnicity 
The cumulative evidence that mainly comes from Western countries indicates 
that MS is present in most ethnic groups but is more prevalent in white 
Caucasians with far lower rates appearing in tropical regions (Ebers and 
Sadovnick 1993). For a long time MS geographical distribution had been the 
most prominent epidemiological clue of MS aetiology (Agranoff and Goldberg 
1974).  However, reports of low MS incidence between certain ethnic groups 
in several hot geographical spots of MS draw attention to the contributory role 
of ethnicity and genetics in risk MS. The variations in the prevalence of MS 
suggest that geography, genetics and ethnicity interact in some complex ways. 
For example, regardless of the geography and the place of living, hardly any 
documented cases of MS have been reported in some ethnic groups, such as 
Maoris (Skegg, Corwin et al. 1987). ,QHSLGHPLRORJ\³HWKQLFLW\´LVDFRPSOH[
term, as it refers not only to the biological differences between individuals 
possibly with different genetic traits, but most importantly points towards 
distinct health beliefs and behaviours. 7KHUHIRUH ³HWKQLFLW\´ HQFRPSDVVHV D
range of factors and characteristics, from biology to health beliefs and 
behaviours. Despite its importance, epidemiologic studies of MS have not 
appreciated the ethnicity fully in its epidemiological concept. Many of these 
studies are only limited to categorising patients into some distinct groups of 
ethnical categories such as Whites vs. Blacks, etc. regardless of their lifestyle 
and/or health beliefs. The other issue in the epidemiological studies of MS is 
the presence of predominantly white Caucasian population. The studies of the 
epidemiology of MS require more between ethnic groups comparisons as this 
may break the confounding due to highly correlated exposures and outcomes 
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observed in conventional white Caucasian MS populations. Thus in MS, 
simple demonstrations of ethnic differences may provide aetiological clues.  
Geography is suggested to be a better determinant of human genetics than 
ethnicity (Manica, Prugnolle et al. 2005).  However, factors such as 
LQGLYLGXDOV¶ DGDSWDWLRQs to the new FRXQWU\¶V¶ OLIHVW\OH should be considered 
when discussing geographical distribution. Geography may also be an indirect 
indicator of distinct lifestyles. This was clearly demonstrated by Swank et al. 
who found that incidence of MS differs significantly between coastal 
communities with high consumption of fish and low consumption of saturated 
animal fats and inland population in Norway with a substantially different 
dietary habits (Swank, Lerstad et al. 1952). In this case geographical 
distribution clearly and indirectly points toward a different life style chosen by 
the coastal communities. 
Valuable knowledge in MS epidemiology has been provided by the studies of 
migrations of ethnic groups to new locations.  Migrants in a new geography 
usually bring their genetic disease risk and within a few generations adopt the 
new country's lifestyle. Studies of migrants have clearly shown the importance 
and mutability of health behaviours, compared with genetic and geographical 
factors (Marmot and Syme 1976). In a classical example of such studies 
Marmot and Syme classified 3809 Japanese-Americans in California based on 
their level of adaptation to the host country and showed that despite the higher 
prevalence of coronary heart disease amongst Japanese-Americans living in the 
US compared with Japanese in the Japan, the most traditional group of 
Japanese-Americans in the US had prevalence as low as that observed in 
Japan.  Thus, we may need to accept that studies of migrants in MS may not 
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provide us definite clue to the aetiology of MS unless some essential 
confounding factors VXFK DV PLJUDQWV¶ level of adaptation in the adopted 
country, PLJUDQWV¶VRFLRHFRQRPLFVWDWXVLQWKHRULJLQDQGDGRSWHGFRXQWU\, etc. 
are taken into account. It is also important to note that migrants are a selective 
proportion of a population usually with better state of health which is required 
for migration and may not necessarily represent the population in the country 
of origin. Hence, results from the studies of migrants in MS should be 
interpreted cautiously. 
Research has shown a significant impact of age at migration in the 
susceptibility to MS. The study of French West Indies population in the islands 
of Martinique and Guadeloupe between 1990 and 2000,showed higher 
incidence of MS for individuals who migrated to the French continent before 
15 years of age (107.2, 95%CI: 52.7 to 161.7) whilst the incidence of MS was 
similar to locals (20.3, 95%CI: 12.7 to 27.9) for those who migrated after 
adolescence (Cabre 2007). Study of children of Caribbean migrants living in 
England also found the contributory role of migration age (Dean and Elian 
1997). Although informative, the influence of age at migration may well be 
due to the fact that normally younger people are at higher risk of adverse 
health behaviours and psychiatric disorders upon immigration (Patterson, Kyu 
et al. 2013). Such migration would have resulted in major changes in 
environmental exposures and lifestyle changes in the migrants such as lack of 
exposure to sunlight during childhood or adopting a more westernised life 
(Phadke 1987). However, the role of genetic predisposition should not be 
neglected as some ethnic groups of northern latitude such as the Inuit and some 
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coastal communities are relatively insusceptible to the disease, regardless of 
where they live (Swank, Lerstad et al. 1952; Kuroiwa and Kurland 1982). 
Studies have OLQNHG LQGLYLGXDOV¶ deficiency of vitamin D to the onset of MS 
(Munger, Zhang et al. 2004; Munger, Levin et al. 2006). This may partially 
explain why people of northern altitude show higher susceptibility to MS 
(Ramagopalan, Handel et al. 2011). It has been shown that MS occurs more 
frequently in people with low vitamin D levels (Munger, Zhang et al. 2004) 
and patients with MS have low serum vitamin D levels compared with healthy 
controls (Ekestern and Lebhart 2004). Vitamin D has shown to regulate the 
expression of the HLA-DRB1*1501 which is the genetic association with MS 
in Northern Europeans (Stromberg, Martensson et al. 2003). Studies have also 
found pronounced effect of vitamin D on the immune system in MS patients. 
Correale and colleagues have shown that Vitamin D significantly increase the 
number of CD4+CD25+ T regulatory cells (Sadovnick 2013)  
The month of birth has also been suggested as a contributing factor to the onset 
of MS with fewer births occurring in cases with MS in November (Willer, 
Dyment et al. 2005; Disanto, Chaplin et al. 2012; Mackenzie, Morant et al. 
2014). However, a recent study by Fiddes and colleagues suggested that the 
correlation between month of birth and incidence of MS is likely to be 
influenced by other factors such as year and place of birth than  month of birth 
alone (Fiddes, Wason et al. 2013). Nevertheless, sunlight exposure and vitamin 
D deficiency cannot fully explain increasing incidence of MS in some Middle 
Eastern countries as well as east-west incidence rate of MS in the United States 
(Sadovnick and Ebers 1993; Etemadifar and Maghzi 2011; Deleu, Mir et al. 
2012).    
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1.5.1.3 Health behaviours and lifestyle 
It is frequently reported that lifestyle factors are correlated with MS onset with 
varying degrees of association. There have been a great interest in the role of 
dietary habits on the risk of MS, although, no definite scientific proof for the 
influence of dietary intake on risk of MS has been found (Coo and Aronson 
2004). Amongst all dietary habits, caffeine and alcohol are widely used 
substances with some well-known effects on the CNS. It has been 
hypothesised that consumption of alcohol and caffeine, which are more evident 
in the western countries where MS is also more prevalent is associated with 
higher risk of MS .  Despite the results from experimental studies which have 
shown that ethanol can alter the autoimmune activity in animal models of MS 
(Kuchroo, Martin et al. 1993; Steinman 2001), several case-control studies 
have failed to show any significant association between alcohol  and caffeine 
consumption and risk of MS (Massa, O'Reilly et al. 2013).  
Epidemiological comparisons of autoimmune disorders in a population of 
Greenland with the matched controls from Denmark provided the first 
evidence of the protective effects of omega-3 polyunsaturated fatty acids 
(PUFAs) in risk of some autoimmune disorders (Kromann and Green 1980). In 
general, studies showed that communities that consume diets high in animal 
fatty acids have higher incidence of MS (Lauer 1994; Esparza, Sasaki et al. 
1995). However, several population-based case-control studies consistently 
reported no association between specific diet and risk of MS (Tola, Granieri et 
al. 1994; Zhang, Willett et al. 2000).  
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Infection (mainly viral) is another commonly studied proposed environmental 
factor involve in the development of MS. The Epstein-Barr virus (EBV) has 
been suggested to play a role in MS aetiology (Ascherio and Munch 2000; 
Ascherio and Munger 2010). The most consistent and important finding in the 
studies of EBV and risk of MS is that approximately 99.5% of MS patients are 
reported to be seropositive for EBV infection in contrast with 94.2% of healthy 
control populations (Ascherio, Munger et al. 2001). The significantly higher 
number of patients who are seropositive for EBV has also been found in 
paediatric MS patients where only 42% of the healthy children were 
seropositive for EBV compared with 83% of MS patients (Alotaibi, Kennedy 
et al. 2004). It is still unclear how EBV infection can lead to development of 
MS in small fraction of all infected individuals but data suggest that the age of 
infection is an important factor for determining MS susceptibility. It has been 
reported that people with MS are more than 2-fold more likely to report past 
infectious mononucleosis (a marker of late EBV infection) than unaffected 
controls (Thacker, Mirzaei et al. 2006). It is also possible that an abnormal 
response to EBV infection in MS patients (e.g. late infection) is a consequence 
of the disease rather than its cause. In principle, the substantially high 
prevalence of EBV seropositivity in children and adults with MS and the fact 
that the risk of the disease increases significantly with high levels of EBV 
antibody titers years before the onset of MS (DeLorenze, Munger et al. 2006) 
suggest a possible contributory role of EBV in aetiology of MS.  Studies have 
also found an interaction between EBV and smoking. This is discussed in 
detail in chapter three. 
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Sexual practice and risky health behaviours were suggested as potential factors 
which could influence the risk of MS onset (Hawkes 2002; Hawkes 2005). It is 
postulated that some geographical distribution of MS can be explained by 
some unknown exogenous factor(s) which can be transmitted via sexual 
intercourse. For example, an epidemic of 42 MS cases which was observed by 
Kurtzke in the Faroe Islands during the Second World War and the decades 
after that (Kurtzke, Hyllested et al. 1993) was attributed to the era when the 
Faroese residents came into contact with (assumed) infected British troops 
possibly via sexual intercourse. In contrast, no association was found between 
sexual habits before the disease onset and risk of MS in a case-control study of 
Danish population (Lidegaard and Svendsen 2008).  
  
1.5.2 Progression 
Like the disease onset, the mechanism underlying progression of the disease is 
yet to be identified. Evidence from the natural history studies of the disease 
suggested two mechanisms of progression in MS. First: accumulation of 
disabilities over time by means of series of relapses followed by partial 
remissions and second: gradual worsening of the symptoms which can occur 
with or without relapses. Almost all of the currently available treatments in MS 
aim to reduce the frequency of relapses with no effective treatment yet 
identified for stopping or at least slowing down the progression of the disease 
in the SP MS or PP MS patients. Despite the relatively high number of patients 
with progressive MS (secondary or primary), the underlying mechanism or 
factor(s) associated with the risk of progressive MS are not known.  
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RR MS is recognised by its inflammatory features while progressive course is 
mainly characterised by axonal damage and suggested to be of 
neurodegenerative nature (Bjartmar, Kinkel et al. 2001; DeLuca, Williams et 
al. 2006; Trapp and Nave 2008). It is unlikely that MS is a clear cut multistage 
disease in terms of physiopathology as evidences of acute axonal damage in 
early MS lesions have also been reported frequently (Ferguson, Matyszak et al. 
1997; Trapp, Peterson et al. 1998; Kornek and Lassmann 1999; Tallantyre, Bo 
et al. 2010). It seems MS is a complex mixture of both inflammatory and 
neurodegenerative components which are vary in degree of activity as disease 
progress. Here in this section I will provide a summary of demographic and 
environmental factors and treatment interventions with potential influence on 
the clinical course and progression of the disease in MS.  
 
1.5.2.1 Age and gender effects  
Age is perhaps the most important factor in the progression of diseases. The 
risk of occurrence and progression of many diseases changes with increase in 
LQGLYLGXDOV¶ age. In MS, the interaction between SDWLHQWV¶ age and disease 
progression is somehow complex. It is well known that older age at the onset 
of MS is associated with progressive onset MS and poor clinical outcomes 
(Confavreux, Aimard et al. 1980). Each year increase in onset age of MS is 
shown to be associated with significant increase in the risk of having 
progressive onset MS (Manouchehrinia, Tench et al. 2013).  Therefore, PP MS 
is characterised by a significantly higher mean age at the onset of the disease 
compared with RR MS. Age at the disease onset has been reported to be 
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around 40 years for PPMS vs. 30 years in RR MS (Ebers 2004; Tremlett, Paty 
et al. 2005). The significant impact of age is also evident in the risk of 
developing progressive phase in relapsing onset MS patients. Onset at age 40 
and 50 years could double and triple the risk of developing SP MS, 
respectively, in relapsing onset MS (Scalfari, Neuhaus et al. 2011). 
Comparison of age at the time of transition to progressive phase in RR MS and 
onset age in PP MS has shown a modest but significant difference. It has been 
estimated that the onset of progressive phase (in those with relapsing onset 
MS) is at the average age of 43 years. This is almost 2 years older than onset 
age in PP MS (Tremlett, Zhao et al. 2009). However, the difference could be 
diminished if factors such as treatment interventions and disease modifiers 
with potential influence on the natural history of the disease are taken into 
account.  
The influence of gender on the progression of the disease is relatively clear. 
Although females are shown to be more susceptible to the disease, male 
patients present with more aggressive clinical course. Examinations of the 
clinical course of MS in males and females clearly indicate a significant 
disadvantage of males in reaching higher disability scores and SP MS 
(Confavreux and Vukusic 2006; Scalfari, Neuhaus et al. 2013). Gender has 
also been shown to influence the initial clinical course of the disease. Male 
patients are shown to have higher risk of PP MS than female patients. In 
comparison with the typical female:male ratio of 2:1, the frequency of females 
is lower in PP MS and estimated to be around 1.3:1 (Cottrell, Kremenchutzky 
et al. 1999). It is noteworthy that with a proper adjustment for the onset age, 
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the ratio tends to approach the conventional 2:1 (Noseworthy, Paty et al. 
1983).  
1.5.2.2 Disease phenotype 
It is somehow difficult to recognise many differences between the principal 
clinical phenotypes of MS in terms of pathology, cause, etc.. Conversely, there 
are major and distinct differences in the clinical presentation of MS 
phenotypes. The clinical course of the disease, particularly at its onset, 
provides the concept behind the categorisation of the disease into its major 
phenotypes. Relapsing onset MS accounts for 85 to 90% of the disease 
phenotypes diagnosed at the disease onset. The remainder present with 
progressive onset (Lublin and Reingold 1996). Unlike relapsing onset MS in 
which courses of exacerbations are followed by partial (rarely complete) 
remissions, progressive onset MS is characterised by uninterrupted progression 
of the disease with or without exacerbation.  
Despite this pronounced difference at the onset of the disease many patients 
with relapsing onset MS will eventually transit to the progressive phase which 
is almost identical in features with progressive onset phenotype. It appears MS 
occurs in 2 discrete stages in terms of clinical manifestation of the disease. 
Studies have shown that disability progression in the progressive phase of the 
disease can be independent of the disease activity in the relapsing phase as 
measuring by estimating times to some disability score milestones (Leray, 
Yaouanq et al. 2010; Scalfari, Neuhaus et al. 2010). In addition, examination 
of age at different disability milestones has shown no meaningful differences 
between relapsing and progressive onset MS (Confavreux and Vukusic 2006; 
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Scalfari, Neuhaus et al. 2011). It seems unlikely that any of the phenotypes of 
MS as currently understood provides us any clue to the mechanism underlying 
the transition to the progressive phase of the disease or strongly indicates a 
particular phenotype of any particular cause.  
1.5.2.3 Treatment 
Disease modifying treatments (DMTs) are available to reduce the frequency 
and severity of relapses in RR MS. It has been hypothesised that this reduction 
in the frequency of relapses could ultimately postpone or reduce the future 
disability progression. First-line DMTs for the treatment of RR MS include 
four interferon beta (IFNB) products; intramuscular (IM) interferon beta-1a 
,)1ȕ-D ,0 $YRQH[ VXEFXWDQHRXV 6& ,)1ȕ-D 5HELI ,)1ȕ-1b 
(Betaseron® or Betaferon®, and Extavia®), and glatiramer acetate (GA) 
(Copaxone®). In addition to the conventional DMTs, natalizumab, and 
fingolimod, the first oral agent, have been more recently introduced in the 
management of MS and are generally considered as the second-line treatments.  
Furthermore, Teriflunomide (Aubagio) has been approved in some palaces and 
BG-12 (dimethyl fumarate) and Alemtuzumab (Lemtrada / Campath) may be 
approved in the US and Europe in the near future. The second line treatments 
are largely recommended for patients with a highly active course of MS who 
have had unsatisfactory response to the first-line treatments 
1.5.2.3.1 First-line treatments: 
Double-blind, placebo-controlled randomised trials have shown that RR MS 
patients taking DMTs experienced a modest but significant improvement. An 
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average one-third reduction in exacerbation rate was observed in treated 
patients compared with placebo group in the first clinical trials of interferon-1b 
(1993; Paty and Li 1993; 1995). Progression of lesion burden was non-
significant compared with the baseline MRI scan in the high dose treatment 
arm of interferon-1b trial. Trials of IM and SC interferon-1a also showed 
significant decrease in relapse rate (Clanet, Radue et al. 2002; Durelli, Verdun 
et al. 2002; Panitch, Goodin et al. 2002) and progression of disability in terms 
of expanded disability status scale (EDSS) score (Jacobs, Cookfair et al. 1996). 
EDSS score was also improved or remained unchanged in the pivotal clinical 
trial of GA in the active treatment group compared with those receiving 
placebo(Johnson, Brooks et al. 1995). Effectiveness of DMTs in RR MS 
patients was confirmed in the extensions of the previous trials and long-term 
follow-ups (2001; Ford, Johnson et al. 2006). The average reduction in 
relapses for all pivotal trials was around 30%. GA showed a slightly lower 
reduction in relapse rate (29%)(Johnson, Brooks et al. 1995); however, it 
VKRZHGHTXDOHIILFDF\WR,)1ȕ-DDQG,)1ȕ-1b in head to head trials (Mikol, 
Barkhof et al. 2008; O'Connor, Filippi et al. 2009). In addition to studies 
conducted to determine the efficiency of first-line treatments in RR MS, four 
large-scale trials have evaluated the effects of early treatment on delaying the 
conversion of clinically isolated syndrome (CIS) to definite MS. Results from 
all four trials indicated that first-line treatments significantly delay the 
development of clinically definite MS and can decrease new lesion formation 
(Jacobs, Beck et al. 2000; Comi, Filippi et al. 2001; Comi, Martinelli et al. 
2009; Kappos, Freedman et al. 2009).  
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1.5.2.3.2 Second-line treatments: 
Recent clinical trials have shown promising results in patients with RR MS 
who received second-line treatment. In the FREEDOMS trail, average 
reductions in relapse rate of 54% and 60% were reported in the lower dose 
(0.5mg) and higher dose (1.25mg) fingolimod treatment groups, respectively, 
compared to placebo. The reduction in the progression of disability was also 
significantly greater in the treatment groups by 30% and 32% respectively 
compared to placebo (Kappos, Radue et al. 2010). Results from two-year 
AFFIRM trial also showed that natalizumab was associated with an average 
reduction in relapse rate of 67% compared with placebo. A significant 
improvement was also seen on the quality of life assessed in the study 
(Polman, O'Connor et al. 2006). Despite this, the main question remains 
whether reduction in the frequency of relapses can stop or postpone later 
disabilities in the course of the disease.  
1.5.2.4 Environment and lifestyle 
IQGLYLGXDOV¶OLIHVW\OH and the environment they live in have pronounced effects 
on their state of health and wellbeing. As an example, it has been suggested 
that relapses are more common in the springtime and least common in the 
winter in Switzerland and higher frequency of relapse was observed in Arizona 
and Cleveland (Ohio) in the summer time (Sibley and Foley 1965; Wuthrich 
and Rieder 1970; Bamford, Sibley et al. 1983). There are few proposed 
environmental and lifestyle factors associated with progression in MS. These 
include SDWLHQWV¶ vitamin D status, tobacco smoking, (which will be discussed 
in details in the following chapters), alcohol and coffee consumption, diet, etc.  
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The effect of vitamin D on the progression of the disease is perhaps one of the 
most commonly studied environmental factor associated with progression in 
MS. Studies have looked at the potential protective role of vitamin D in 
reducing the frequency of relapses, disability progression and measures of 
disease activity on MRI scans. Reports from these studies have yielded some 
mixed results in terms of the magnitude of the effect. While many of these 
studies have found a significant increase in MRI activities and relapse rate in 
individuals with lower levels of serum vitamin D (Mowry, Krupp et al. 2010; 
Loken-Amsrud, Holmoy et al. 2012; Runia, Hop et al. 2012), many other have 
failed to show any beneficial effects of the vitamin D on measured clinical 
outcomes of MS including relapse rate and disability progression (Mowry, 
Krupp et al. 2010; Kampman, Steffensen et al. 2012; Soilu-Hanninen, Aivo et 
al. 2012). An issue here is that while some of the findings are statistically 
significant, the change has little clinical significance. For example, in a study 
by Mowry et al. an increase in disability score of 0.04 (95%CI: -0.091 to -
0.003) was found per 10 ng/mL lower vitamin D in a 4-year follow-up period 
(Mowry, Waubant et al. 2012). This could mean that for a period of 20 years, 
10 ng/mL higher vitamin D volume can only reduce disability progression by 
0.2 score. It is unlikely that this score can have a significant contribution to 
most of the disability score already accumulated after 20 years and even more 
unlikely to have pronounced HIIHFW RQSDWLHQWV¶ TXDOLW\RI OLIH In addition, a 
study by Zivadinov and colleagues (Zivadinov, Treu et al. 2013) has shown 
that the effects of sun exposure on MRI measures can be independent of 
patients vitamin D status.  
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A limitation in the studies in which the influence of vitamin D on the clinical 
course of MS has been investigated, is the possibility of reverse causality 
where it is not clear whether low vitamin D levels causing the higher levels of 
disability or disability affecting vitamin D levels by preventing patients to be 
physically active and get sufficient sun light. Another possibility in such 
studies is the presence of interaction and/or effect modification. For example, 
ethnicity has been shown to have an influence on factors associated with 
vitamin D levels in individuals with MS (Amezcua, Chung et al. 2012). 
Nevertheless, the influence of vitamin D in the progression of MS deserves 
further investigation as most studies do not address the influence of vitamin D 
in progressive MS.  
Infections and in particular upper respiratory tract infections have found to 
trigger exacerbations in MS (Sibley, Bamford et al. 1985; Andersen, Lygner et 
al. 1993; Panitch 1994). A study by Correale and colleagues has shown the 
impacts of both viral and bacterial infections on relapse rate, disease activity 
on MRI scan and T cell activation in relapsing onset patients during the first 2 
weeks after the clinical onset of infection. (Correale, Fiol et al. 2006). They 
pointed out that relapses which were triggered by systemic infection were more 
severe and longer. Diet is one of the most commonly studied factors 
influencing the progression in MS. However, dietary interventions have shown 
no association with disability progression in MS (Farinotti, Vacchi et al. 2012).  
1.5.2.5 Comorbidity 
MS is a lifelong chronic disease often associated with a range of comorbid 
conditions complicating the disease and the choice of therapeutic interventions 
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(Marrie, Horwitz et al. 2008). Although the presence of one or more comorbid 
diseases may result in less desirable clinical outcome and in the case of MS 
delay the diagnosis (Marrie, Horwitz et al. 2009), comorbidity may facilitate 
identifying the at risk population and underlying mechanisms more robustly, 
bearing in mind that the concept behind epidemiology is that diseases are not 
randomly distributed amongst individuals in a population. Amongst a range of 
comorbidities associated with MS, autoimmune diseases (ADs) are of 
particular interest as they may share some immunological similarities which 
could facilitate identifying the underlying mechanism of MS as an immune 
mediated condition. The coexistence of some ADs in MS patients has been 
investigated and studies have reported an inverse association with Rheumatoid 
Arthritis (Somers, Thomas et al. 2006; Nielsen, Frisch et al. 2008) and positive 
association with autoimmune thyroid disease (Sloka, Phillips et al. 2005; 
Munteis, Cano et al. 2007). The frequency of rheumatoid arthritis reported to 
be in range from 1% to 4.5%. Thyroid disease can occur in about 9% of MS 
population, significantly more than what would have been observed in the 
general population (Jacobs, Wende et al. 1999; Niederwieser, Buchinger et al. 
2003; Barcellos, Kamdar et al. 2006). Cases of patients with both MS and 
systemic sclerosis, autoimmune hepatitis, myasthenia gravis have also been 
reported in smaller scales in some case-control studies (Achari, Trontelj et al. 
1976; de Seze, Canva-Delcambre et al. 2005; Pelidou, Tsifetaki et al. 2007). 
Accurately defining the association of MS and other ADs based on the 
incidence and/or prevalence data can be limited due to possible sources of 
error in the rate calculation and the fact that the standards and criteria may vary 
significantly among different studies performed. A problem arises from 
Chapter one: introduction and our hypothesis 
32 
 
variations in diagnostic criteria. One classic example of such a problem is 
clearly demonstrated in a study by O'Sullivan and Cathcart (O'Sullivan and 
Cathcart 1972) comparing the prevalence of rheumatoid arthritis (RA) using 
New York Rheumatoid Association and the American Rheumatoid Association 
(ARA) diagnosis criteria. The survey showed significant variation in the 
results of the population of Sudbury from 3.8% for women and 1.3% for men 
by ARA criteria to 0.5% for women and 0.1% for men by New York criteria. 
This notable variation in diagnostic criteria may also have significant effects 
on our evaluation of the associations of MS with other ADs. In addition to the 
presence of publication bias, mainly affecting negative results, many of the 
studies investigating the association of MS with other ADs were conducted as 
population surveys and only some of the estimates in the current literature are 
drawn from MS specific population-based cohorts. These have resulted in 
substantial differences in the rate estimated and significant between-study 
heterogeneity. There are also limitations in generalisability of the results due to 
such factors as geography. Therefore most of our current estimations of the 
incidence and prevalence rates and consequently the association of MS and 
other ADs may be over- or underestimation of the real-world data. 
Furthermore treatment interventions may influence the rates greatly. One 
treatment may increase the risk of particular comorbid AD and another 
treatment can keep the concurrent AD hidden in its preclinical stage. For 
H[DPSOH LQWHUIHURQ ȕ KDV EHHQ VKRZQ WR PRGLI\ WKH FOLQLFDO FRXUVH RI 5$ 
(Alsalameh, Manger et al. 1998). Cases of sclerosing skin disorder while 
UHFHLYLQJLQWHUIHURQȕhave also been reported in MS patients (Hugle, Gratzl et 
al. 2009).  
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Comorbidity can potentially complicate and limit the process of prescribing 
rational medicinal therapy. However, information drawn from studies looking 
at treatment response in MS patients with concomitant comorbid diseases can 
also be invaluably informative. Despite the relatively high interest in the 
association of MS with other ADs, little knowledge exists about their impact 
on treatment decisions, treatment responses and MS clinical outcomes. Data 
are mixed regarding the frequency of asthma and allergies in MS patients 
(Monteiro, Souza-Machado et al. 2011) and no study has looked at the 
association of asthma and disability progression in patients with MS. 
MS is often associated with psychiatric disorders. Amongst the range of 
psychiatric symptoms in people with MS, major depression is the most 
commonly reported comorbid condition with reported life-long prevalence 
between 25 to 50% (Feinstein 2002; Feinstein 2004). As one would expect, 
depression has been shown to decrease the quality of life in MS patients but no 
evidence of its effect on MS clinical course has been found yet  (Amato, 
Ponziani et al. 2001; Koch, Uyttenboogaart et al. 2008; Goksel Karatepe, Kaya 
et al. 2011). Unlike depression visual and vascular comorbidities were 
associated with higher disability scores. In a study by Marrie and colleagues 
visual comorbidity was associated with 1.47 (95%CI: 1.37 to 1.59) times 
higher risk of mild visual disability (Marrie, Cutter et al. 2011). 
Vascular comorbidities and in particular hypertension are also amongst 
common comorbid conditions in MS patients. The frequency of hypertension 
has been reported to be about 30% in MS patients (Marrie, Rudick et al. 2010) 
which is similar to what has been reported from the general population data 
(Hajjar, Kotchen et al. 2006). In another study Marrie and colleagues examined 
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the effects of vascular comorbidity on the risk of ambulatory disability. They 
found that any vascular comorbidity whether present at the time of diagnosis or 
any time after MS onset was associated with almost 50% increase risk of 
ambulatory disability (Marrie, Rudick et al. 2010).  
Despite its clinical relevance and importance, the effects of comorbidities on 
MS progression seem to be poorly investigated. Better identifying 
comorbidities commonly associated with disease can not only increase 
SDWLHQWV¶ TXDOLW\ RI OLIH EXW PD\ DOVR EH KHOSIXO LQ LGHQWLI\LQJ WKH SDWKZD\V
behind the aetiology of the disease. It is also important to establish the effects 
of MS on comorbidities LISDWLHQWV¶ZHOOEHLQJLVWREHimproved. For example, 
a large study of cancer risk in MS patients has shown larger tumour sizes at 
cancer diagnosis in MS patients compared with the matched controls 
(Kingwell, Bajdik et al. 2012).  
 
1.5.3 Mortality 
MS is usually associated with range of mainly irreversible and progressive 
disabilities but not considered as a lethal disease. Life span in patients with MS 
is generally estimated to be 5 to 10 years shorter than general population 
primarily due to complications arise from the disease (Sadovnick, Ebers et al. 
1992; Bronnum-Hansen, Koch-Henriksen et al. 2004). MS survival from the 
onset or diagnosis of the disease has been reported to be in a range from 24 to 
43 years with some studies showing an increase in MS survival (Phadke 1987; 
Riise, Gronning et al. 1988; Wallin, Page et al. 2000; Bronnum-Hansen, Koch-
Henriksen et al. 2004; Hirst, Swingler et al. 2008).  It is hard to accurately 
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comment on possible trends in MS survival as many of the studies 
investigating MS survival did not compare MS mortality rates with that of 
general population. Hence, the reported increase in MS survival may the result 
of increased life expectancy in the general population.  
The large population-based study of Danish MS registry has shown that the 
excess mortality in MS patients (relative to general population) has almost 
halved during the past 50 years (Bronnum-Hansen, Koch-Henriksen et al. 
2004). However the more recent study of the large British Columbia cohort 
could not find any evidence of improvement in MS excess mortality over time 
(Kingwell, van der Kop et al. 2012).  
1.5.3.1 Incidence and rates 
Studies have shown a significant decrease in the mortality incidence rates over 
time. From 1951-1958 to1967-1973 time periods incidence mortality rates 
have decreased in Scotland (from 3.0 to 2.1), Switzerland (from 2.2 to 1.8) and 
France (from 2.2 to 0.8) and have increased or remained stable in New Zealand 
(from 1.2 to 1.1), US (from 0.9 to 0.8) and Finland (from 0.9 to 0.6) (Massey 
and Schoenberg 1982). Whether MS mortality rates are changing is debatable 
but the absolute mortality rates reported in most of these studies have no value 
in establishing the trend in MS survival as they were not compared to the rates 
from the general population. Furthermore the potential impact of calendar and 
birth cohort effects should be examined intensively. 
Despite the evidence regarding increased absolute MS survival and decreased 
incidence of mortality amongst MS patients, two probably the largest MS 
survival studies estimated that MS patients have almost 3-fold increased 
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mortality rates relative to the general population (Bronnum-Hansen, Koch-
Henriksen et al. 2004; Kingwell, van der Kop et al. 2012). These findings 
clearly shows that the reported decrease in incidence of MS mortality can be a 
direct reflective of the increase in general life expectancy in the general 
population during the past decades. Similar to these, in Wales, it was found 
that MS patients were 2.8 times more likely to die prematurely relative to the 
general population (Hirst, Swingler et al. 2008). In the UK it was estimated 
that patients with MS have 3.5-fold increased mortality (Lalmohamed, 
Bazelier et al. 2012). Evidence is consistent with regard to the standardised 
mortality ratios (SMR), although lower mortality rates have also been reported. 
For example, French data showed excess mortality ratio of 1.8 which is 
considerably lower than that reported from the studies stated above (Leray, 
Morrissey et al. 2007). Methodological differences, length of the follow-up, 
sample size and differences in the medical practice may explain parts of this 
discrepancy in the results.  
1.5.3.2 Cause of death and potential risk factors 
Studies have shown that more than 50% of MS patients die from the 
complication of the disease. Regardless of several possible biases  
(misdiagnoses and underreporting) which can be present in the data acquired 
from the death certificates (Malmgren, Valdiviezo et al. 1983; Midgard, Riise 
et al. 1996), results are almost consistent regarding the percentage of patients 
who die from MS-related causes. Major causes of death in MS patients 
include: respiratory (mainly pneumonia), sepsis (mainly urosepsis), 
cardiovascular disease and cancers. Cases of suicide have also been reported in 
MS patients and are shown to be more frequent in MS compared with general 
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population (Stenager, Stenager et al. 1992). Data regarding the incidence of 
cancer in MS are mixed but in general the overall risk of cancer in MS patients 
is either reduced or is at the level of the general population (Sadovnick, Eisen 
et al. 1991; Koch-Henriksen, Bronnum-Hansen et al. 1998; Kingwell, Bajdik et 
al. 2012). However, it is not clear whether mortality rates due to cancer is also 
at the level of rates in the general population.  
There are potential risk factors associated with increased mortality rates in MS 
patients. It has been shown that female patients with MS have higher mortality 
ratio than males, relative to the general population (Poser, Kurtzke et al. 1989; 
Wallin, Page et al. 2000; Grytten Torkildsen, Lie et al. 2008).  
Life-style, environmental risk factors and treatment interventions can also 
influence the mortality rates. For example, a hypothetical cohort of MS 
patients with a significantly higher number of smokers than the general 
population is expected to have more death due to cardiovascular disease or 
FDQFHU DQG KHQFH KLJKHU 605¶V 7KH difference between the proportion of 
smokers in MS and the general populations may explain some of the 
discrepancy seen in the studies comparing cancer-related mortality ratios in 
MS patients to those of the general population (Bronnum-Hansen, Koch-
Henriksen et al. 2004; Grytten Torkildsen, Lie et al. 2008). Amongst the all 
life-style risk factors, cigarette smoking is a significant health risk which has 
previously been linked to more severe disease in MS patients (Hernan, Jick et 
al. 2005; Hawkes 2007; Di Pauli, Reindl et al. 2008; Sundstrom and Nystrom 
2008; Healy, Ali et al. 2009) and has recently been reported to be associated 
with a significant decrease in people life span (Huxley and Woodward 2012; 
Sakata, McGale et al. 2012). A recent survey of MS patients in the UK has 
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shown a significant influence of cigarette smoking on the risk of death in MS 
patients compared with the referent subjects (Lalmohamed, Bazelier et al. 
2012). Despite the relatively large number of studies investigating mortality in 
MS, the influence of life-style factors, mainly cigarette smoking, on mortality 
rates in MS patients remained to be examined.  
1.5.3.3 Gender effect 
Contrasting the general perception towards higher mortality ratio amongst 
male patients with MS, studies have fail to show any advantage of female 
patients in terms of excess mortality when the mortality rates in MS cohorts 
are compared with that of the general population (Poser, Kurtzke et al. 1989; 
Wallin, Page et al. 2000; Kingwell, van der Kop et al. 2012). It appears that 
when compared to the general population female patients have higher mortality 
ratios than males.  
1.5.3.4 Treatment effects 
Data is very limited regarding the potential influence of treatments on 
mortality rates in MS patients. Many of the survival studies in MS predate the 
treatment era or have very few percentage of their population exposed to the 
DMTs. Accurately commenting on the potential beneficial role of DMTs in 
MS has some limitations. The most pronounced and important bias is lack of 
randomisation. For example, in the UK relapsing patients only have access to 
the DMTs if they can walk independently (at least 100 metres without 
assistance) and have had at least two clinically significant relapses in the last 
two years. Such criteria can potentially put patients with active disease on 
treatments and introduce selection bias to the cohort. Recently, Goodin and 
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colleagues estimated the survival rate and examined the effects of treatment in 
WKH SDWLHQWV ZKR SDUWLFLSDWHG LQ WKH ILUVW SLYRWDO FOLQLFDO WULDO RI ,)1ȕ-1b. In 
their study the risk of death was almost halved for pDWLHQWVUHFHLYLQJ,)1ȕ-1b 
treatment, at either dose, compared with placebo group (Goodin, Reder et al. 
2012). Cause of death was concluded to be MS related in 78% of patients with 
some excess MS related death recorded in placebo group compared with the 
active treatment arm (Goodin, Ebers et al. 2012). There are issues that need to 
be addressed as far as the results are concerned. First, with the mean age at the 
onset of 31 and disease duration of 9 years, after only 21 years of follow up the 
mean age of the cohort reaches 60 at the time of study. With the reports of 
survival with MS of up to 78 years in North America, 60 seems a remarkably 
young age to precisely comment on the effects of treatment on survival in MS. 
The actual mean age at the time of death reported in the study was 51.7 (±8.7) 
years. Second and most importantly, the effects of treatments after the trial 
have completely been ignored. Nevertheless, additional work into the 
covariates and underlying causes of death in this cohort of patients is needed to 
systematically comment on the effects of treatment on MS survival.  
 
1.6  Disease Burden 
To assess the burden of a disease, both mortality and morbidity are taken into 
account using the disability-adjusted life year (DALY). DALY is a time-
dependent variable which combines years of life lived with disability or state 
of health less than ideal health and potential years of life lost due to premature 
mortality (PYLL). MS is a very disabling disease with an average age at the 
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onset of 32 year old during the primary productive time of life. It is usually 
associated with a range of severe impairments and disabilities, which can 
negatively influence SDWLHQWV¶TXDOLW\RIOLIH (Handel and Ramagopalan 2010). 
In addition to the vast range of comorbidity associated with the disease, MS is 
also frequently associated with premature mortality. On average it has been 
estimated that patients with MS live 5 to 10 years less than the general 
population (Scalfari, Knappertz et al. 2013). Considering that many of these 
patients spend a significant proportion of their lives with restricting 
impairments and disabilities and given the fact that MS is a relatively prevalent 
disease particularly in the Europe and North America the overall burden of the 
disease is considerable. The total cost of MS combines direct and indirect 
costs. Direct costs usually represent the costs of resources used to treat the 
disease or its symptoms. While indirect costs represent the value of production 
lost due to the disease.  
1.6.1 Cost of the disease 
Many studies have evaluated the cost of MS in various countries. While the 
costs varies largely between studies and in different parts of the world, the 
general findings imply that indirect costs account for the majority of the 
disease costs and also costs increase significantly as the disease progress. Costs 
of MS (direct and indirect) can increase by nearly twofold in patients with 
('66VFRUHWRFRPSDUHGZLWKWKRVHZLWK('66VFRUHIURP
to £12,875 per patient per year (Kobelt, Berg et al. 2006). 
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1.6.2 Cost of treatment 
It has been estimated that 34 % of total costs (direct and indirect) of MS can be 
attributed to DMTs (Kobelt, Berg et al. 2006). MS drug expenditure has 
increased significantly during the past years (Schafer, Gunderson et al. 2010). 
From 2006 to 2010, the average wholesale prLFH RI ,)1ȕ-1a increased by 
approximately US$18,000. The price of GA has also increased by about 
US$25,000 for the same time period. The acquisition cost of all DMTs 
increased in 2011 as competition increased with the introduction of 
natalizumab and fingolimod. Fingolimod was approved by the FDA in 
September 2010, with an average wholesale price of around US$57,000 per 
year. The FDA approval of second-line treatments means that substitution of 
natalizumab and fingolimod for one of the most commonly used DMTs would 
add around US$10,000±15,000 a year to treatment costs. In the UK, patients 
had access to DMTs only after NHS and the drug manufacturers agreed to the 
risk-sharing scheme that provides the drugs on the basis that they meet certain 
clinical and cost-effectiveness outcomes. However, it has been argued that 
even cost reductions by 67% in the UK  achieved by the scheme would be 
unlikely to make DMTs cost-effective (Boggild, Palace et al. 2009). Table 1-2 
compares the price of treatments in the UK, US and Denmark.   
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Table 1-2: Comparison of drug costs per patient per year 
Drug UK a US 2009 d  US 2012 e Denmark 2012 f 
,)1ȕ-1a IM  £9,061 $US 26,916 $US 45,878 ¼ 



















-- $US 55,776 ¼ 
a source: NICE. TA32 Beta interferon and glatiramer acetate for the treatment of 
multiple sclerosis; 2002. 
 
b source: NICE. TA127 Multiple sclerosis - natalizumab: costing template 
 c source:  NICE. Multiple sclerosis (relapsing-remitting) - fingolimod 
d source: Drug Topics Red Book.  
e source: http://www.destinationrx.com/ 
f source: Danish medicines agency, Price period: 14.05.2012 - 27.05.2012 
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1.7  Tobacco smoking in the UK; prevalence and general 
features 
Tobacco smoking is a major risk factor for many diseases and is the biggest 
preventable cause of premature death accounting for nearly 6 million deaths 
worldwide (WHO 2011). Tobacco smoking will continue to be the biggest 
cause of premature death during the 21st century with approximately 1 billion 
smoking-related deaths (Jha 2009). It causes billions of dollars of economic 
damage each year (Allender, Balakrishnan et al. 2009). Cigarette smoke 
contains roughly 4,000 compounds, some of which are highly toxic with 
significant negative impacts on human tissues.   
It is important to identify the problem and develop appropriate strategies to 
reduce both the incidence and the prevalence of this major public health issue. 
Here I provide an overview of the general patterns of cigarette smoking in the 
UK. The main source of data presented here for smoking prevalence in the UK 
is the General Lifestyle Survey (GLF), formerly known as the General 
Household Survey (GHS), published by the Office for National Statistics 
(ONS). The GLF is a national survey covering adults aged 16 and over living 
in Great Britain. Since 1998 the survey has included a core section of questions 
on smoking, drinking and drug use. Based on the 2011 data, 20% of adults 
(20% of men and 19% of women) reported smoking (current smokers) an 
average of 12.7 cigarettes a day which is similar to 2009 where 21% of adults 
reported smoking. Smoking prevalence was decreased significantly in 2010 
compared with the 39% in 1980. The proportion of never smokers or only 
occasional smokers has been rising steadily, from 43% in 1982 to 55% in 
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2010. Filter cigarettes are the most common type of cigarettes smoked, 
although there have been substantial increases in the numbers smoking hand-
rolled tobacco since 1990. Probably cost is the most influential factor in this 
trend. There was a substantial numerical difference in the prevalence of 
smokers in different age groups and those aged 20 to 24 (28%) and 25 to 34 
(26%) continue to have the highest prevalence of cigarette smoking. In 2010, 
5% of children aged 11 to 15 reported smoking at least one cigarette a week, 
while 25% of them have tried smoking at least once. Smoking prevalence was 
different amongst people with different demographic characteristics and was 
higher in the routine and manual socio-economic group than managerial and 
professional group. There were also geographical differences in the prevalence 
of smoking. Table below compares geographical distribution of smoking in the 
East Midlands and England.   
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Smoking prevalence - 
routine & manual group 
(%) 
30.3 29.5 32.6 32.1 30.2 22.4 
Smoking Prevalence 
(total) (%) 
20.0 19.8 23.3 19.7 18.6 17.1 
Smoking status at time of 
delivery (%) 
13.2 15.7 18.5 18.2 15.6 11.3 
Smoking attributable 
mortality (per 100,000) 
210.6 209.2 294.3 211.5 207.9 170.2 
Lung cancer registrations 
(per 100,000) 
45.8 56.3 70.1 46.3 44.6 39.7 
Deaths from lung cancer 
(per 100,000) 
37.7 36.7 57.3 38.1 34.5 30.4 
Deaths from chronic 
obstructive pulmonary 
disease (per 100,000) 
25.8 24.7 40.0 26.0 24.0 18.9 
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1.8  The present investigation, aims and the hypothesis 
Improving the health and well-being of the population is a moral imperative 
and is essential for stability and development. The vast efforts and resources in 
science and technologies have given us the opportunity to reduce disease and 
improve health in our population. 0XFKRIDQLQGLYLGXDO¶VOLIHVW\OHEHKDYLRXU
has implications on health and illness status and the degree of physical and 
mental wellbeing an individual can enjoy. Engagement in health-risk 
behaviours such as tobacco smoking increases the likelihood of development 
of diseases such as cardiovascular disease (CVD) and various cancers. 
However, the roles of lifestyle habits in MS are yet to be confirmed. In the 
current work I investigate risk factors with potential impact on MS to provide 
foundation and knowledge for the future research and also to inform efforts for 
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2.1  Summary of the chapter 
The aim of this chapter is to describe our study procedure and to lay the 
foundation and justification for the data used in all the following chapters. I 
acknowledge that information on outcomes and covariates in each analysis was 
not always available (missing data), resulting in slightly different numbers of 
patients in each analysis.  
In the next section, section 2.2, I will give a brief description about the 
Nottingham City and the MS registry at the Nottingham University hospital 
(QMC). 
Section 2.3 will provide a summary of our assumption at the beginning of the 
study and the rationales behind our sample size and data collection.  
Section 2.4 describes our study procedure. 
Section 2.5 summarises our inclusion and exclusion criteria. 
Section 2.6 provides information on our ethical considerations. 
Section 2.7 and section 2.8 define the procedures taken for the data collection 
and the types of clinical outcomes used in our study. 
In the final section, section 2.9 VWXG\¶V UHVSRQVH UDWH JHQHUDO IHDWXUHV DQG
demographic characteristics of our cohort are presented. 
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2.2  Nottingham city and Nottingham university hospital MS 
registry 
Nottingham (52.9700° N, 1.1800° W) is a city and unitary authority in the East 
Midlands of England in the traditional county of Nottinghamshire. The total 
population of Nottingham city was 305,680 in 2011 with more than 70% of the 
population being white. Over the past decade Nottingham has faced 
pronounced changes in terms of population characteristics. The following lines 
provide basic counts of Nottingham City residents based on their answers to 
the 2011 Census (The 2011 Census programme, Office for National Statistics). 
In 2011, RIWKH&LW\¶VSRSXODWLRQwere aged 30 or under with an average 
age of 34.8. This made Nottingham the fourth youngest city outside London. 
Most likely the two universities are the principal reason for the high proportion 
of young people in the City. In total, RI1RWWLQJKDP¶VSRSXODWLRQZDV
born outside the UK. Nottingham has seen an increase in the number of people 
of mixed or multiple ethnic groups (from 3.1% to 6.7%) as well as a significant 
fall in the proportion of White population of the City since 2001. There has 
been a large numerical increase in the Black African and Pakistani groups. 
Now, Nottingham has the third highest proportion of people of mixed ethnicity 
RXWVLGH/RQGRQRI1RWWLQJKDP¶VSRSXODWLRQ UHSRUWHGKHDOWKSUREOHPV
or disabilities in 2011 census which is slightly lower than the national average 
of 18.4%. However, amongst people of working age which are usually young 
adults, 14.2% of people had health problems or disabilities compared to 12.7% 
nationally. Nottingham has a higher proportion than nationally of residents 
with no qualifications. As a result Nottingham residents are less likely to be in 
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managerial or professional occupations and are more likely to have jobs in 
routine, semi routine and lower supervisory or technical occupations.  
Nottingham University Hospitals NHS Trust (NUH) is based in the heart of 
Nottingham city on three separate sites around the city providing health care 
for residents of Nottingham and across the East Midlands region. 4XHHQ¶V
Medical Centre is one of the largest hospitals in the UK with currently more 
than 1300 beds. In partnership with the University of Nottingham the trust has 
achieved a national and international reputation for many of its specialist 
services, including stroke, renal, neurosciences, cancer services and trauma. 
 
2.3  Power of the study 
In England, there are an estimated 120,000 people with MS (Investigators, 
Coles et al. 2008). National surveys in England estimated that around 20% of 
British adults aged over 18 smoke tobacco products regularly. Our previous 
survey in the centre suggested that the prevalence rate of current smokers at the 
time of disease onset and/or diagnosis is around 29% (Manouchehrinia, Tench 
et al. 2013). With 95% confidence interval and to have a margin of error less 
than 5%, sample size was calculated according to: 
݊ ൌ ݖ ݌ሺ ? െ ݌ሻݖଶܯܧଶ  
Where ME is the margin of error, P is the prevalence rate (29%) and z is the z-
score (1.96 for 95% confidence intervals).  
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Based on the above assumptions, a sample size of 620 was required to compare 
the prevalence of smoking between our MS cohort and England general 
population. We anticipated a response rate of about 45 to 55% based on the 
previous research in our centre and in the UK. Based on this response rate and 
the sample required for the study, it was estimated that questionnaire should be 
sent to at least 1400 MS patients to achieve the sample required for the study. 
We expected the average SDUWLFLSDQWV¶age in our study to be around 50 years, 
with a 2:1 female:male split.  
 
2.4  Selection of patients 
Participants were identified and recruited from Nottingham University 
Hospital MS clinics database. The study subjects consist of those enrolled in 
the Queen's Medical Centre MS clinic registry. Patients in this registry are 
referred from in and around Nottingham. For inclusion in the study a patient 
must have diagnosis of MS made by the neurologist and be > 18 years of age. 
Patients in the registry are seen routinely in the clinics and undergo 
neurological examination. The examination usually includes estimation of 
disability score, reports of comorbidity and treatment interventions. The 
patients in this study were those whose baseline visit was between 1994 and 
2012. Patients recruited into the registry undergo an extensive medical 
evaluation with standardised reporting of history, physical evaluation, Imaging 
and laboratory investigations. Eligible patients were contacted by letter to 
inform them of the study. The patient information sheet and questionnaire 
booklets were included with the letter. A separate consent form was also 
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LQFOXGHG LQ WKH SDFNDJH DV WKH VWXG\ LQYROYHG UHYLHZLQJ SDUWLFLSDQWV¶ 06
clinic medical notes. The medical notes in this clinic are different from those 
RQ*3¶VGDWDEDVHDQGFRQVLVWRI records of extensive neurological evaluation 
with standardised reporting of history, physical evaluation, imaging and 
laboratory investigations. Some participants were recruited on their MS clinic 
appointment in order to reduce the data collection time, postal costs and 
environmental impact. Efforts were made to keep this at minimum to reduce 
any unforeseen biases which could arise from clinic recruitments. If the 
patients wished to take part in the study they were asked to sign the consent 
form and complete the questionnaires and return them by the prepaid envelope 
proviGHG7KHSDWLHQWV¶LQIRUPDWLRQVKHHWSUHSDUHGE\WKHUHVHDUFKWHDPgave 
the participant adequate information regarding all aspects of the study and 
information pertaining to participation in the study. The research team and 
chief investigator contact detail were included for patients to peruse and 
contact the research team. In the patient information sheet it was explained to 
the potential participant that entry into the study is entirely voluntary and that 
their treatment and care will not be affected by their decision. It was also 
explained that they can withdraw at any time. 
 
2.5   Inclusion and exclusion criteria 
2.5.1 Inclusion criteria 
x Clinically definite MS diagnosed at least 12 months beforehand.  
x Adults: aged between 18 and 90 years old.  
x Men and women.  
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2.5.2 Exclusion criteria 
Patients with current or concomitant illness that would interfere with the 
LQGLYLGXDO¶VDELOLW\WRcomplete the study results were excluded. Furthermore, 
children, prisoners, and those unable to give consent were not to be included.  
 
2.6  Ethical Considerations 
As the study did not involve any potential harmful treatments or any sort of 
invasive interventions or lifestyle alterations, the main ethical issue was 
confidentiality of data and adequate and proper data storage. Confidentiality of 
data were addressed by coding all patient data and arranging appropriate secure 
storage of paper and electronic data (which were labelled with coded ID only).  
The study was conducted in accordance with the ethical principles that have 
their origin in the Declaration of Helsinki, 1996; the principles of Good 
Clinical Practice, and the Department of Health Research Governance 
Framework for Health and Social care, 2005. All participating researchers 
adhered to ICH-GCP and good clinical governance guideline. The study was 
conducted at the Nottingham University Hospital and all the paper data were 
kept in a secure and locked storage at the Division of Clinical Neurology. All 
the data analysis and electronic data were conducted and stored on the 
University of NottingKDP¶V FRPSXWHUV DQG ZHUH SDVVZRUG SURWHFWHG 7KH
password was issued to the chief investigator and the research team only. The 
study was initiated after the protocol, consent forms and participant 
information sheets received approval from the Research Ethics Committee 
(REC), and the respective National Health Service (NHS) Research & 
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Development (R&D) department. The study was approved by the NRES East 
Midlands Ethics Committee- Derby-1 and Nottingham university hospital 
R&D office.  
 
2.7  Data collection and questionnaire booklet 
Data used in our study were collected from SDWLHQWV¶ PHGLFDO UHFRUGV, a 
prospective cohort database started in year 2000 by Professor Constantinescu 
(Edwards and Constantinescu 2004) and a questionnaire booklet designed 
specifically for the study as we aimed to collect additional data which was not 
exist on the database and was not SDUWRIWKHSDWLHQWV¶URXWLQHFDUHWRHQKDQFH
RXU µVQDS VKRW¶ RI HDFK SDWLHQW¶V VPRNLQJ VWDWXV DV ZHOO DV WKHLU OHYHO RI
disability.  
Since year 2000, more than 4070 EDSS scores were recorded in the 
prospective cohort database. This represents almost four EDSS scores per 
patient, which were estimated by a neurologist during SDWLHQWV¶ routine clinic 
visits.  
The recorded EDSS scores in the database and new updated scores obtained 
from the medical records were then used for the time series analysis. When 
estimating the time to EDSS score milestones 4 and 6, extra care was taken to 
ensure that the year which was recorded as the time in which patients reached 
the scores is a true value, no EDSS scores 4 and 6 are recorded before this year 
and the score is either sustained or escalated in the following years. Due to the 
uncertainty about the date in which some of the patients escalated to EDSS 
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scores 4 and 6, 12% to 15% of the patients were dropped from the time-series 
analysis. 
In case of a gap between two scores, the median year between the scores were 
recorded as the year of reaching that particular score. For example, if a patient 
had an EDSS score of 3.0 in year 2005 and 5.0 in year 2007, the year 2006 was 
chosen as the year in which the patient has reached EDSS score 4.   
Four validated, self-report questionnaires were combined and used in our 
study. In the questionnaire booklet, patients were asked to answer a series of 
questions regarding any history of asthma, allergy, eczema, appendectomy and 
tonsillectomy. In order to be able to conduct a case-control study investigating 
the potential contributory role of smoking in development of MS, patients in 
our registry were asked to answer the exact questions obtained from the 
England health survey 2010. Specifically for the asthma, smoking and allergy 
part, patients were asked to complete a series of questionnaires in the booklet 
format containing questions from following questionnaires: 
 Questions from the European Community Respiratory Health Survey II 
(ECRHS II) 
 Questions from General Household Survey and England Health Survey 
2010 
7KH OHYHO RI SDWLHQWV¶ GLVDELOLW\ ZDV PHDVXUHG YLD WZR YDOLGDWHG VHOI-report 
questionnaires. Booklet contains following questionnaires: 
 Multiple Sclerosis Impact Scale (MSIS-29) 
 Patient Determined Disease Steps (PDDS) 
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There are several patient oriented outcome measures in MS including Guy's 
Neurological Disability Scale (GNDS), Multiple Sclerosis International 
Quality of Life questionnaire (MusiQoL), Multiple Sclerosis Quality of Life-
54 (MSQOL-54), etc. We selected MSIS-29 and PDDS scores for several 
reasons. First, number of items and time required for answering the questions 
by patients. Due to the high number of the questions already included in the 
first part of the questionnaire, we had to use the most informative outcomes 
with relatively few number of items. Second, good responsiveness to clinical 
change and possibility of continuing evaluation of individual patients in form 
of a longitudinal follow-up and third, being easy to administer with minimal 
contact required with patients (due to the high number of participants). 
MSIS-29 and PDDS scores are responsive patient-based outcome measures 
covering a broad range of domains of MS- and health-related quality of life. 
The two questionnaires were used to improve our understanding of the impact 
of MS and to increase the generalizability of our evaluation as they have been 
widely used in epidemiologic studies of MS. In addition MSIS-29 gave us the 
ability to measure the psychological impairment (in more details than 
conventional measurements such as the Short Form (36) Health Survey) in our 
sample population and investigate the impact of smoking RQSDWLHQWV¶SK\VLFDO
and psychological wellbeing.  
A copy of the questionnaire booklet is shown in appendix 1. 
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2.8  Measurements 
2.8.1 Clinical outcomes 
In order to measure the effects of tobacco smoking on the progression of 
disability and severity of the disease in individuals with MS, we used range of 
validated clinical outcomes. The clinical outcomes used included EDSS, 
PDDS, MSIS-29 scores and Multiple Sclerosis Severity Score (MSSS). The 
measures are extensively discussed in the literature and briefly discussed 
below. 
2.8.1.1 EDSS 
EDSS was developed from the formerly known Disability Status Score (DSS) 
in 1983 (Kurtzke 1983). DSS was developed in 1955 (Kurtzke 1955) and used 
in the first randomised, placebo-controlled, double-blind trial of MS (1957). 
Like DSS, EDSS is based on the neurologic examination of seven Functional 
Systems (FS): Pyramidal (P), Cerebellar (Cll), Brain Stem (BS), Sensory (S), 
Bowel & Bladder (BB), Visual (V), Cerebral or Mental (Cb). Unlike DSS, 
EDSS measures twenty levels of impairment from 0 to 10 in 0.5 increments 
(except that no intermediate score of 0.5 exists between 0 and 1). Regardless of 
all shortcomings attributed to the scale, EDSS is still the gold standard in 
measurements of neurological deficit in MS.   
2.8.1.2 MSSS 
MSSS was proposed in 2005 by Roxburgh and colleagues to assess the 
severity of MS by aggregating EDSS score and disease duration using the 
clinical data from 9892 mainly European MS patients (Roxburgh, Seaman et 
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al. 2005). MSSS is different from the simple progression index score (EDSS 
divided by disease duration) as it corrects EDSS for disease duration by 
FRPSDULQJHDFKLQGLYLGXDO¶V('66VFRUHZLWKthe distribution of EDSS scores 
in individuals with similar disease duration. Hence, MSSS is capable of 
measuring disease severity in MS using single EDSS scores. MSSS can be 
generated using either local (study dataset) or global (data from 9892 patients) 
EDSS scores. For the propose of this study we generated the global MSSS 
score where the EDSS scores from our sample population were compared to 
the larger sample of 9892 MS patients as this first, increases the 
generalizability of our results and second, the disease severity in our cohort 
could be compared with that of a larger MS population.  
2.8.1.3 MSIS-29 
The MSIS-29 is a 29-item patient-reported scale for measuring physical and 
psychological functioning impact of MS. It has two subscales a 20-item 
physical impact scale (questions 1 to 20) and a 9-item psychological scale 
(questions 21 to 29). The scale was generated in 2001 by Hobart and 
colleagues using traditional psychometric methods (Hobart, Lamping et al. 
2001). The MSIS-29 has been comprehensively compared with a range of 
other scales and has shown validity to be used in clinical trials and studies of 
MS. 
2.8.1.4 PDDS 
The PDDS was adapted from a physician administered scale called disease 
steps (Hohol, Orav et al. 1995). The PDDS is a patient-reported measure of 
disability developed and widely used by the North American Research 
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Committee on Multiple Sclerosis (NARCOMS). Although there is no direct 
correspondence between scores in EDSS and PDDS, studies have shown a 
significant correlation of EDSS and PDDS scores (Learmonth, Motl et al. 
2013).  
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2.9  Response rate, general features and demographic 
characteristics of our cohort 
2.9.1 Response rate 
The questionnaire was sent to 1404 patients. Figure 2-1VKRZV SDWLHQWV¶
postcode plotted on a map to visualise the geographical distribution of our 
sample population. The response rate was calculated as the total number of 
questionnaires sent to the patients divided by the total number 
of questionnaires received. The clinical and demographic data were collected 
from 1246 eligible patients. By March 2013, overall 681 questionnaires were 
returned and their responders were qualified to participate in the study on the 
basis of our inclusion criteria. This gave us response rate of 48.4%. Mean age 
in non-respondents was 53 (SD ±11.03) with 2:1 female:male ratio. Non-
respondents were significantly more likely (P < 0.001) to live in more deprived 
geographical areas than respondents as measured by the index of multiple 
deprivation (IMD 2007). The IMD is a relative measure of deprivation in a 
particular geographical area which can be used to compare the extent of 
deprivation across local authorities and different groups of patients. Many 
surveys have found non-respondents to be from lower socio-economic status 
(Bakke, Gulsvik et al. 1990). Our findings confirm this, however, little is 
known about non-respondents and impact of socio-economic status in surveys 
of MS. Differences in socio-economic status between our respondents and 
non-respondents can potentially influence our estimates of the prevalence of 
smoking and level of disability as surveys of tobacco smoking in the general 
population has constantly shown that the prevalence of smoking is 
significantly higher in more deprived areas of the country (Hiscock, Bauld et 
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al. 2012). There is also a possibility of reverse causality where disability due to 
MS can lead to patients being from lower socio-economic class. As is evident 
from our survey, not only are non-respondents representing more patients of 
lower socio-economic status but they are significantly more disabled compared 
with respondents. Hence, our estimates of the prevalence of smoking may be 
slightly lower than the true prevalence. In general, non-respondents were more 
likely to be off treatment, have slightly longer disease duration (2 years) and be 
more disabled (0.5 EDSS score). Baseline characteristics of 1246 MS patients 
are summarised in Table 2-1. 
Nevertheless, the general demographic and clinical features of our cohort of 
respondents were similar to those reported from other MS cohorts. For 
example with regard to the disease phenotype, 58% of our bout onset patients 
had transited to SP MS after median 20 years of follow-up which is almost 
similar to the reported percentage of 66 (after median 23 years of follow-up) in 
the London Ontario cohort (Scalfari, Neuhaus et al. 2010). Slightly more than 
10% of our patients were diagnosed with PP MS which was also consistent 
with the reports from other MS cohorts (Kingwell, van der Kop et al. 2012).    
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Table 2-1: summaries of baseline characteristics of respondent and non-respondent 
patients. 
 Respondent  Non-respondent  
Age (mean(SD)) 52.89 (±11.33) 52.88 (±11.03) P = 0.99 
Sex (female percentage) 71.47% 69.8% P = 0.56 













P = 0.12 
DMT (%) 54% 40% P < 0.001 
Disease duration  
(mean(SD)) 19.28 (±10.44) 21.37 (±10.16) P = 0.001 
Latest EDSS score 5.5 (3.5 to 6.5) 6 (3 to 6.5) P = 0.03 
IMD (mean (SD)) 16.7 (±11.83) 21.35 (±14.93) P < 0.001 
DMT: disease modifying treatment 
EDSS: expanded disability scale status 
IMD: index of multiple deprivation.  
SD: standard deviation 
 





distribution of our sample population 
 
 
2.9.2 Demographic and general MS characteristics 
From the total of 1246 cases 69.6% were female. Average age at the time of 
study was 53.4 (SD ±11.55). The majority of the patients were RR MS 
(51.2%), 10% had PP MS and 37.6% had been diagnosed as SP MS (Figure 
2-2). Forty six percent of the patients had been exposed to DMT for at least 
one year. The mean age at the onset of MS was 32.7 (SD ±10) and mean 
duration from the date of the first manifestation of the disease was 20.6 (SD 
±10.4) years.  




            
Figure 2-2: Bar chart showing the frequency of MS phenotypes in our sample 
population 
 
2.9.3 General features 
2.9.3.1 Asthma and allergy 
Data with regard to coexistence of asthma and allergic diseases and MS is 
contradictory. Traditionally, it was believed that the two conditions are 
mutually exclusive one mediated by Th2 and the other Th1 cells. In 2004, an 
epidemiologic survey of more than 650 MS patients in our centre found an 
increased susceptibility of MS patients to asthma and all atopy compared with 
the general population (Edwards and Constantinescu 2004). In contrast, a non-
age and ±sex matched study by Oro and  colleagues reported lower prevalence 
of allergic disease in a population of 24 patients with MS compared to 18 
controls (Oro, Guarino et al. 1996). Further epidemiologic study by Tremlett 
and colleagues on 306 MS patients obtained from general practitioner data 
base in Wales showed an inverse association between asthma and MS and no 
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association to any Th1associated disease (Tremlett, Evans et al. 2002). Besides 
the biological plausibility of coexistence of MS and asthma and its effect on 
the disease progression and its potential therapeutic interference, the 
association between MS and asthma remains controversial. A systematic 
review and meta-analysis by Monteiro and colleagues (Monteiro, Souza-
Machado et al. 2011) has shown that there is no evidence of an association 
between asthma and MS (OR: 0.83; 95%CI: 0.48 to 1.44). On the other hand, 
it has been shown that MS patients and their families have an increased 
susceptibility to autoimmune diseases (Broadley, Deans et al. 2000). In the 
current work, we investigated the prevalence of asthma in our MS population 
and compared it to the prevalence in the general England population. The 
prevalence rate of asthma in England population was obtained from the Health 
Survey for England 2010.  
In our survey, 12.3% (n = 84) of the patients reported a previous history of 
asthma confirmed by their GPs (Figure 2-4). Mean age at the onset of asthma 
was 18.8 (SD ±14.5).  The percentage of asthma was not significantly different 
by gender in our population (76% female with asthma vs. 71% female without 
asthma, P = 0.2). The majority of MS patients with asthma presented with 
relapse-onset MS compared to MS patients without asthma (96.5% of MS 
patients with asthma vs. 89.5% of MS patients without asthma, P = 0.048). The 
mean age at the onset of MS was 30.5 (SD ±9.2) in patients with asthma 
compared with 33.9 (SD ±9.9) patients without asthma (P = 0.003). 15.2% and 
19.7% of MS patients with asthma reported a history of asthma in their fathers 
and mothers, respectively. 45.8% of MS patients with asthma were receiving 
treatment for their asthma and 28.2% of them reported at least one attack of 
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asthma in the past 12 months. Overall, 66.6% of MS patients with asthma 
received at least one year of DMT (median 2 years) compared with 54% of the 
whole cohort (P = 0.01). 1.1% of MS patients with asthma lived in the farm, 
19.5% lived in a small village, 42.5% lived in a small town, 25.3% lived in a 
suburb of a city and 11.5% lived inner city when they were under the age of 
five years. This is compared with 4.5%, 24.9%, 32.1%, 31.5% and 7% in MS 
patient without asthma (P = 0.08) (Figure 2-3). 
 
 
Figure 2-3: percentage of patients by the place of living under the age of five years by asthma 
status. 
 
35.2% of MS patients reported a previous history of eczema or any kind of 
skin allergy, 27.1% reported history of hay fever or nasal allergy and 19.8% 
reported that they have previously had an itchy rash that was coming and going 




























Place lived when were under the age of five years 
No
Yes
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Figure 2-4: Left: percentage of MS patients who reported history of asthma. Right: 
percentage of asthma in the MS patient cohort stratified by the initial clinical course 
 
2XU FRKRUW¶V  SUHYDOHQFH UDWH RI DVWKPD ZDV VLJQLILFDQWO\ ORZHU WKDQ
16.1% prevalence rate in the England general population before matching for 
sex and age (Ȥ2 (1) = 5.43, P = 0.02). Age at the first attack of asthma was 
significantly older amongst people with MS compared with their counterparts 
in the England general population (16.4 vs. 18.8; P < 0.001). This was 
predominantly caused by older age at the onset of asthma in female patients 
with MS (19.4 in females vs. 16.5 in males, P < 0.001). In order to investigate 
the difference in the prevalence rate of asthma between MS patients and the 
general population, we performed a sex and age matched case-control study. 
For each case of asthma in MS patients we randomly selected 2 exact age and 
sex matched from over 14,000 participants in the Health Survey for England 
2010. We made sure that our MS patients answered the exact questioned asked 
from the controls in the Health Survey for England 2010.  
Logistic regression was then used to measure the likelihood of asthma in MS 
patients compared to their matched controls. Our regression model failed to 
show any association between occurrence of MS and asthma (OR: 0.83, 
95%CI: 0.64 to 1.09, P = 0.19). Nor adjustment of the model for smoking 
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status (ever- vs. never-smoked) neither for parental smoking did not change the 
risk of asthma in MS patients (OR: 0.84, 95%CI: 0.63 to 1.11, P = 0.22). The 
only significant risk factor for asthma was age. In our MS population (without 
controls) each year increase in age was associated with 4% reduction in the 
risk of asthma (OR: 0.96, 95%CI: 0.94 to 0.98, P < 0.001). In MS patients, the 
risk of asthma was higher in females but did not reach significance level (OR: 
1.26, 95%CI: 0.73 to 2.1, P = 0.4). Separate logistic regression models with 
one covariate only (excluding age and sex which were present in all the 
models) were run to measure the effects of individual and parental smoking on 
the likelihood of asthma in MS patients. Table 2-2 summarises the results of 
these logistic regression models. As shown in the table, no evidence of any 
association between asthma in people with MS and individual and parental 
smoking was found.  
Table 2-2: Results of conditional logistic regression models 
 Odds ratio P-value 95% Confidence interval 
MS 0.83 0.19 0.64 to 1.09 
Ever-smoking * 1.12 0.62 0.69 to 1.81 
Regular smoking * 0.98 0.94 0.62 to 1.55 
Father smoking * 0.93 0.77 0.58 to 1.49 










0.66 to 1.75 
0.55 to 1.53 
0.61 to 1.70 
First model investigates the likelihood of having asthma in MS patients and their 
exact age and sex matched controls from the England general population.  
* MS patients only. Results obtained from four separate statistical models all adjusted 
for age and sex. 
One logistic regression model adjusted for age and sex. In MS patients only 
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2.9.3.2 Tobacco smoking status 
Detailed smoking data was obtained through the questionnaire. From the 681 
cases who returned questionnaires and had completed the smoking part of the 
questionnaire, 62.5% reported that they have tried tobacco products at some 
points during their life (Figure 2-5). 51.1% of the patients reported having 
smoked at least 20 packs of cigarettes or 12 oz (360 grams) of tobacco in a 
lifetime, or at least one cigarette per day or one cigar a week for one year 
which is defining regular smoking in our study. 35.2% of regular smokers had 
given up smoking while 16% reported current tobacco consumption. Smoking 
status was different at the time of the disease onset. At the time of the onset of 
the disease 18% and 33% of individuals were ex-smoker and current smokers, 
respectively (Figure 2-6). The percentages of non-, ex- and current smokers 
were significantly different between genders.  At the time of study 40.4%, 45% 
and 14.5% of males were non- ex- and current smoker compared with the 52%, 
31.2% and 16.5% of females, respectively (P = 0.003) (Figure 2-7). Mean age 
at the start of regular smoking was 17.5 (SD ±4.4). Our patients smoked for an 
average duration of 22.8 (SD ±13.4) years with average smoking intensity of 
18.7 (SD ±12.5) cigarettes per day.  
   
Figure 2-5: Left: percentage of regular smokers. Right: percentage of ever-smokers 
including patients who has never smoked regularly 






Figure 2-6: percentage of smoking status at the time of the onset of the disease 




Figure 2-7: percentage of current smoking status stratified by gender  
 
 
2.9.3.3 Disability  
Table 2-3 shows the mean (SD) and median (IQR) of measured disability scores 
in our sample population. EDSS score and MSSS were available for 1245 
patients while PDDS and MSIS-29 were available in 681cases.  
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Table 2-3: Summaries of disability and severity scores 
 Mean (SD) Median (IQR) 
EDSS 4.94 (±2.1) 6 (3 to 6.5) 
MSIS-29 
20-item physical impact scale (questions 1 to 20)  




85 (60 to 106) 
62 (41 to 76) 
23 (16 to 31) 
PDDS 3.93 (±2.3) 4 (2 to 6) 
MSSS  4.91 (±2.6) 5.09 (2.4 to 7.1) 
EDSS: expanded disability scale status 
IQR: interquartile range 
MSIS-29: multiple sclerosis impact scale 
MSSS: multiple sclerosis severity score 
PDDS: Patient Determined Disease Steps 
SD: standard deviation 
 
2.10 Comments 
The aim of this chapter was to give an introduction to our cohort setting and 
characteristics. However, some very interesting facts were found when data 
was being analysed. Our study of the prevalence of asthma in patients with MS 
and its comparison with the prevalence rate of the England general population 
is the largest study of its kind to date. Here we found that the prevalence of 
asthma in patents with MS is not significantly different from that of the 
England general population. Our finding contradict the results from a previous 
survey in our centre which showed a significantly higher prevalence of asthma 
in MS patients (Edwards and Constantinescu 2004) and the results from a 
survey in Wales which showed reduced prevalence of asthma in patients with 
MS (Tremlett, Evans et al. 2002). However, our result is compatible with the 
results from the meta-analysis by Monteiro and colleagues (Monteiro, Souza-
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Machado et al. 2011). The exact reason for this discrepancy needs further 
investigations but matching strategies and characteristics of both cases and 
controls may be responsible for this in part. The significant lower prevalence 
rate of asthma in our MS population compared with the England general 
population before matching for age and sex (P = 0.02) was disappeared when 
patients and controls were matched for age and sex. This very clearly shows 
the influence of demographics and in particular age on the results. 
Nevertheless, use of DMTs and steroids in MS patients should be considered 
as these drugs and in particular IFN-ȕ can alleviate asthma symptoms 
(Traynor, Alexander et al. 2003). 
Tobacco smoking in our MS population showed some unique characteristics. 
The percentage of current smokers at the time of the disease onset was 39% in 
males and 31% females. This seems significantly higher than what would have 
been expected if the percentage was similar to that of England general 
population. Potential contributory rule of smoking on the risk of MS will be 







3. Chapter three: Smoking and MS. Effects on 
the occurrence of MS 
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3.1 Summary of the chapter 
Epidemiologic studies point toward an influence of tobacco smoking on the 
risk of MS. In this chapter we present our finding from a matched case-control 
study wLWKUHJDUGWRWKHSRWHQWLDOHIIHFWVRILQGLYLGXDOV¶DQGSDUHntal smoking 
on the risk of MS. Our main objectives here were to identify whether parental 
VPRNLQJ GXULQJ FKLOGKRRG DQG LQGLYLGXDOV¶ VPRNLQJ ODWHU LQ OLIH KDYH DQ\
influence on MS susceptibility. 
In the section 3.2 a comprehensive review of the previous literature is 
presented.  
Section 3.3 describes our methodology and our approach for conducting a 
matched case-control study. 
Our findings are presented in section 3.4 and the next section, section 3.5 








Early Research:  
The association between cigarette smoking and the risk of MS development 
was first suggested by Antonovsly et al. in 1965 (Antonovsky, Leibowitz et al. 
1965). In their retrospective case-control study, ever smoking (prior to disease 
onset) was associated with an increased risk of developing MS (OR = 1.4, P <  
0.02) among ever smokers (n = 106) compared with never smokers matched 
for age, sex and region of birth. This represented the first positive results on 
the influence of smoking on MS risk, but, in view of the lack of confidence 
intervals and a small sample size it was hard to scientifically rule out the 
possibility of some inaccuracies.  
In 1966 an investigation in North England by Simpson et al. (Simpson, Newell 
et al. 1966) raised the possibility of a gender effect in terms of disease 
susceptibility and smoking. Simpson suggested that female smokers have a 
higher risk of developing MS than male smokers. The study was carried on 
 ³SUREDEOH´ 06 FDVHV  PDOHV DQG  IHPDOHV and found no 
difference between the intensity of smoking in cases compared with age-
matched controls.  
In 1993 a retrospective case-control study was performed in the UK by 
Villard-Mackintosh et al. (Villard-Mackintosh and Vessey 1993) as part of a 
study investigating the association of oral contraceptive pills with the risk of 
MS (Oxford Family Planning Association Study). This incident case study on 
63 new MS patients (female only) found a borderline significant association 
between the intensity of smoking and the risk of MS (P = 0.05). However, the 
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suggested relative risk of 1.8 (95% CI: 0.8 to 3.6) for current smokers (more 
than 15 cigarettes per day) and the relative risk of 1.5 (95% CI: 0.6 to 3.3) for 
ex-smokers compared with non-smokers were not significant. The study was 
repeated after ILYH \HDUV WKH 5R\DO &ROOHJH RI *HQHUDO 3UDFWLWLRQHUV¶ 2UDO
Contraception Study) on the 114 incident MS cases, yielding almost similar 
and no significant results (Thorogood and Hannaford 1998).  
In 2001, significant results on the association of tobacco smoke and MS risk 
was suggested in a case-control study (education-, age- and sex-matched) by 
Ghadirian et al. (Ghadirian, Dadgostar et al. 2001). In their study, data from a 
year prior to MS diagnosis were collected from 197 incident MS subjects from 
Montreal. Data analysis showed an odds ratio of 1.6 (95% CI: 1.0 to 2.4) for 
ever-smokers compared with never smokers. A significant trend between the 
number of cigarette consumption and the risk of MS was also suggested where 
it was shown that compared with never-smokers, the risk of MS for cases who 
smoked 20-40 cigarettes per day was almost twice with an odds ratio of 1.9 
(95% CI: 1.2 to 3.2) and was even higher for cases with intensity of > 40 per 
day with an odds ratio of 5.5 (95% CI: 1.7 to 17.8). However, results from this 
study should be interpreted cautiously as the large confidence interval (1.7 to 
17.8) means that there is a large uncertainty about the true value perhaps due to 
the small numbers of cases with smoking consumption of more than 40 
cigarettes per day. The study also used the smoking data from a year before the 
MS diagnosis while it is well-known that in many of MS patients, disease 
onset occurs several years before the diagnosis date.  
Data from two on-going cohorts RI 86 IHPDOH QXUVHV WKH 1XUVHV¶ +HDOWK
6WXG\ 1+6 DQG WKH 1XUVHV¶ +HDOWK 6WXG\ ,, 1+6 ,, ZHUH H[DPLQHG E\
 Chapter three: smoking and MS: effects on MS occurrence  
77 
 
Hernan et al. (Hernan, Olek et al. 2001) aiming to find an association between 
tobacco consumption and risk of MS. Of 121,700 female nurse registered in 
the 1976 cohort, and of 116,671 in the 1989 cohort overall 315 incident cases 
of MS were identified (181 cases in the NHS (127 definite and 54 probable) 
and 134 (103 definite and 31 probable) in the NHS II). After adjusting for age, 
statistical analysis showed an increased risk of MS in both cohorts for ever-
smokers compared with never-smokers with a pooled relative ratio of 1.6 (95% 
CI: 1.2 to 2.1). Furthermore, the study revealed a borderline significant level 
(P = 0.05) of the MS risk increased by the number of cigarettes consumed. 
Repeated analyses with definite cases of MS further increased the pooled 
relative risk of 1.4 (95% CI: 1.0 to 2.0) for ex-smokers to 1.9 (95% CI: 1.3 to 
2.8) for smokers RI  25 pack-years. However, the study was limited to 
females only.  
The early epidemiologic studies investigating the influence of smoking on the 
occurrence of MS encountered major limitations.  Small sample size, restricted 
demographic characteristics (females only) and lack of appropriate matching 
approaches are amongst some of the limitations of these earlier studies. In 
addition many of these surveys were conducted when the MRI as the main MS 
diagnostic tool was not routinely available and hence the diagnosis may have 
been subjected to bias. The quality of studies conducted after year 2000 has 
been substantially improved with fewer limitations and improved 
methodological approaches. These studies are presented below.  
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Recent Findings:   
The association between cigarette smoking and risk of MS has been the focus 
of several case-control and population based studies after year 2000. A large 
population based study by Riise et al. (Riise, Nortvedt et al. 2003) in 2003 in 
Norway showed higher risk of developing MS (self-report diagnosis) for ever-
smokers compared with never-smokers with a rate ratio of 1.81 (95% CI: 1.1 
to 2.9; P = 0.014).  
In 2005, in the second attempt, Hernan et al. (Hernan, Jick et al. 2005) in a 
prospective nested case±control study of 201 definite MS cases and 1913 age- 
and sex-matched controls found an odds ratio of 1.3 (95% CI: 1.0 to 1.7) for 
ever-smokers compared with never-smokers. The risk was found to be similar 
for both RR MS and PP MS.  
The first meta-analysis investigating the association of smoking and MS 
development risk was undertaken by Hawkes et al. (Hawkes 2007). Their 
pooled analysis of six qualified previous studies (two included 100% women) 
indicated a risk ratio of 1.24 (95% CI: 1.04 to1.48) for the increased risk of MS 
after smoking.  
In 2009, Jafari et al. (Jafari, Hoppenbrouwers et al. 2009) conducted a family 
based matched case control study in order to assess the influence of smoking 
on the risk of MS using unaffected siblings as controls in multiplex MS 
families. Analysis of 136 MS patients from 106 multiplex MS families 
compared with their 204 unaffected siblings showed no significant risk of MS 
for ever-smokers compared with never-smokers (OR 1.09; 95%CI: 0.68 to 
1.73). Although the overall differences were not significant, the study found 
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slightly higher risk of MS in the groups with more smoking consumption, 
longer smoking duration and also in female patients. The study offered 
enhanced genetic and environmental matching of controls, due to using 
siblings from the same family as the control group. However, one important 
limitation of such studies is the presence of similar smoking behaviours within 
families. The findings of this study are of particular importance as they may 
point to a stronger genetic or environmental confounder(s) overriding smoking 
effects.  
 
Role of Nicotine:  
The role of nicotine, as the major component of tobacco smoke, in the 
development of MS was questioned in some studies. In one of the studies 
undertaken by Hedstrom et al. in 2009 (Hedstrom, Baarnhielm et al. 2009), the 
risk of MS by using tobacco and/or Swedish snuff (smokeless tobacco) was 
assessed in the patients with clinically definite MS. The study population was 
comprised of 902 MS cases and 1,855 age, sex and residential area matched 
controls from Sweden. As expected, the study suggested an odds ratio of 1.5 
(95% CI: 1.3 to 1.8) for ever-smokers compared with never-smokers. 
Interestingly, a protective effect of Swedish snuff and decreased risk of MS 
was found in the snuff-takers of more than 15 years who had never-smoked 
(OR: 0.3; 95% CI: 0.1 to 0.8; P = 0.02). These findings were confirmed in a 
study by Carlens et al. a year later in 2010 and a more recent study by 
Hedstrom and colleagues in 2013 (Carlens, Hergens et al. 2010; Hedstrom, 
Hillert et al. 2013). 
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Further experimental studies have also supported the neuroprotective 
properties of nicotine. It has been shown that treatment with nicotine can 
significantly reduce the disease activity and inflammation in EAE (Naddafi, 
Reza Haidari et al. 2013).  The pathway in which nicotine enters the body and 
the form of used tobacco, in this case smokeless tobacco, seem to be important 
factors when the association of smoking and MS risk is questioned.  
 
Interaction between smoking and other risk factors 
Since both genetic and environmental factors including smoking displayed low 
or at best modest associations with MS risk, the hypothesis of gene-
environmental interaction was tested in 2010 when combined effects and 
potential interactions of three well-known risk factors for MS; smoking, EBV 
exposure (as assessed by anti-EBNA antibodies), and HLA-DRB1*1501 were 
assessed by Simon et al. (Simon, van der Mei et al. 2010).  442 cases and 865 
controls in this study were those from three previous case control studies.  
While the anti-EBNA titers were significantly higher in ever-smokers with 
MS, the risk of MS for ever-smokers was only significant among the cases 
with high anti-EBNA titers. The study also suggested that smoking is unlikely 
to influence the association of HLA-DR15 and MS risk, a result which is in 
contrast with the results from a study by Hedstrom et al. (Hedstrom, Sundqvist 
et al. 2011) in which a significant interaction between smoking, HLA-DR15 
and risk of MS was found. In this case control study (843 cases, 1209 controls) 
undertaken in Sweden, the potential interaction of smoking and two human 
leukocyte antigen genes, presence of DRB1*15 and absence of A*02, was 
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assessed. The odds ratio for ever-smokers compared with never-smokers in the 
group with neither of genetic risk factors was similar to those from previous 
studies (OR: 1.4; 95%CI: 0.9 to 2.1)). Non-smokers with both genetic risk 
factors were 4.9 (95%CI: 3.6 to 6.6) and ever-smokers with both genetic risk 
factors were 13.5 (95%CI: 8.1 to 22.6) times more likely to have MS compared 
with never-smokers with neither of the genetic risk factors. 
In 2011 Palacios and colleagues (Palacios, Alonso et al. 2011) compared the 
gender rate ratio of MS incidence with that of smoking data. They showed that 
the gender ratio of MS is correlated with the gender ratio of smoking and that 
smoking is one of the factors responsible for the difference in female:male 
ratio of MS.  The study compared the cross-country data from each country 
birth cohorts and smoking statistics (in depth for Canada and Denmark). Under 
the assumption that both males and females have equal increase in the risk of 
MS an overall incidence rate ratio of 1.50 (95% CI: 1.17 to 2.01) of MS for 
ever-smokers was suggested in the cross-country data analysis.  
 
Summary: 
In summary, there is ample epidemiological evidence that tobacco smoking is 
a significant risk factor in the development of MS. However, it should be noted 
that smoking may mark out a certain group of population with an increased 
risk to develop MS by means of lifestyle. In this regard, the validity of the 
association is not supported by the relationship between other diseases known 
to be related to smoking such as lung cancer and risk of MS. Surprisingly, it 
has been found that the risk of lung cancer is reduced in MS patients (Handel, 
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Joseph et al. 2010). The recent study by Riise et al. (Riise, Kirkeleit et al. 
2011) on the Norwegian workers gave weight to the conclusion, reached in 
some but not all the previous studies, that smoking itself in fact explains the 
higher risk of MS . The study found a marked inverse association between the 
level of education and the risk of MS. Their statistical analysis showed a rate 
ratio of 0.43 (95% CI 0.27 to 0.66) for workers with a graduate degree 
compared to workers with elementary school only. They could also find an 
inverse association between the level of education and the risk of colorectal 
cancer, bronchus/lung cancer and mortality due to vascular diseases for all of 
which smoking is a risk factor. To enable a better interpretation of the 
association between education and the risk of MS the study data were 
compared to the data from the general population and it has been shown that in 
2009 only 7% of those with a graduate education were regular smokers, 
compared to 26% of those with only an elementary school education. Hence, 
smoking may explain much, although not all, of the association between MS 
and education. Table 3.1 contains the summery of some of the studies 
reviewed here.  
The exact mechanism in which smoking alters the immune system is not clear. 
Chronic exposure to tobacco smoke has been shown to alter a wide range of 
immune functions including reduction and inhibition in production of 
SURLQIODPPDWRU\ F\WRNLQHV 71)Į- , IL-1, IL-6, IL-8) (Chen, Cowan et al. 
2007; Mortaz, Lazar et al. 2009). Chronic exposure to tobacco smoke has also 
been shown to be associated with Th17 and Treg imbalance in mice (Wang, 
Peng et al. 2012) and patients with Psoriasis (Torii, Saito et al. 2011). Data 
with regard to the effects of smoking on the development of some autoimmune 
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conditions such as rheumatoid arthritis is strong. Although not entirely known, 
possible mechanisms include the ability of tobacco smoke to augment auto-
reactive B cells, stimulation of the proliferation of peripheral T-lymphocytes 
(Kingwell, Marriott et al. 2013) and production of free radicals. 
In the current work we examined the hypothesis of smoking being a risk factor 
for MS in our sample population and investigated whether parental smoking 
during childhood can increase the risk of MS. 
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Table 3-1: Summary of some of the studies investigating the association of cigarette smoking and risk of MS 
Author/Year Sample (Case/Control) Odds Ratio (OR) or Risk Ratio (RR) Study Type 
Antonovsly/1965 241/61 1.4 OR (95% CI: 1.05 to1.86) Retrospective, case-control 
Simpson/1966 584/ 1958 Not stated Case-control 
Villard-Mackintosh/1993 63/- 1.8 (95% CI: 0.8 to 3.6) Prospective cohort incident study 
Thorogood/1998 114/56 1.2 RR (95% CI: 0.8 to 1.8) Prospective, cohort incident cases. 
Ghadirian/2001 197/202 >15/day 1.4 RR (CI: 0.9 to 2.2) Ever smoked 1.6 OR (CI:1.0 to 2.4) Incident case-control 
Hernan/2001 315 / 128,638 1.6 RR (95% CI: 1.2 to 2.1) Prospective cohort incident study 
Riise/2003 87/23,312 1.81 RR (95% CI 1.1 to 2.9). Case-control population base 
Hernan/2005 201/1,913 1.3 OR (95% CI: 1.0 to 1.7) Prospective nested case±control study, 
Mikaeloff / 2007 129/1038 2.12 (95% CI: 1.43 to 3.15) Population-based, case-control study 
Hawkes / 2007 --- 1.24 RR (95% CI: 1.04 to 1.48) Meta-analysis 
Sundstrom/2008 109/208 2.9 OR (95% CI: 1.3 to 6.3). Matched case-control study 
Jafari/2009 136/204 1.09 OR (95% CI: 0. 68 to 1.73) Family-based matched case-control study 
Hedstrom/2009 902 / 1,855 1.4 OR (95% CI: 1.2 to 1.7) for Male 1.8 OR (95% CI 1.3 to 2.5) for Female Population-based case-control study 
Simon/2010 442 / 865 1.7 OR  (95% CI: 1.1 to 2.6) among those 
with high anti-EBNA titers 3 case-control studies and a nested case-control 
Handel/2010 3,052 / 457,619 1.48  RR (CI 1.35 to 1.63) Meta-analysis 
Carlens/2010 214 / 277,777 1.9  RR (95% CI, 1.2 to 3.1) Cohort incident case-control study 
Alonso/2011 394/394 Female: 6.48 OR (95% CI:1.46 to 28.78) Male 0.72 OR (95% CI: 0.31 to 1.68) Case±control study 
Palacios / 2011 --- 1.50 OR (95%CI: 1.17 to 2.01) Cross-Country and within-country birth cohort analysis 
Hedstrom/2011 843/1209 
1.4 OR (95%CI: 0.9 to 2.1) 
4.9 OR (95%CI: 3.6 to 6.6) 
13.5 OR (95%CI: 8.1 to 22.6) 
Case-control Study 
Sundqvist/2013 552/625 1.30  OR (95%CI: 1.03 to 1.64) Case-control Study 
 3.3 Methodology  
In order to measure the influence of tobacco smoking on the risk of MS 
occurrence, we conducted a case-control study with cases recruited from the 
Nottingham MS registry. In anticipation of including controls from a 
population-based data, questions from the Health Survey for England  2010 
questionnaire were included in the study questionnaire booklet (questions; 6, 
6.6, 6.7, 7.5 and 7.6).  
Obtaining controls from a population-based data not only increased the 
accuracy of our estimates, but also reduced the efforts and costs of finding 
exact matches for a large number of patients. Doing this, we ensured that 
identical questions were answered by both cases and controls in our study. In 
the questionnaire patients were specifically asked whether they have ever 
smoked tobacco product (cigar, cigarette and pipe) and also whether their 
father and/or mother did smoke regularly during their childhood.  
 
3.3.1  Study population 
Study population included patients with definite diagnosis of MS with 
complete detailed smoking history obtained via the questionnaire booklet and 
population-based matched controls (matched for age, sex) randomly obtained 
from the participants in the Health Survey for England 2010. We aimed to 
match two controls for each MS case from the England general population. 
Analyses were conducted while controlling for area of residence. Area of 
residence was defined as the East Midlands health authority.  
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3.3.2 Statistical analysis 
The association of individuals and parental tobacco smoking with MS 
occurrence was estimated using conditional logistic regression for matched 
case±control data. Using identification number and conditional logistic 
regression model enabled us to match each case of MS to its exact age and sex 
controls. A logistic regression model was also used when matching for 
residential area as not enough healthy controls were available for matching 
(only 1350 controls from East Midlands were available from the Health Survey 
for England 2010). This logistic regression model was adjusted for sex, age 
and residential area. Multivariable analysis was performed after initial models 
for each of the confounders. Models were controlled for sex, age and area of 
residence. In the models investigating the association of parental smoking and 
MS occurrence, individual¶s smoking history was also taken into account. All 
statistical analyses were performed with Stata 11 (StataCorp. 2009. Stata 
Statistical Software: Release 11. College Station, TX: StataCorp LP). 
 
3.4  Findings 
A total of 676 cases of MS with fully detailed smoking history with 1349 exact 
age and sex matched controls were included in the model (Table 3-2). Ten 
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Table 3-2: Mean age and number of cases and id matched controls by gender. 
 Male Female Total 
Control  
Number 386 963 1349 
Age (mean) 54.55 52.30 52.94 
Case 
Number 193 483 676 
Age (mean) 54.55 52.26 52.93 
 
 
3.4.1 Individual smoking 
Compared with MS patients, controls started smoking at slightly but 
significantly (P = 0.02) older age. The average age at the start of smoking was 
17.5 in controls compared with 16.8 in MS patients. More than half (51.1%) of 
the MS patients reported a history of regular smoking compared with the 
RIWKHUDQGRPO\VHOHFWHGFRQWUROVLQWKHJHQHUDOSRSXODWLRQȤ2 = 48.8, P 
<  0.001). The percentage of ever-smokers including those who had never 
smoked regularly was also significantly higher in our MS population compared 
with WKHFRQWUROVYVȤ2 = 100.8, P < 0.001).  
As expected, females were more likely to develop MS (OR: 1.94, 95%CI: 1.62 
to 2.32, P < 0.001). We found that regular smokers were 64% (OR: 1.64, 
95%CI: 1.35 to 1.99, P < 0.001) more likely to develop MS than non-smokers. 
Ever-smoking (including non-regular smokers) was associated with 44% 
(95%CI: 1.19 to 1.74, P < 0.001) increase in risk of MS. When controls were 
limited to the East Midlands health authority the MS risk was increased to 2.13 
(95%CI: 1.65 to 2.75, P < 0.001) for regular smokers and 2.14 (95%CI: 1.73 to 
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2.65, P < 0.001) for ever-smokers. Of note, the latter estimates are based on 
non-matched controls and with fewer numbers of individuals.  
3.4.2 Parental smoking during childhood 
We found no association between parental smoking during patients¶ childhood 
and risk of MS occurrence. Parental smoking showed a significant influence on 
our patients smoking habits. MS patients were 52% (OR: 1.52, 95%CI: 1.11 to 
2.08, P = 0.008) and 51% (OR: 1.51, 95%CI: 1.10 to 2.07, P = 0.009) were 
more likely to become regular smokers if the father or mother smoked 
regularly during the subjects childhood, respectively. The risk was further 
increased to 85% (OR: 1.85, 95%CI: 1.26 to 2.73, P = 0.002) when both 
parents smoked regularly during the subjecW¶VFKLOGKRRG  In our age and sex 
matched case-control population, the risk of MS development (accounting for 
LQGLYLGXDO¶VVPRNLQJVWDWXV was 0.88 (95%CI: 0.73 to 1.07, P = 0.22) if the 
mother smoked regularly during the VXEMHFWV¶ FKLOGKRRG )DWKHU¶V regular 
VPRNLQJ GXULQJ VXEMHFWV¶ FKLOGKRRG VKRZHG SURWHFWLYH HIIHFW DJDLQVW
developing MS (OR: 0.79; 95%CI: 0.65 to 0.96, P = 0.02), however became 
LQVLJQLILFDQWZKHQWKHPRGHOZDVFRQWUROOHGIRUPRWKHU¶V smoking status (OR: 
0.82; 95%CI: 0.67 to 1.01, P = 0.07).  
 
3.5  Discussion 
This large UK-based cohort study found and confirmed that tobacco smoking 
is associated with a significant increased risk of MS onset. No evidence of an 
association between exposure to parental smoking during childhood and MS 
 Chapter four: smoking and MS: effects on disability progression and disease severity 
89 
 
occurrence was found. The lack of association with exposure to parental 
smoking during childhood may indicate that second hand exposure is unlikely 
to represent a significant risk of MS amongst offspring of smokers. Our results 
contradict with the results from the previous case±control study by Mikaeloff 
and colleagues (Mikaeloff, Caridade et al. 2007) which found a positive 
association between parental smoking at home and risk of childhood-onset 
MS. We could not investigate the influence of tobacco smoking on the risk of 
childhood-onset MS as only 17 individuals in our population had their first 
attack of MS before age 18 years. A case-control study by Montgomery and 
colleagues (Montgomery, Bahmanyar et al. 2008) found no association 
between MS risk and maternal smoking during pregnancy. This is somehow in 
line with the results from our study as many mothers who have smoked during 
pregnancy are likely to continue to smoke after pregnancy, during their 
RIIVSULQJV¶ FKildhood (Cnattingius, Akre et al. 2006; Janson, Kunzli et al. 
2006). While the association of individuals¶ smoking and risk of MS has been 
extensively established, surprisingly none of the two previous studies 
investigating the role of parental smoking in MS onset has controlled for the 
significant contributory role of individuals¶ smoking habits. Parental smoking 
may play an indirect behavioural role in the development of MS as children of 
smokers are more likely to initiate smoking later in life (Hill, Hawkins et al. 
2005). ,QRXUDQDO\VLVIDWKHU¶VVPRNLQJVKRZHGVRPHSURWHFWLYHHIIHFWVDJDLQVW
MS when tested alone. We could not find any explanation for this but the 
effects diminished when the model was FRQWUROOHG IRU PRWKHU¶V VPRNLQJ
status. Indeed, better measures of parental smoking are required to 
systematically rule out the potential effects of parental smoking in MS. 
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Another case-control study by Hedstrom and colleagues (Hedstrom, 
Baarnhielm et al. 2011) has found that exposure to environmental tobacco 
smoke increases the risk of MS by 30% (95%CI: 1.1 to 1.6). These findings 
are in contradiction with our results. Demographic differences may explain the 
discrepancy.  
Our results KHUH ZLWK UHJDUG WR LQGLYLGXDOV¶ VPRNLQJ are consistent with the 
previous studies showing modest role of tobacco smoking on MS risk. It 
seems, though currently it is not fully understood, that the timing and type of 
exposure to tobacco smoke is an important factor in the risk of MS (Salzer and 
Sundstrom 2013).  
The selection of controls is a major challenge for conducting a case-control 
study. We chose our controls from the England general population, which gave 
us the ability to choose two exact age and sex matched controls for each case. 
A potential bias may result from the 50% non-respondent rate among cases as 
our non-respondents were from more deprived areas which are often associated 
with higher smoking prevalence. Therefore, our risk estimates here may be 
lower than the actual estimates. However, non-respondents had similar 
baseline characteristics to the cases used in our study with no statistically 
significant differences in age and sex distribution (see Table 2-1). 
Nevertheless, the general demographic and clinical features of our cohort of 
respondents were similar to those reported from other MS cohorts. For 
example with regard to the disease phenotype, 58% of our bout onset patients 
had transited to SP MS after median 20 years of follow-up which is almost 
similar to the reported percentage of 66 (after median 23 years of follow-up) in 
the London Ontario cohort (Scalfari, Neuhaus et al. 2010). Slightly more than 
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10% of our patients were diagnosed with PP MS which was also consistent 
with the reports from other MS cohorts (Kingwell, van der Kop et al. 2012).   
(Table 2-1). The basis of the underlying mechanism between smoking and MS 
risk is unclear but various mechanisms have been postulated. These include 
increase risk of infection through immune suppression or stimulation amongst 
smokers and elevation of nitric acid (Hernan, Jick et al. 2005). Some studies 
suggested a dose-response effect of smoking on MS risk (see introduction). 
Our estimated odds ratios in the current study showed higher risk for regular 
smokers compared with ever-smokers including those who have never smoked 
regularly. This shows the potential influence of duration and/or intensity of 
smoking on the risk of MS.  
It is very unlikely that tobacco smoking is the only factor playing a role in the 
complex aetiology of MS. The magnitude of the effects of smoking on MS risk 
is modest, which may indicate potential interactions between tobacco smoking, 
other environmental factors and genetics. For example, smoking has been 
shown to be associated with higher levels of Epstein±Barr virus antibodies 
(Nielsen, Pedersen et al. 2007) and genetic susceptibility (the presence of HLA 
DR15*15 and absence of HLA-A*02) has been shown to influence risk on MS 
(Hedstrom, Sundqvist et al. 2011).  
 
3.6 Conclusion 
In this case-control study we found that individuals¶ tobacco smoking but not 
parental smoking during childhood is associated with increased MS 
susceptibility. A dose response effect may also exist.  










4. Chapter four: smoking and MS. Effects on 
disability progression and disease severity
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4.1 Summary of the chapter 
Smoking is an avoidable exposure that as shown in the previous chapter and 
previously has been linked with an estimated 50% increased risk of developing 
MS. However, it is not entirely clear whether smoking also influences the 
clinical course of the disease. The few studies addressing this issue having 
yielded conflicting results. Hence, it is important to identify the problem and 
design appropriate strategies. 
Our main objective here was to identify whether patients smoking habits have 
any influence on the clinical outcomes of MS. 
In the section 4.2 a comprehensive review of the previous literature is 
presented.  
Section 4.3 describes our methodology and our approach for conducting the 
study. 
Our findings are presented in section 4.4 and the next section, section 4.5 
contains a brief discussion on the influence of tobacco smoking on the risk of 
disability progression and higher disease severity.  




Signs and symptoms of MS are vary from time to time and can change in 
severity and duration. MS can result in physical disability and/or cognitive 
impairments. Table 4-1 summarises some of the most common signs and 
symptoms of MS. 
 
Table 4-1: summary of the most common signs and symptoms of MS 
Visual 
Afferent Pupillary Defect, Optic Neuritis, Diplopia, Nystagmus, 
Ocular Dysmetria, Internuclear Ophthalmoplegia 
Motor 
Paresis, Paraparesis, Hemiparesis, Paraplegia, Hemiplegia, 
Spasticity, Spasms, Cramps, Restless Leg Syndrome, Foot drop, 
Dysfunctional Reflexes 
Sensory 
Paraesthesia, Neuralgia, Neuropathic and Neurogenic pain, 
L'Hermitte's, Proprioceptive Dysfunction, Trigeminal Neuralgia 
Coordination 
and balance 




Frequent Micturition, Urgency,  Bladder Spasticity, Flaccid 
Bladder, Erectile Dysfunction, Constipation,  
Cognitive and 
language  
Depression, Cognitive dysfunction, Dementia, Mood swings, 
euphoria, Bipolar syndrome, Anxiety, Aphasia, Dysphasia 




Since the pioneer work of Courville  in 1964 who first proposed the adverse 
effects of smoking on MS progression (Courville, Maschmeyer et al. 1964), 
studies have reached conflicting results  regarding the potential influence of 
smoking on MS clinical course. Measuring the effects of smoking on 
LQGLYLGXDOV¶ KHDOWK UHTXLUHV FDUHIXO DQG DFFXUDWH PHDVXUHPHQWV RI ILUVW, the 
outcomes used in the studies and second: indiviGXDOV¶ OLIHORQJ VPRNLQJ
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history. Many epidemiologic studies of smoking in MS are subject to two 
inherent biases that may lead to under- or over-estimation of this association. 
First is the causality bias which may occur when patients start or stop smoking 
due to symptoms and second, a healthy smoker bias which suggests that 
current smokers have better state of health compared with ex-smokers 
(Montgomery, Hassan et al. 2013).  This observation can be explained by the 
fact that many of ex-smokers probably quit smoking because of the worsening 
of their symptoms. As a consequence, the remaining current smokers are those 
who have experienced fewer smoking-related symptoms or worsening of their 
MS. Hence, the relationship between smoking and MS may be biased by 
selection of those current smokers which are more healthy and continued to 
smoke. In addition, epidemiological studies of MS have used variety of 
different outcomes which toughens reporting any firm conclusion.  
In 2005, Hernan and colleagues (Hernan, Jick et al. 2005) investigated the risk 
of transition to SP MS in 179 cases of clinically definite MS from General 
Practice Research Database (GPRD) in the UK followed for a median duration 
of 5.3 years. In their study overall 20 patients (15 smokers and 5 non-smokers) 
transited to SP MS during the cohort follow up time. Time to the date at the 
onset of SP MS was assessed using Cox proportional hazard regression 
analysis which revealed a hazard ratio of 3.6 (95%CI: 1.3 to 9.9) for ever-
smokers compared with never-smokers. In contrast with the results from the 
study by Hernan, in 2007 Koch et al. (Koch, van Harten et al. 2007) assessed 
the effects of smoking on the transition to SPMS in 364 MS patients in the 
Netherlands. The study outcomes comprised time to EDSS scores 4 and 6 and 
development of SP MS. Cox proportional hazard regression model was used to 
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estimate the risk of developing SP MS and assessing the time to EDSS scores 4 
and 6 comparing ever- and never-smoking groups, and could not find any 
significant influence of cigarette smoking on disease progression in patients 
with MS. In a study by Di Pauli et al. (Di Pauli, Reindl et al. 2008) in Austria, 
the risk of developing Clinically Definite MS (CD MS) for smokers was 
assessed in 129 patients with the diagnosis of CIS. At the end of 3 years of 
follow up, 44 smokers and 36 non-smokers developed CD MS. Comparison of 
time to CD MS in the two groups suggested a hazard ratio of progression to 
CD MS of 1.83 (95%CI: 1.2 to 2.8) for smokers compared with non-smokers 
(in case all the missing data coded as never-smokers). Ever-smokers also had a 
higher number of lesions on T2-weighted MRI scans (Hazard ratio = 1.20, 
95%CI: 1.10±1.32), but the comparison of EDSS scores after 3 years in the 
two smoking groups did not show any statistically significant difference (P = 
0.9).  
Adverse effects of cigarette smoking on the clinical course of the disease were 
supported in a study by Sundström and colleagues (Sundstrom and Nystrom 
2008) which showed that MS patients who ever smoked are more likely to 
present with the progressive onset MS at the time of diagnosis. In this study 
risk of progression to SP MS was also compared in 122 incidence cases of MS 
with three different smoking statuses. They assessed the effects of smoking in 
SDWLHQWV ZLWK DQ HDUO\ VPRNLQJ VWDUW DJH   ODWH VWDUW  15) and never 
smokers. Higher rate of progressive disease among ever-smokers compared 
with never-smokers was found which was more prominent in smokers with an 
early smoking start age. Additionally, the risk of transition to SP MS was 
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higher among smokers who were also more likely to have PP MS at the time of 
diagnosis.  
The largest study to date assessing the adverse effects of smoking on the 
clinical course of MS was undertaken by Healy and colleagues in 2009 on 
1465 MS cases (Healy, Ali et al. 2009). Despite the significantly higher EDSS 
and MSSS scores in smokers at the baseline, no sign of any change in EDSS 
scores was observed. However, weak evidence of higher T2 hyperintense 
lesion volume (P = 0.02) in MRI scan of smokers compared with never-
smokers and higher risk of transition to SP MS (2.5 HR 95%CI: 1.42 to 4.41) 
for smokers after mean follow up duration of 3.29 years were found. 
Unfortunately, the authors did not include a control group of smokers without 
MS to facilitate the assessment of whether smoking has effects on brain 
imaging measures of smokers without the disease. In a 3-year prospective 
cohort study in Australia (Pittas, Ponsonby et al. 2009) smoking was positively 
associated with an increase in MSSS score. It was shown that current smoking 
is not associated with the possibility of developing a relapse in RR MS patients 
while smoking was associated with an increased risk of PP MS at MS onset.  
Smoking is reported to be associated with some MRI markers of disease 
activity or progression such as increased in number of contrast-enhancing 
lesions, number of T2 lesion volume, number of T1 lesion volume, lateral 
ventricle volume,  third ventricle width and decreased  brain parenchymal 
fraction (Zivadinov, Weinstock-Guttman et al. 2009). Evidence of more severe 
disease (Gholipour, Healy et al. 2011), shorter time to walking aid (D'Hooghe 
M, Haentjens et al. 2012) and higher relapse rate (Mowry, Waubant et al. 
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Almost all of the studies which have investigated the association of cigarette 
smoking and MS progression suggest adverse influences of smoking on the 
progression of the disease and accumulation of disabilities. There are still some 
unsettled questions with regard to the smoking and its effects on MS clinical 
outcomes. For example, the role of age at the smoking initiation, potential 
beneficial effects of smoking cessation and the effects of intensity and duration 
of smoking have not been examined yet. One of the constraints to doing 
research in MS is the lack of standardised definitions. For the studies 
suggesting the effects of smoking on the transition to SP MS, identifying and 
categorising cases correctly is essential to be certain about the results. Most of 
the previous studies lack proper duration of follow up. The fact that EDSS 
score did not change in two of the studies may indicate the inability of the 
studies to identify the influence of the smoking on the disease course when the 
follow up period is relatively short. This brief review shows that there is a 
preeminent need for further population based epidemiologic studies. Current 
evidence seems inadequate to systematically accept the role of tobacco smoke 
in MS. 
The average annual cost to the National Health Service of £30,263 per 
individual makes MS one of the most costly conditions in the United Kingdom 
(Kobelt, Berg et al. 2006; Orme, Kerrigan et al. 2007; Manouchehrinia and 
Constantinescu 2012). Given the fact that MS is a life-long chronic disease and 
with estimated prevalence rates between 84 and 203 per 100,000 population in 
the United Kingdom alone (Ford, Gerry et al. 1998; Rothwell and Charlton 
1998), the impact of MS, in terms of the strain on health services as well as 
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cost, is considerable. It is therefore important to identify means to prevent the 
onset, and slow the progression of MS. 
Smoking is an avoidable exposure that, as shown here, has been linked with an 
estimated 50% increased risk of developing MS in case-control studies 
(Antonovsky, Leibowitz et al. 1965; Ghadirian, Dadgostar et al. 2001; Hernan, 
Olek et al. 2001; Riise, Nortvedt et al. 2003; Hawkes 2007; Hedstrom, 
Baarnhielm et al. 2009; Simon, van der Mei et al. 2010; Hedstrom, Sundqvist 
et al. 2011; Riise, Kirkeleit et al. 2011). However, it is not entirely clear 
whether smoking also influences the clinical course of the disease, the few 
studies, discussed above, addressing this issue having yielded conflicting 
results.  The results of a recent meta-analysis of these studies examining the 
role of smoking in disease progression fell short of statistical significance and 
showed high heterogeneity  (Handel, Williamson et al. 2011). The possible 
correlation between smoking and disease progression in MS is of particular 
interest in view of reports on a negative correlation between smoking and some 
neurodegeneUDWLYHFRQGLWLRQVHJ3DUNLQVRQ¶VGLVHDVHCheckoway, Powers et 
al. 2002)) and some autoimmune disorders (e.g. Ulcerative colitis (Boyko, 
Koepsell et al. 1987)). The evaluation of the magnitude of the effect of 
cigarette smoking on the clinical course of MS may help to determine 
underlying disease mechanisms and is important, as studies have reported a 
high percentage of smokers amongst MS patients (Koch-Henriksen, Bronnum-
Hansen et al. 1998; Marrie, Cutter et al. 2009). Here we examine the effects of 
smoking on the disability progression and explore the potential benefit of 
smoking cessation using data from a well-documented, substantial, clinical 
cohort of patients with MS. 
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Table 4-2: Summaries of some of the studies investigating the impact of smoking on disease outcomes 
Author/Year Sample size Results Outcome of interest 
length of follow-
up (mean or 
median) 
Emre / 1992 21 cases / 11 
controls -- -- -- 
Hernan / 2005 179 cases 3.6 HR (95%CI: 1.3 to 9.9) progression to SPMS 5.3 years 
Koch / 2007 364 cases 
0.97 HR (95%CI: 0.65 to 1.46) 
1.11 HR (95%CI: 0.63 to 1.97) 
0.93 HR (95%CI: 0.66 to 1.33) 
0.88 HR (95%CI: 0.61 to 1.28) 
age at the progression to SPMS 
age at the progression to PPMS 
time to EDSS 4.0 
time to EDSS 6.0 
-- 
Di Pauli / 2008 129 cases 1.8 HR (95%CI: 1.2 to 2.8) Conversion to clinically definite MS 3 years 
Sundstrom / 
2008 122 cases 2.4 HR (95%CI: 0.96 to 6.0) Risk for progressive disease 6 years 
Healy / 2009 1465 cases 
2.5 HR (95%CI: 1.42 to 4.41) 
P = 0.02 
Not Significant 
progression to SPMS 
T2 hyperintense lesion volume 
EDSS progression 
3.29 years 
Pittas / 2009 198 cases 
0.34 (95%CI: 0.28 to 0.66) 
0.41 (95%CI: 0.03 to 0.85) 
0.99 (95%CI: 0.41 to 1.58) 
increase in mean MSSS 0 to 1 Pack-Year 
increase in mean MSSS 1 to 2 Pack-Year 
increase in mHDQ06663DFN-Year 
909 days 
Zivadinov / 2010 368 cases 
P = 0.004 
Increased, P = 0.001 
Increased, P = 0.009 
Increased, P = 0.003 
Decrease, P = 0.047 
Increased, P = 0.001 
Increased, P = 0.023 
Increased EDSS score 
number of contrast-enhancing lesions 
number of T2 lesion volume 
number of T1 lesion volume 
brain parenchymal fraction 
lateral ventricle volume 
third ventricle width 
Cross-sectional 




We used multiple analysis approaches to measure the influence of smoking on 
the clinical course of MS. Likelihood of developing progressive onset MS, 
differences in average severity score, time to EDSS score milestones 4 and 6 
and also time to SP MS were examined between smoking groups using 
appropriate statistical models. The effects of age at smoking initiation and 
number of pack-years smoked ((number of cigarettes smoked per day × 
number of years smoked) ÷ 20)) were also examined. 
Descriptive statistics were used to summarise the baseline demographic 
characteristics and clinical outcomes. We examined the association between 
smoking and the type of MS at its onset (RR MS or PP MS) using logistic 
regression models. Linear regression models were used to determine the effects 
of pack-years of cigarettes smoked on the severity of the disease and level of 
disability measured by MSIS-29 and PDDS scores. The numbers of pack-years 
smoked were categorised into three categories of non-smokers, less than 10 
pack-years and more than 10 as previously used by Koch and colleagues 
(Koch, van Harten et al. 2007). Detailed models were adjusted for onset age, 
sex, type of MS at the onset of the disease (RR vs. PP) and use of treatment. 
The disease phenotype was stratified into two binary groups of RR MS vs. PP 
MS. Although it may be interesting to look at differences between SP MS and 
PP MS in term of the influence of smoking on the progression of the disease, 
such analysis requires additional data including exact date of transition to SP 
MS which was not available for all the patients in our dataset. If the SP MS 
patients were going to be included in the analysis as a separate, bias might 
have arisen by using post-baseline values for modelling were data was missing 
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on the date of transition in many of the patients. If the most recent value before 
end of follow-up (2013) was used this could have introduced bias in estimating 
the hazard for PP MS and SP MS by lack of data on the date of transition to SP 
MS in many of the patients. Using the value at baseline was the approach that 
could eliminate this potential bias.   
Although regression models of large sample size are robust to some degree of 
non-normality (Lumley, Diehr et al. 2002), all the linear models were 
controlled for homogeneity and distribution of residuals to avoid violation of 
underlying normality assumption. 
Time to two EDSS milestone scores of 4 and 6 and to the onset of SP MS were 
estimated using the Kaplan-Meier method taking into account participation of 
those that has not yet reached the events. The smoking-specific rate ratios were 
calculated using Cox proportional hazard regression models (Cox and Oakes 
1984) controlled for sex, onset age (continuous in years), use of DMTs (in a 
ELQDU\JURXSRI \HDURU \HDU DQG LQLWLDO FOLQLFDOFRXUVHRI WKHGLVHDVH
(RR vs. PP). Cox regression models were also used to estimate the rate ratios 
of reaching MSSS score categories 5 or above (patient progress faster than half 
of the MS population) between smoking groups. Age is one of the most 
important factors in accumulation of disabilities in MS and the hazard will 
significantly change as a function of age. To account for this, patients in the 
cohort were followed from the date of birth, entered the study at the age at the 
onset of the disease (left truncation or late entry) and exited at their 
event/censoring age. This way the impact of age was controlled for more 
effectively (Korn, Graubard et al. 1997). The final Cox models were checked 
for proportionality assumption based on the Schoenfeld residuals and were 
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stratified by the factor violating the proportionality. A comparison of the 
effects of smoking on the likelihood of patients being in the upper quartiles 
(MSSS > 7.5) versus lower quartiles (MSSS < 2.5) of the MSSS spectrum was 
made using logistic regression model to ensure the robustness of the results 
when using MSSS as an outcome of interest. The use of extreme ends of the 
MSSS spectrum allows comparison of those with somehow an atypical disease 
clinical course compared with the majority of patients. Where possible (due to 
violation of normality assumptions) we also used MSSS in linear regression 
models. All statistical analyses were performed with Stata 11 (StataCorp. 




Clinical and demographic data were available for 1245 patients. This included 
681 patients with detailed smoking history.   
 
4.4.1 Likelihood of progressive onset MS 
We could not find any association between smoking and having progressive 
onset MS (PP MS). While controlling for sex and onset age, risk of developing 
PP MS was not associated with smoking. Pack-years smoked before the onset 
of MS was also not associated with the risk of progressive onset MS. As 
expected, male patients and those with older age at the onset of MS were more 
likely to develop PP MS (Table 4-3). As seen, each year increase in the age at 
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the onset of the disease was associated with 9% (95%CI: 7 to 11) increase in 
the risk of having progressive onset MS. 
 
Table 4-3: Relation between cigarette smoking and progressive onset MS.  
 n Odds ratio (95%CI) P-value 
Smoking (ever vs. never) 1166 0.82 (0.54 to 1.24) 0.36 
Smoking* (ever vs. never) 657 0.88 (0.49 to 1.59) 0.68 
Pack-years smoked 615 1.00 (0.98 to 1.02) 0.90 
Gender (female vs. male) 1166 0.34 (0.22 to 0.52) < 0.001 
Onset age 1166 1.09 (1.07 to 1.11) < 0.001 
* Patients are limited to those with returned questionnaire. 
4.4.2 Disease severity 
Average MSSS was 4.73 (±2.6) in our cohort. All the analyses in this section 
were conducted on data from those patients who returned the questionnaire and 
had detailed smoking data for calculating pack-years smoked and age at 
smoking initiation (n = 645). We used the linear regression model to measure 
the average MSSS differences between groups. Models were controlled for 
onset age, initial disease course, use of DMT and gender. Ever-smokers had an 
average 0.5 (95%CI: 0.11 to 0.87, P = 0.01) MSSS higher than never-smokers. 
Compared with never-smokers, the average MSSS was 0.8 (95%CI: 0.26 to 
1.35, P = 0.004) and 0.35 (95%CI: -0.07 to 0.77, P = 0.1) higher in current and 
ex-smokers respectively. Age at smoking initiation did not influence the 
disease severity as average MSSS was not different between those who had 
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started smoking before or after the age of 15 years (Coef: -0.18, 95%CI: 0.79 
to 0.41, P = 0.54). The number of pack-years smoked had a significant effect 
on the average MSSS. Those with pack-years smoked more than 10 had an 
average 0.62 (95%CI: 0.17 to 1.06, P = 0.006) MSSS higher than non-smokers 
(zero pack-years). Pack-years smoked from 1 to 10 was associated with 0.26 
(95%CI: -0.28 to 0.81, P = 0.34) score increase in the severity of MS 
compared with non-smokers. Kaplan-Meier method was used to estimate the 
time to MSSS > 5.0 in different smoking groups. The estimated median time to 
MSSS > 5.0 from birth was 51 (95%CI: 47 to 55) years in current smokers, 57 
(95%CI: 55 to 58) years in ex-smokers and 57 (95%CI: 55 to 59) in non-
smokers. Log-rank test for equality of survival function showed significant 
difference between time to MSSS > 5.0 amongst these smoking groups (P < 
0.001) (Figure 4-1). 
 
Figure 4-1: Kaplan-Meier estimates shows median time to MSSS > 5 from birth by 
smoking status 
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When stratified by smoking status, comparison of two upper and lower quartile 
MSSS showed significant difference in the proportion of patients in each 
quartile Ȥ2 = 10.51, P = 0.005). While 20% of patients in upper quartile MSSS 
were current smokers only 10% were current smokers in the lower quartile and 
63% of patients in the lower quartile were non-smokers compared with 45% in 
the upper quartile MSSS. Likelihoods of being in the upper quartile MSSS 
were obtained from the logistic regression model when controlling for onset 
age, initial phenotype of the disease and gender (Table 4-4). Each cigarette 
smoked per day was associated with an average 0.03 (95%CI: 0.1 to 0.4, P < 
0.001) increase in MSSS.  
 
 
Table 4-4: likelihoods of being in the upper quartile MSSS (MSSS > 7.5) compared 
with lower quartile (MSSS < 2.5) 
 







1.3 (0.7 to 2.42) 







1 to 10 
More than 10 
 
--- 
1.06 (0.45 to 2.49) 





Odds ratios obtained from logistic regression models by current smoking status and 
pack-years of cigarettes smoked. 
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4.4.3 PDDS and MSIS-29 scores 
Median PDDS score was 4 (range from 0 to 8) in our patients. Similar to 
MSSS, the PDDS score was significantly influenced by patients smoking 
status. We used multiple regression models to measure the differences between 
smoking groups in terms of PDDS score while controlling for the usual 
confounders including onset age, disease duration, sex, initial disease 
phenotype and use of treatment. Our analysis showed that the average PDDS 
was 0.41 (95%CI: 0.09 to 0.73, P = 0.01) score higher in ever-smokers 
compared with never-smokers. Smoking cessation appeared to have beneficial 
effects. The average PDDS score was 0.71 (95%CI: 0.25 to 1.17, P = 0.002) 
score and 0.27 (95%CI: -0.07 to 0.63, P = 0.12) score higher in current and ex-
smokers compared with non-smokers respectively. Due to the non-normal 
distribution of PDDS score normality assumption behind the regression models 
was tested after each analysis (Figure 4-2).  
 
Figure 4-2: the Kolmogorov-Smirnov test for equality of distribution functions in 
PDDS 
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Using MSIS-29 as an outcome limited our analysis choices as no linear 
regression model could be used due to the violation of the underlying 
normality assumption. Hence, our analysis of MSIS-29 here is limited to a 
non-parametric test (Kruskal-Wallis one-way analysis of variance) of 
hypothesis to investigate the differences amongst smoking groups.  
Table 4-5 presents median MSIS-29 (range from 29 to 145), MSIS 
psychological scale (range from 9 to 45) and MSIS physical scale (range from 
20 to 100) scores stratified by current smoking status, gender and MS initial 
clinical course. Detailed analysis of MSIS-29 psychological scale showed 
higher level of impairments and disability for ever-smokers in all the questions 
asked (Table 4-6). 
 
Table 4-5: median MSIS-29 scores by smoking status 
 Non-smokers Ex-smokers Current smokers P-value * 
MSIS-29 77 92 90 < 0.001 
MSIS 
(physical scale) 56 65 67 < 0.001 
MSIS 
(psychological scale) 21 26 28 < 0.001 
MSIS-29: multiple sclerosis impact scale 
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Table 4-6: MSIS-29 psychological scale amongst smoking groups. 















Feeling unwell? 2.4 
(±1.24) 
2 ( 1 to 3) 2.74 
(±1.3) 
3 ( 2 to 4) < 0.001 
Problems sleeping? 2.45 
(±1.4) 
2 ( 1 to 4) 2.66 
(±1.37) 
3 ( 1 to 4) 0.02 
Feeling mentally fatigued? 2.92 
(±1.34) 
3 ( 2 to 4) 3.36 
(±1.31) 
4 ( 2 to 4) < 0.001 




2 ( 1 to 3) 2.73 
(±1.39) 
3 ( 2 to 4) 0.001 
Feeling anxious or tense? 2.44 
(±1.28) 
2 ( 1 to 4) 2.78 
(±1.34) 
3 ( 2 to 4) < 0.001 
Feeling irritable, 




2 ( 1 to 3) 2.92 
(±1.33) 
3 ( 2 to 4) < 0.001 
Problems concentrating? 2.68 
(±1.34) 
2 ( 2 to 4) 3.06 
(±1.3) 
3 ( 2 to 4) < 0.001 
Lack of confidence? 2.48 
(±1.39) 
2 ( 1 to 4) 2.84 
(±1.44) 
3 ( 2 to 4) < 0.001 
Feeling depressed? 2.11 
(±1.29) 
2 ( 1 to 3) 2.61 
(±1.4) 
2 ( 1 to 4) < 0.001 
* P-value from Mann-Whitney test for differences in medians between ever- and 
never-smokers. 
 
4.4.4 Time to EDSS score milestones 4 and 6 
Data needed (including information regarding whether patient has reached the specific 
EDSS score milestone and if yes at what age) to estimate the time to EDSS score 4 
was available in 1026 of 1246 patients (82.3%) and data to estimate the time to EDSS 
score 6 was available in 1090 (87%). Form 1026 patients, 628 patients had reached 
EDSS score 4 in median 14 (95%CI: 13 to 15) years after the disease onset and 
median age of 49 (95%CI: 48 to 50). For time to EDSS score 6, from 1090 patients 
with available data, 530 patients had reached EDSS score 6 in median 20 (95%CI: 18 
to 21) years after the disease onset and median age of 53 (95%CI: 52 to 54).  
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Amongst those patients with returned questionnaire time to EDSS score 4 could be 
estimated in 83.3% and time to EDSS score 6 in 87.5% of patients. In this group of 
patients, 337 patients (of 577) had reached EDSS score 4 and 279 (of 607) had 
reached EDSS score 6. Table 4-7 summarises the median time to two EDSS score 
milestones 4 and 6 amongst smoking groups.  
We estimated the smoothed hazard of reaching EDSS score 6 in males and females 
(Figure 4-3), relapsing and progressive onset MS (Figure 4-4) and ever- and never-
smokers (Figure 4-5) in all the 1245 patients. Our estimated time to EDSS score 6 
from the onset of the disease (20 years (95%CI: 18 to 21)) is comparable with the 
results reported from Lyon, France and Flemish MS register (Confavreux, Vukusic et 
al. 2000; D'Hooghe M, Haentjens et al. 2012) with reported median time to EDSS 
score 6 of 21 years, although it is shorter than the 27.9 years found in British 
Columbia cohort (Tremlett, Paty et al. 2006) and 28.6 years in Olmsted County, 
Minnesota (Pittock, Mayr et al. 2004).  
 
Table 4-7: Median times to EDSS score milestones 4 and 6 from the birth and onset of 
MS by ever- and never-smoking status 
 
From the disease 
onset (95%CI) P-value 
From birth 
(95%CI) P-value 
Time to EDSS score 4     
Never-smoked 15 (14 to 18)  
< 0.001 
44 (41 to 46) 
 
< 0.001 Ever-smoked 13 (11 to 14) 38 (16 to 43) 
Time to EDSS score 6  
   
Never-smoked 21 (18 to 25)  
0.001 
50 (48 to 52)  
0.01 Ever-smoked 19 (16 to 21) 43 (16 to 49) 
EDSS: expanded disability scale status 
CI: confidence intervals 









Figure 4-4: Smoothed hazard estimates of reaching EDSS score 6 by MS initial 
clinical course 
 




Figure 4-5: Smoothed hazard estimates of reaching EDSS score 6 by SDWLHQWV¶ life-
long smoking status (regular smoking) 
 
Cox proportional hazard regression models were used to estimate the risk of 
reaching EDSS scores 4 and 6. With the models controlled for onset age, 
DMT, MS onset phenotype and gender, ever-smoking was associated with 
20% (95%CI: 1.00 to 1.42, P = 0.04) increased risk of reaching EDSS score 6 
and 32% (95%CI: 1.12 to 1.55, P = 0.001) increased risk of reaching EDSS 
score 4. Our further analyses of the effects of current smoking status on the 
risk of reaching the two EDSS milestones were limited to the patients with the 
returned questionnaire. At the age of EDSS score 4, 20.75% and 30% of the 
patients were current and ex-smokers respectively. This was not changed 
significantly at the age of EDSS score 6. At the time of EDSS score 6, 20.45% 
and 30.3% were current and ex-smokers respectively. The Cox regression 
models showed that smoking cessation could be beneficial in reducing the risk 
of reaching EDSS score 4. In our cohort current smokers had 88% (95%CI: 
1.43 to 2.48, P < 0.001) higher risk of reaching EDSS score 4 compared with 
non-smokers. Ex-smokers had no increased risk of reaching EDSS score 4 
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compared with non-smokers (HR: 0.93, 95%CI: 0.72 to 1.20, P = 0.6). When 
ex-smokers were stratified to those who gave up smoking before and after the 
disease onset, smoking cessation after the onset of MS was still beneficial. 
Risk of reaching EDSS 4 was 14% (95%CI: 0.84 to 1.54, P = 0.37) for patients 
who gave up smoking after the onset of MS and 12% (95%CI: 0.83 to 1.52, P 
= 0.44) for those who developed MS after smoking cessation compared with 
non-smokers. Risk of reaching ('66VFRUHZDVDOVRLQIOXHQFHGE\SDWLHQWV¶
smoking status. Similar to the risk of reaching EDSS score 4, current smokers 
had 66% (95%CI: 1.17 to 2.35, P = 0.004) higher risk of reaching EDSS score 
6. There was no increased risk of reaching EDSS score 6 in ex-smokers (HR: 
0.81, 95%CI: 0.58 to 1.12, P = 0.21) whether they quit before or after MS 
onset (Figure 4-6).  
 
Figure 4-6: Left: Kaplan-Meier graph shows time to EDSS score 4 by patients' 
smoking status adjusted for durations and intensity of smoking. Right: Kaplan-Meier 
graph shows time to EDSS score 6 by patients' smoking status adjusted for durations 
and intensity of smoking. 
 
We then investigated the influence of smoking intensity and time since 
smoking cessation on the risk of reaching EDSS score milestone 6 while 
dealing with the smoking duration as a time varying covariate. The intensity of 
smoking was significantly associated with the risk of reaching EDSS score 6. 
We found that each cigarette smoked per day was associated with 3% (95%CI: 
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1.01 to 1.05, P < 0.001) increased risk of reaching EDSS score 6. Each year 
increase in the time since cessation of smoking was associated with 5% (HR: 
0.95, 95%CI: 0.93 to 0.97, P < 0.001) decreased risk of reaching EDSS score 6 
(Figure 4-7).  
   
Figure 4-7: Relative hazard of reaching EDSS score 6 plotted against left, time since 
smoking cessation, right, intensity of smoking 
 
 
4.4.5 Time to SP MS 
Data needed to estimate the time to the onset of SP MS was available in 735 
patients (including RR MS patients who had not transited to SP MS). In total 
130 patients had transited to SP MS during the study period. Median age at the 
time of transition to SP MS was 61 (95%CI: 59 to 67) years. We could not find 
any differences in time to SP MS between ever- and never-smokers (P = 0.58). 
Also, no influence of ever- or never-smoking on the risk of SP MS was evident 
when using Cox hazard regression model. After controlling for onset age, 
treatment and gender, the risk of transition to SP MS was independent of 
SDWLHQWV¶ VPRNLQJ VWDWXV +R: 1.16, 95%CI: 0.81 to 1.65, P = 0.39). Further 
stratification of ever-smokers into current and ex-smokers showed significant 
effect of current smoking on the risk of developing SP MS. We found that 
current smokers have 2.38% (95%CI: 1.39 to 4.08, P = 0.001) higher risk of 
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developing SP MS. The risk of transition to SP MS was not increased amongst 
ex-smokers compared with non-smokers (HR: 0.9, 95%CI: 0.54 to 1.51, P = 
0.71) (Figure 4-8). Pack-years cigarettes smoked also showed a significant 
impact on the risk of transition to SP MS. In our Cox regression model, each 
unit increase in the pack-years smoking was associated with 1% (95%CI: 
1.001 to 1.02, P = 0.03) increased risk of developing SP MS. Each year 
increase in time since smoking cessation was associated with 3% decreased 
risk of developing SP MS (HR: 0.97, 95%CI: 0.95 to 0.99, P = 0.04). 
 
Figure 4-8: Kaplan-Meier graph showing time to SP MS from birth by patients' 
smoking status adjusted for intensity and duration of smoking 
 
 
4.4.6 Effects of comorbidity 
Comorbidity in MS is complex in terms of diagnosis and classification. In this 
part of the analysis we intended to only use the data from those patients with 
no concomitant comorbid condition. The comorbidity data used here was 
based on the data collected from the patients at the time of diagnosis and/or 
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their routine clinic follow-ups. In order to validate the comorbidity information 
in our database, data from 28 (10%) randomly selected patients in our subset 
analysis of comorbidity was independently rechecked for report of any 
concomitant comorbid condition using hospital electronic records. From the 28 
patients, 21 had no comorbid condition reported, two were using treatment for 
depression, however, it was felt that depression is secondary to MS. One 
patient had cholecystectomy in the past, one had psoriasis in the leg which 
required 2 sessions of phototherapy, one patient had uterine fibroids and two 
patients had the diagnosis of osteoporosis. Overall, there was more than 80% 
agreement between the data recorded in the database and those rechecked later. 
As expected the prevalence of concomitant comorbid diseases was 
significantly higher in ever-smokers (58% in ever-smokers vs. 42% in never-
smokers, P = 0.002). In order to measure the influence of higher comorbidity 
prevalence on our outcomes, we compared the average MSSS amongst 
smoking groups and measured the risk of reaching EDSS score milestone 6 
amongst those patients who had no reports of concomitant comorbid 
conditions which could have interfered with the disability scores.  
When the analysis was limited to the patients with no concomitant medical 
condition, the average MSSS was still significantly higher in ever-smokers 
compared with never-smokers (Coef: 0.89, 95%CI: 0.46 to 1.32, P < 0.001). 
Average PDDS score was also significantly 0.77 (95%CI: 0.31 to 1.23, P = 
0.001) score higher in ever-smokers compared with never-smokers. 527 
patients with available data on time to EDSS score 6 and no concomitant 
comorbid condition were included in our survival analysis. After stratifying the 
model by sex and controlling for the disease initial clinical phenotype, onset 
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age and use of treatment, ever-smokers had 34% (95%CI: 1.02 to 1.75, P = 
0.03) higher risk of reaching EDSS score 6.  
 
4.4.7 Correlation between outcomes 
Table 4-8 summarises the Spearman correlation coefficient between outcomes 
used in our study. The highest correlation was seen between EDSS score and 
MSSS and the lowest were between MSIS-29 and MSSS score. Nevertheless, 
the impact of smoking was evident on all the outcomes used in our research.   
 
Table 4-8: correlation between outcomes used in our research 
 PDDS EDSS MSSS MSIS-29 
PDDS 1 
   
 
    
EDSS 0.8616 1 
  
P-value < 0.001 
   
MSSS 0.7054 0.9098 1 
 
P-value < 0.001 < 0.001 
  
MSIS-29 0.7104 0.6262 0.5432 1 
P-value < 0.001 < 0.001 < 0.001 
 
P-values from Spearman correlation coefficient with Bonferroni adjustment. 
EDSS: expanded disability scale status 
MSIS-29: multiple sclerosis impact scale 
MSSS: multiple sclerosis severity score 
PDDS: Patient Determined Disease Steps 
 





Figure 4-9: Matrix graph showing correlation between outcomes used in our research 




In this study, we found that disease progression is more rapid in ever-smokers. 
Current smoking in our cohort was associated with a significant increase in all 
of the clinical outcomes (PDDS, MSIS-29, time to SP MS and EDSS scores). 
Here we present, to our knowledge for the first time, evidence on the potential 
beneficial effects of smoking cessation on disability progression in MS 
patients. By using MSIS-29 psychological scale, we also showed that the 
HIIHFWV RI WREDFFR VPRNLQJ RQ SDWLHQWV¶ TXDOLW\ RI OLIH DUH EH\RQG SK\VLFDO
impairments. Our ever-smokers had significantly higher levels of sleep 
problems, anxiety, fatigue, etc. We found that ex-smokers have a significantly 
reduced risk of reaching EDSS score milestones 4 and 6 as well as SP MS 
compared with current smokers, and that this risk reduction was similar 
between those who stopped smoking before or after the onset of MS and each 
outcome. Thus, there are positive effects of smoking cessation on disease 
progression even after MS onset. Our study provides new, important clinical 
findings on the influence of tobacco use in a cohort of patients with MS. We 
used a population of MS patients, all with clinically definite MS confirmed by 
MS specialist neurologists. Most importantly, our clinic and consequently our 
cohort, has a population based nature as it is estimated to cover majority of the 
MS patients in Nottinghamshire and defined parts of Lincolnshire and 
Derbyshire regions. Our findings are based on diagnosis, identification and 
classification of patients and like any other study may be subject to bias in 
ascertainment, recruitment, and misclassification of status. However, the fact 
that the confirmation of the diagnosis and the disability scores in our study 
were obtained from a clinical database of MS specialist neurologists increases 
 Chapter four: smoking and MS: effects on disability progression and disease severity 
120 
 
the homogeneity and integrity of our results. Thus, our findings are robust, and 
characteristics such as gender distribution, age of onset and type of MS 
distribution of our cohort are similar to those reported in most other MS 
cohorts. Thus our sample population appears to be representative of the MS 
population at large and our findings can be generalised and are reflective of 
routine clinical practice. Our study has some limitations that may have 
influenced our estimates. It is likely that our cohort missed some patients with 
very severe disease who died before attending our MS clinic.  
We believe our study is one of the most comprehensive studies to examine the 
correlation of tobacco smoking and MS clinical outcomes, with particular 
emphasis on disability progression. In a study of a United Kingdom 
population, Hernan and colleagues found a risk ratio of 3.6 (95%CI: 1.3 to 9.9) 
for transition to SP MS in 179 cases of MS with median 5.3 years follow-up 
using the General Practice Research Database (Hernan, Jick et al. 2005). In our 
study we could not find any influence of ever-smoking on the risk of transition 
to SP MS. What we found was that current smoking was significantly 
associated with the risk of developing SP MS but not ever-smoking. We also 
estimated the risk of reaching EDSS score 6 which is a robust outcome 
measure and almost a surrogate of time to SP MS (Scalfari, Neuhaus et al. 
2010) and also allows inclusion of PP MS. Using these outcomes we found a 
higher risk ratio of reaching EDSS score 6 in smokers, although the risk ratio 
was lower than the risk ratio reported by Hernan et al. for development of SP 
MS. While the risk ratios were in the same direction, differences in patient 
sample size (1245 in our study vs. 179 in the Hernan et al study), longer 
duration of follow-up (20 vs. 5.3), and number of patients reaching the 
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outcome (450 vs. 20) may account for the difference. Others have also used 
time to EDSS 4 and 6 however with no significant evidence of association 
between cigarette smoking and progression (Koch, van Harten et al. 2007). We 
believe that greater sample size and longer duration of follow-up makes our 
estimates more robust. Our results are in accordance with the results from an 
observation by D'hooghe et al. which showed higher risk of reaching EDSS 
score 6 amongst occasional and daily cigarette consumers (D'Hooghe M, 
Haentjens et al. 2012). D'hooghe and colleagues relied on questionnaires for 
obtaining data on disease onset and self-reported disability scores which may 
introduce some bias. The advantage of our study is its higher homogeneity in 
terms of clinical data used such as disease type and EDSS scores which were 
based on face to face patient examination and recorded by MS specialist 
neurologists. By comparing the two lower and upper MSSS quartiles we 
showed that smokers are more likely to have a severe disease course as shown 
previously (Gholipour, Healy et al. 2011).  A higher probability of progressive 
onset amongst smokers has been observed previously (Sundstrom and Nystrom 
2008; Healy, Ali et al. 2009); however, our estimate in a much larger sample 
showed no evidence that smoking favours a progressive onset of the disease.  
Smoking is known to be a significant risk factor for the development and 
progression of several autoimmune diseases (Prummel and Wiersinga 1993; 
Saag, Cerhan et al. 1997; Hardy, Palmer et al. 1998; Hudson, Lo et al. 2011) 
and is a frequently studied health behaviour because of its well-known 
associations with chronic diseases. Since disease progression is more rapid in 
ever-smokers, preventing smoking may be important in reducing the 
progression of MS. Estimating the impact of smoking in terms of costs shows 
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its relevance. Costs of MS (direct and indirect) can increase by nearly twofold 
in patients with EDS6VFRUHWRFRPSDUHGZLWKWKRVHZLWK('66VFRUH
from £7,273£ to £12,875 per patient per year (Kobelt, Berg et al. 2006). In the 
UK, it has been estimated that each quality adjusted life year gained in MS by 
means of DMTs costs from £18,700 to £25,500 (Gani, Giovannoni et al. 2008). 
Based on our results and compared to these figures, preventing or stopping 
smoking could be an economical strategy and an effective way to improve 
outcomes in MS which can be implemented along other MS therapeutic 
approaches.  
It is not entirely clear whether this additional increase in impairment and 
disability in smokers is purely due to the biological influence of tobacco 
smoking on MS specifically, or is due to other underlying factors such as 
increase in comorbidities associated with smoking. It has been previously 
reported that smokers with MS are more likely to report comorbid autoimmune 
diseases (Marrie, Horwitz et al. 2011). Here we also showed that ever-smokers 
are significantly more likely to have concomitant comorbid diseases. 
Comorbidity has been hypothesised to be liable for parts of the progression 
seen in ever-smokers. We tested the hypothesis by limiting our analysis to the 
patients with no reported concomitant medical condition. The effects of 
smoking on the selected outcomes were still present even in the absence of any 
concomitant medical condition. This finding indicates that tobacco smoking 
may have direct biological impact on the clinical course of MS. There are lines 
of evidence that suggest a potential pathophysiological role of tobacco smoke 
on the progression of the disease in MS. Of note, findings from MRI studies, 
evidence on the negative impact of smoked tobacco but not moist snuff on risk 
 Chapter four: smoking and MS: effects on disability progression and disease severity 
123 
 
of MS as demonstrated by Hedstrom and colleagues (Hedstrom, Baarnhielm et 
al. 2009) as well as a significant association between smoking intensity and 
disease severity (dose-response rate) as demonstrated in our study may suggest 
a direct impact of tobacco smoke on MS progression. Nevertheless the 
possibility of an indirect impact of smoking on MS progression, or a 
combination of direct and indirect effects cannot be excluded. There are some 
likely biological explanations for a mechanistic pathway between smoking and 
disability accumulation in MS (Pryor, Stone et al. 1998; Bijl, Horst et al. 2001; 
Malkawi, Al-Ghananeem et al. 2009). Exposure to tobacco smoke has been 
shown to alter the innate and adaptive immune cells (Holt and Keast 1977). 
Increased risk of cancer, cardiovascular and other chronic diseases amongst 
smokers may possibly be related to smoking-induced changes in the immune 
system. Further work is needed to elucidate the mechanism by which smoking 
increases the risk of progression in MS.  
 
4.6 Conclusion 
In summary, we found that ever-smokers with MS accumulate more disability 
over a shorter period of time, reach progressive stage faster, have higher level 
of psychological and physical impairments and disabilities and suffer from 
more severe disease than never-smokers. Our findings point toward the 
beneficial effect of smoking cessation even after the disease onset in patients 
with MS. Measures to prevent and reduce smoking may lead to improved 
outcomes in MS.  We observed that the longer the time since smoking 
cessation, the lower the risk of reaching disability scores milestones in older 
















5.1 Summary of the chapter 
Mortality in patients with MS has been studied in several populations but not 
many studies have evaluated environmental factors associated with increased 
PRUWDOLW\ULVN7KHFXUUHQWZRUNZDVXQGHUWDNHQWRGHWHUPLQHZKHWKHUSDWLHQWV¶
life style and in particular their smoking habits can describe some of the excess 
mortality reported in MS populations.  
In the next section, section 5.2, we performed a systematic review and pooled 
meta-analysis of standardised mortality ratios obtained from the previous 
studies of MS mortality. We believe that this has been able to summarise the 
mortality in MS more effectively. 
We then performed a survival analysis to investigate the influence of tobacco 
smoking on the risk of death due to all-cause mortality in MS patients. Section 
5.3 discussed our methodology.  
The findings of our analyses were presented in section 5.4.  
Section 5.5 discusses our findings and presents implication, generalisation and 






MS is an unpredictable and disabling disease and individuals with MS are 
found to have a life expectancy shorter than the general population (Scalfari, 
Knappertz et al. 2013).  It has been shown that patients with the diagnosis of 
MS usually live 7 to 14 years shorter than their counterparts in the general 
population (Scalfari, Knappertz et al. 2013). In MS it has been hypothesised 
that the excess mortality is mainly due to the enhanced susceptibility to 
concomitant comorbid diseases such as infection or complications raised from 
severe disability rather than direct impact of physiological changes in the brain 
and spinal cord. To date several studies which examined excess mortality in 
MS have suggested an increased risk of death in MS patients compared with 
the general population, but the results are not consistent in all the studies and 
long survivals in MS patients have also been reported frequently. In 2013, 
Scalfari and colleagues (Scalfari, Knappertz et al. 2013) reviewed the current 
literature of mortality in MS and accurately pointed out two very important 
issues in the way of reaching meaningful conclusions regarding mortality in 
MS patients. First, from the current literature it is not entirely clear whether the 
improved survival in MS patients is also seen when the survival rates are 
compared with the rates from the general population. Second, data with regard 
to the influence of gender on the mortality rates is contradicting.  
Due to the ambiguity of the results we performed a pooled meta-analysis of 
studies with report of standardised mortality ratios (SMR). SMRs will enable 
us to investigate whether mortality rates in MS patients are different from 
those reported from the general population. In addition to this we measured the 




in the current work concerns the gender difference in the SMRs in MS patients 
as it is commonly believed that female patients have survival advantage over 
males. We investigated whether mortality in MS patients has changed during 
the past decades compared with the general population. 
 
5.2.1  Design and Methodology 
5.2.1.1 Data source 
Medline, Embase and the Cochrane Library up to May 2013 were searched 
XVLQJ WKH NH\ZRUGV ³0XOWLSOH 6FOHURVLV´ DQG ³VWDQGDUGLVHG PRUWDOLW\´ RU
³VWDQGDUGL]HG PRUWDOLW\´ The search resulted in a number of publications 
which were identified and screened.  
 
5.2.2 Inclusion criteria 
Inclusion criteria were availability of data on the number of deaths and mean 
or median patient follow-up, reports of SMR and being a longitudinal study. 
For multiple studies using the same cohort, the study with the longest duration 
of follow-up was used that met the study inclusion criteria.  
5.2.3 Data extraction 
Total number of patients, number of deaths, mean or median duration of 
follow-up, person-year, type of the study, study onset and publication date 
were extracted from the papers. Incidence mortality rates (IMR) with 95% 
confidence intervals were calculated. SMR with 95% confidence intervals 




5.2.4 Data analysis 
For each study, IMR was calculated as follows: number of deaths during the 
study follow-up period divided by the mean (or median if mean was not 
available) number of patients during the study follow-up multiplied by the 
mean or median patient follow-up or total person year follow-up time. The 
IMRs and SMRs then were pooled by the method of the inverse of the 
variance. Natural logarithm of the SMRs were used in our analyses as log-
SMR has more normalised sampling distribution and it is preferred when the 
reference population is different between studies (Breslow and Day 1987). The 
pooled log-SMRs were then back-transformed for interpretation. The standard 
error of log-SMR was estimated by  ?Ȁ ?݊ݑܾ݉݁ݎ݋݂݀݁ܽݐ݄ݏ (Breslow and Day 
1987) in order to be used in a meta-regression model. We performed meta-
regression to assess the trend in SMRs over the past 50 years. Random effects 
models were used and heterogeneity was measured by the I2. In case of high 
heterogeneity sub-analysis was repeated multiple times, each time with 
removal of a single study to estimates its effect on the heterogeneity. %HJJH¶V
test was used to investigate whether any publication bias is present in the 
model with the least heterogeneity.  
5.2.5 Results 
Figure 5-1 shows the study identification procedure according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guideline (Moher, Liberati et al. 2009). From 16 full-text articles assessed for 
eligibility four were from the same cohort (Danish MS cohort), hence, three 




overall SMR (Tassinari, Parodi et al. 2001). No SMR was reported in one 
study (Llorca, Guerrero et al. 2005). One study was excluded due to reports of 
SMR for suicide only (Fredrikson, Cheng et al. 2003). One study reported 
SMR but not the confidence interval, therefore it was excluded (Wallin, Page 
et al. 2000). Overall nine studies were included (Bronnum-Hansen, Koch-
Henriksen et al. 2004; Leray, Morrissey et al. 2007; Grytten Torkildsen, Lie et 
al. 2008; Hirst, Swingler et al. 2008; Smestad, Sandvik et al. 2009; Ragonese, 
Aridon et al. 2010; Sumelahti, Hakama et al. 2010; Kingwell, van der Kop et 
al. 2012; Lalmohamed, Bazelier et al. 2012). Table 5-2 summarises included 
studies. These studies represented 23,289 patients. In total 6,589 deaths 
occurred during 402,909 person-year follow-up time. The pooled IMR was 
12.45/1000 person-years (95%CI: 8.97 to 17.28) ranging from 2.8/1000 
person-years (95%CI: 2.2 to 3.5) in France to 38.8/1000 person-years (95%CI: 
33.8 to 43.9) in Wales (Figure 5-4). The pooled SMR was calculated for both 
sexes and each sex separately from the reported SMRs extracted from the 
studies (Table 5-1). The pooled overall SMR was 2.65 (95%CI: 2.44 to 2.88, 
I2 = 81.0%) for both sexes, 2.25 (95%CI: 1.98 to 2.55, I2 = 78.3%) in males 
and 3.01 (95%CI: 2.76 to 3.28, I2 = 68.4%) in females. The sensitivity analysis 
of the model showed that a single study explained the high heterogeneity 
(Leray, Morrissey et al. 2007). Hence, the study was excluded in our 
sensitivity analysis and pooled SMR was calculated for the rest of the studies. 
This resulted in slightly higher pooled SMR but with almost no heterogeneity. 
The pooled overall SMR was 2.84 (95%CI: 2.74 to 2.94, I2 = 15.7%) for both 
sexes, 2.45 (95%CI: 2.25 to 2.66, I2 = 48.8%) in males and 3.12 (95%CI: 3.02 




figures 5-4 to 5-7. No evidence of LQIOXHQFH RI FRKRUWV¶ PLG-year on overall 
SMR was found (P = 0.72) (Figure 5-3). We also could not find any evidence 
of publication bias (Figure 5-2). 
 
                 Figure 5-1: diagram of the study identification procedure 
 
 
Figure 5-2: Begg's funnel plot with pseudo 95% confidence intervals 
Studies included in quantitative synthesis (meta-analysis) 
(n = 9  ) 
Studies included in qualitative synthesis 
(n = 9 ) 
Full-text articles assessed for eligibility 
(n =10) 
Records screened 
(n = 16)  3 same cohort, 1 suicide, 1 no CI, 1 no overall SMR 
Records after duplicates removed 
(n =  25) 8 not MS related, 3 conference papers 
Additional records identified through other sources 
(n = 2  ) 
Records identified through database searching 
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Figure 5-3: Impact of cohort mid-year on SMR. Results from meta-regression analysis 
(P = 0.72) 
 

























































Hansen et al. (Denmark) 2.89 2.81 2.98 2.66 2.54 2.78 3.14 3.01 3.27 
Torkildsen et al. (Norway) 2.66 2.31 3.06 2.23 1.81 2.76 3.11 2.58 3.74 
Ragonese et al. (Italy) * 2.14 1.32 3.46 2 0.89 4.46 2.22 1.23 4 
Sumelahti et al. (Finland) 2.8 2.6 3.1 2.2 1.9 2.6 3.4 3 3.9 
Smestad et al.(Norway) 2.47 2.09 2.9 2.02 1.56 2.58 2.94 2.36 3.62 
Leray et al. (France) 1.8 1.4 2.2 1.4 1 1.9 2.2 1.7 2.9 
Kingwell et al. (Canada) 2.88 2.71 3.06 2.68 2.43 2.96 3.01 2.79 3.25 
Hirst et al. (Wales) 2.79 2.44 3.18 2.26 1.79 2.85 3.14 2.67 3.69 
Lalmohamed et al. (UK) 3.51 2.63 4.69 2.96 1.84 4.77 3.94 2.73 5.68 
SMR: standardised mortality ratios 
CI: confidence intervals 










































































Hansen et al. (Denmark) 1949 2004 Cohort 9881 4254 21.03 207862 1949-1996 20.466 19.857 21.074 
Torkildsen et al. (Norway) 1953 2008 Population based survey 878 198 40 35120 1953-2003 5.638 4.855 6.421 
Ragonese et al. (Italy) 1960 2010 Population based survey 193 30 21.7 4188.1 1960-2007 7.163 4.609 9.717 
Sumelahti et al. (Finland) 1971 2010 Survey 1595 464 36 32165 1971-2006 14.426 13.123 15.729 
Smestad et al.(Norway) 1972 2009 Cohort 386 263 40 12172 1972-2005 21.607 19.024 24.190 
Leray et al. (France) 1976 2007 MS Clinic 1879 68 12.7 23906 1976-2004 2.844 2.169 3.520 
Kingwell et al. (Canada) 1980 2011 Cohort 6841 1025 47.5 77950 1980-2004 13.149 12.350 13.949 
Hirst et al. (Wales) 1985 2006 Population based survey 366 218 18.5 5609 1985-2005 38.866 33.808 43.924 
Lalmohamed et al. (UK) 2001 2012 Population based survey 1270 69 3.1 3937 2001-2008 17.526 13.427 21.625 
IMR: incidence mortality rate 






Figure 5-4: pooled incidence mortality rate per 1000 person-year sorted by study 
onset  
 
Figure 5-5: pooled standardised mortality ratios for both sexes sorted by study 
onset 
 
Figure 5-6: pooled standardised mortality ratios in males sorted by study onset 
 
 
Figure 5-7: pooled standardised mortality ratios in females sorted by study onset
NOTE: Weights are from random effects analysis
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5.2.6 Comment  
This pooled analysis of SMRs suggests that both male and female patients with 
MS are at higher risk of death compared to their matched controls in general 
population. However, contrary the general concept that female patients have 
better prognosis, they had higher overall SMR than males. The analysis also 
shows that the reported increase in MS survival rates may be explained by 
increased life expectancy in general population as no change in the SMR was 
observed over time. The calculation of IMR enables us to make a direct 
comparison between the IMR of each cohort and SMR. Heterogeneity can 
offer valuable insights if explained. The removed study by Larey et al. (Leray, 
Morrissey et al. 2007) in our analysis explained much of the heterogeneity 
(almost 65%) hence it was excluded. However, exclusion of this study made 
essentially no difference to the pooled SMR in our analysis. The study is based 
on the data acquired from MS clinics. It is possible that patients with severe 
disease have died before the data collection (selection bias) in their study. It 
seems that short duration of follow-up and consequently low number of deaths 
may explain the low SMR reported in this study. Nevertheless, the relatively 
high number of patients (57%) who had at least 6 months exposure to 
treatment should also be considered as a potential factor in altering mortality 
rates in this study.  Our study of pooled SMRs has some limitations. Pooled 
SMRs from different population settings and observational studies can be 
controversial because of the biases which can arise from observational studies 
and various methodological approaches undertaken by these studies. In this 
case presenting a single pooled estimate of SMR without additional details 




1998). Nevertheless, a single summary statistics of SMR could be highly 
appealing for clinicians and health professionals working with MS patients. In 
addition, our pooled meta-analysis showed relatively little heterogeneity 
particularly when the study by Leray and colleagues were excluded. The 
implication of our study is that the SMR in these studies was essentially the 
same over almost 50 years.  
There is ample epidemiologic evidence that, regardless of gender, MS patients 
still have significantly higher mortality rates compared with the general 
population. Like many diseases, there are risk factors associated with increased 
mortality rates in MS patients. Some of these factors are demographic such as 
gender. As shown here and previously (Poser, Kurtzke et al. 1989; Wallin, 
Page et al. 2000; Grytten Torkildsen, Lie et al. 2008), female patients with MS 
have higher mortality rates than males, relative to the general population. 
In addition to the influence of demographics like gender, environmental risk 
factors as well as healthcare interventions can also influence the mortality 
rates. For example, a hypothetical cohort of MS patients with a significantly 
higher number of smokers than the general population is expected to report 
more deaths due to cardiovascular disease or cancer and hence have higher 
SMRs. Thorough investigation of the role of environmental factors in MS can 
provide valuable explanations for some of the still unsettled and controversial 
questions. For example, the proportion of smokers in the studied cohorts can 
explain some of the discrepancy seen in the studies comparing cancer-related 
mortality rates in MS patients to those of the general population (Bronnum-
Hansen, Koch-Henriksen et al. 2004; Grytten Torkildsen, Lie et al. 2008). 




preventable cause of premature death accounting for nearly 6 million deaths 
worldwide (WHO 2011). Tobacco smoking will continue to be the biggest 
cause of premature death during the 21st century with approximately 1 billion 
smoking-related deaths (Jha 2009). Tobacco smoking has previously been 
linked to more severe disease in MS patients (Bailey 1922; Hernan, Jick et al. 
2005; Hawkes 2007; Di Pauli, Reindl et al. 2008; Sundstrom and Nystrom 
2008; Healy, Ali et al. 2009) and has recently been reported to be associated 
ZLWKDVLJQLILFDQWGHFUHDVHLQVPRNHUV¶OLIHVSDQ(Huxley and Woodward 2012; 
Sakata, McGale et al. 2012). Despite the relatively large number of studies 
investigating mortality in MS, the influence of life-style factors, mainly 
cigarette smoking, on mortality rates in MS patients remained to be examined. 
A recent survey of MS patients in the UK has shown a significant influence of 
cigarette smoking on the risk of death in MS patients compared with the 
reference subjects (Lalmohamed, Bazelier et al. 2012). On the basis of our 
previous findings with regard to the influence of tobacco smoking on the 
progression of disability and severity of the disease we raised the question of 
such an influence on the risk of MS- and non-MS-related mortality in patients 
with MS. In this study we investigated the impact of tobacco smoking on life 
span and mortality rates in a large cohort of MS patients and tried to find 
ZKHWKHUFDQSDWLHQWV¶VPRNLQJKDELWVGHVFULEHVRPHRIWKHLQFUHDVHGPRUWDOLW\





5.3 Design and Methodology 
5.3.1 Settings and study design 
We studied participants enrolled in the Nottingham University Hospitals MS 
Clinic data base. These clinics are a major regional referral centre for MS in 
the East Midlands Counties of England. Our methods and cohort 
characteristics have been described in detail elsewhere (Manouchehrinia, 
Tench et al. 2013). Briefly, the centre covers more than 3000 MS patients. 
Among all the patients who are regularly seen in these MS specialised clinics, 
1,032 patients were routinely followed-up and details of the disease clinical 
course, disability scores, date of diagnosis and disease onset, treatment, 
comorbid conditions, results of medical investigations, etc. were systematically 
documented. Our final study population consisted of patients with clinically 
definite MS according to the McDonald and/or Poser criteria (Poser, Paty et al. 
1983; McDonald, Compston et al. 2001) made by an MS specialist neurologist. 
5.3.2 Measurements 
5.3.2.1 Clinical data and smoking history 
Smoking history was obtained during the SDWLHQWV¶ILUVWFOLQLFYLVLWDWWKHWLPH
of disease onset and/or diagnosis and patients were grouped as non-smokers, 
ex-smokers or current smokers. In the majority of the cases smoking history 
was updated and recorded more than once after the disease onset during 
regular clinic follow-ups. For this study we used the latest smoking status 
recorded in the database. Date of the first manifestation of the disease, date of 
diagnosis, duration of exposure to disease modifying treatments (DMTs), latest 




initial clinical course of the disease (relapsing-remitting (RR) vs. Primary-
progressive (PP)) were used in this study. We also calculated a global MS 
severity score (MSSS) which integrates EDSS score and disease duration 
according to the guidelines published by Roxburgh et al. (Roxburgh, Seaman 
et al. 2005).  
5.3.2.2 Vital Status and cause of death 
Vital status of patients was monitored and the exact date of death was obtained 
through linkage of the MS cohort to the National Health Service (NHS) vital 
statistics as of December 2012 (index date). For the cause of death, both 
medical records and death certificates were used. In England the death 
certificate is issued upon death and divided in to two parts. Part l shows the 
immediate cause of death and is further subdivided into section a, b and c 
which are used to highlight any underlying cause or causes. Part II is used for 
any significant condition or disease not leading directly to death but 
contributing to the death. Causes of death were categorised into MS-related 
(death due to MS disability such as bronchopneumonia, pulmonary embolism, 
sepsis) and non-MS-related deaths (e.g. cancers, suicides, cardiovascular 
diseases) (Hirst, Swingler et al. 2008). 
5.3.2.3 Statistical analysis 
Patient data were included from the time of entry into the database until either 
death or the index date (December 2012), whichever occurred first.  Time at 
risk and death rates were calculated per 1000 person-years. Confidence 
intervals for median survival age could not be calculated as the survival 




we used parametric measures and calculated mean survival from birth and after 
MS onset using the Kaplan-Meier method. Smoking-specific rates were 
calculated using Cox proportional hazard regression models controlled for sex, 
RQVHWDJHXVHRI'07VLQDELQDU\JURXSRI\HDURU\HDUDQGLQLWLDO
clinical course of MS (RR vs. PP). The final model was checked for the 
proportionality assumption based on the Schoenfeld residuals and stratification 
was made if necessary to hold the proportionality assumption. We also 
calculated SMRs and performed external comparison of our mortality to the 
England general population data to investigate whether mortality in our cohort 
differs from that of the general population of England. SMR was calculated by 
dividing the observed number of deaths in the  cohort by the number of deaths 
expected from the general population for each sex and age band stratum (20-
24, 25- « XS WR ! \HDUV 6LQFH DOO WKH GHDWKV n=80) in our cohort 
occurred in the 2001 to 2012 calendar period we used 2006 England mortality 
rates as the corresponding reference rates, obtained from the UK Office for 
National Statistics for each sex and age group (2012). All statistical analyses 
were performed with Stata 11 (StataCorp. 2009. Stata Statistical Software: 
Release 11. College Station, TX: StataCorp LP). The study was approved by 






From the original 1032 subjects with records in the database we excluded 45 
subjects with missing smoking data, 3 with missing date of onset, 30 not 
fulfilling criteria for clinically definite MS (12 clinically isolated syndrome 
and 18 suspected MS only) and 30 patients with only one visit to the clinic. 
Our final cohort consisted of 923 (89% of 1032 subjects) individuals with 
clinically definite MS and full data for analysis.  
70% of the subjects were female, 11% had PP MS at disease onset compared 
with 89% RR MS. Of those RR MS subjects 40% had transited to secondary 
progressive (SP) MS.  In general, deceased patients in our cohort had 
significantly higher onset age, longer disease duration and higher MSSS and 
EDSS scores compared with survivors. 58% of the deceased patients were 
male while 30% of survivors were male. 45% of the survivors had received 
DMTs for one year or longer compared with only 16% of deceased subjects.  
No survival advantage was found for relapsing onset MS patients compared 
with progressive onset (P = 0.93). Despite the decrease in the prevalence of 
ever-smoking in the UK general population, there was an increase of 
approximately 12% in the proportion of ever-smokers in our cohort in 2000-
2010 compared with of the proportion before 1990 (Figure 5-8 and Table 5-4) 
in the MS cohort.  Table 5-3 shows the baseline demographic and MS-specific 





Table 5-3: general demographic characteristics of the MS cohort stratified by vital 
status at December 2012 
  Deceased (n = 
80 ) 
Alive (n = 843) 
P 
 Sex     (female) 34 (42%) 610 (72%) < 0.001 
Last recorded EDSS 
(median(IQR)) 
7.5 (±1.5) 5.5 (±3.5) < 0.001 
MSSS (mean) 7.9  (±2.23) 5.34 (±2.59) < 0.001 
Age at the onset (mean) 35 (±10.67) 32(±9.74) 0.02 
Disease duration (median) 20 (±17) 15 (±14) < 0.001 
Type of MS 
       Relapsing-remitting 
       Primary-progressive 










'07\HDU 13 (16%) 384 (45%) < 0.001 
DMT: disease modifying treatment 
EDSS: expanded disability status scale  
IQR: interquartile range 




Figure 5-8: Standardised prevalence ratio (SPR) of ever-smoking in the MS cohort the 




































Table 5-4: age and sex standardised prevalence ratios of smoking in the MS cohort 
during the past three decades. 
Decade sex observed expected SPR 95% CI P-Value 
1981-
1990 
male 37 40 0.92 0.62 to 1.22 0.66 
female 73 79.6 0.91 0.70 to 1.13 0.80 
1991-
2000 
male 65 57.08 1.13 0.87 to 1.45 0.16 
female 109 108.83 1.00 0.82 to 1.20 0.50 
2001-
2010 
male 37 24.47 1.51 1.06 to 2.08 0.01* 
female 56 47.65 1.17 0.88 to 1.52 0.12 
SPR: standardised prevalence ratios 
CI: confidence intervals 
* Note that SPR has reached significance level in the last decade in male patients 
 
5.4.1 Length of follow-up and smoking status 
The 923 patients contributed a total of 18,717 person-years of data. There were 
80 deaths recorded in our cohort, representing a mortality rate of 4.35 (95%CI: 
3.43 to 5.34) per 1000 person-years. This rate was higher in males (8.68, 
95%CI: 6.52 to 11.56) than in females (2.47, 95%CI: 1.76 to 3.48). Compared 
to the frequency of 50% in the whole cohort, 54 (67%) of the deceased subjects 
were ever-smokers. All nine patients with RR MS who died were ever-
smokers, compared with 44% of PP MS and 68% of SP MS. Age at onset was 
slightly but significantly higher in ever-smokers (30.4 vs. 31.2; P = 0.003). 
The crude mortality rates were 6.66 (95% CI: 4.71 to 9.43) per 1000 person-
years among current smokers, 5.06 (95% CI: 3.3 to 7.77) for ex-smokers and 





5.4.2 Survival rates and impact of smoking 
Mean survival was 76.8 years (95% CI: 74.6 to 79) for the whole cohort, but 
compared with ever-smokers, never-smokers lived almost 6 years longer. 
Mean survival was 81 (95%CI: 78 to 83.6) years in non-smokers, 78.4 (95% 
CI: 75.2 to 81.5) years in ex-smokers and 71.5 (95% CI: 68.8 to 74.2) in 
current smokers (Figure 5-9).  
Current smokers and ex-smokers were at higher risk of death, with a hazard 
ratio relative to never smokers of 2.70 (95% CI: 1.59 to 4.58; P < 0.001) and 
1.30 (95% CI: 0.72 to 2.32; P = 0.37) respectively. Limiting our survival 
analysis to those who died from MS-related causes, current smokers were still 
at higher risk for death, with a hazard ratio of 2.93 (95% CI: 1.48 to 5.76; P < 
0.001) relative to non-smokers. Among ex-smokers, the hazard ratio was 1.18 
(95% CI: 0.53 to 2.61; P = 0.67), not statistically significant. 
 
Figure 5-9: A, Kaplan-Meier graph showing survival age of MS patients by lifelong 
smoking status, B, Kaplan-Meier graph showing survival from birth by smoking 
status 
 
5.4.3 Disability status and cause of death 
As shown in Table 5-3, disability status immediately preceding death was 




EDSS score and MSSS. Time to EDSS score milestone 6 (requires assistance 
to walk for 100 meters) was available in 72 of 80 deceased patients. Never-
smokers reached an EDSS score 6 almost 11 (95%CI: 6 to 12) years after the 
disease onset whereas ever-smokers reached same disability score in 7 years 
(95%CI: 5 to 12), though this difference was not statistically significant. We 
could not obtain causes of death in two of the decedents. Cause of death was 
MS-related in 60% of cases (Table 5-5), with bronchopneumonia accounting 
for the majority of MS-related deaths. Cancer (17.5%) was the commonest 
non-MS-related cause, and lung cancer the dominant cancer (6 deaths). Deaths 
from cardiovascular diseases (11 cases), suicide (one case), motor neuron 
disease (one case), kidney failure (two cases), liver cirrhosis, and intestinal 
infarction were also recorded.     
 
Table 5-5: summaries of causes of death, onset age, disability score and disease 
severity stratified by smoking status 



























































Cancer 10 33 6 5.65 4 27 7 7.12 
Cardiovascular 7 38 6 6.35 4 36.5 7 6.60 
Other  2 27.5 7 8.19 4 38 8 7.98 
EDSS: expanded disability status scale  







All-cause mortality in MS patients was significantly higher than expected in 
age and sex matched general population, the SMR being 2.41 (95%CI: 1.95 to 
2.96; P < 0.001) for males, 1.80 (95%CI: 1.40 to 2.30; P < 0.001) for females, 
and 1.99 (95% CI: 1.70 to 2.33; P < 0.001) for both sexes combined. Among 
current smokers, the all-cause SMR was increased to 3.83 (95%CI: 2.71 to 
5.42; P < 0.001) and in ex-smokers by 1.96 (95%CI: 1.27 to 3.0; P < 0.001); 
there was no significant increase among never-smokers, SMR was 1.27 
(95%CI: 0.87 to 1.86; P > 0.05). 
5.5 Discussion  
In this MS population current smoking was associated with more than 2.5-fold 
increased risk of death. Current smokers with MS had a reduction of about 10 
years in their life expectancy relative to non-smokers with MS. Compared with 
the general population, increased mortality in this cohort as measured by SMR 
was seen in current and ex-smokers but not non-smokers. However, the risk of 
death in ex-smokers was considerably lower than in current smokers. Our data 
suggest that much of the excess mortality seen in MS populations can be 
H[SODLQHGE\SDWLHQWV¶VPRNLQJKDELWV7KLVGDWDLVFRQVLVWHQWZLWKRXUUHFHQW
findings of the negative impact of smoking on disability progression and 
severity of the disease in MS (Manouchehrinia, Tench et al. 2013).  
The survival age of 77 for our MS population in the present study is 
comparable to the findings from a recent study in British Columbia (Kingwell, 
van der Kop et al. 2012). The observed number of deaths in our cohort was 




the mortality rates of the English general population. Others have reported 
higher mortality rates for MS patients (Poser, Kurtzke et al. 1989; Midgard, 
Albrektsen et al. 1995; Wallin, Page et al. 2000; Sumelahti, Tienari et al. 2002; 
Grytten Torkildsen, Lie et al. 2008; Ragonese, Aridon et al. 2010; 
Lalmohamed, Bazelier et al. 2012), relative to the general population, which 
was also evident in our results. Our patients were 2 times more likely to die 
prematurely compared with their age- and sex-matched counterparts in the 
general population. Although SMR cannot be compared due to differences in 
the distribution of the standardisation variable (age and sex) across the study 
populations, our presented SMR here is slightly lower, though still comparable 
with those reported previously (Sumelahti, Tienari et al. 2002; Bronnum-
Hansen, Koch-Henriksen et al. 2004; Hirst, Swingler et al. 2008; Smestad, 
Sandvik et al. 2009; Kingwell, van der Kop et al. 2012). The reported SMR 
here is similar to the reported SMR in an Italian MS cohort (1.81) (Ragonese, 
Aridon et al. 2010). Apart from methodological variations, treatment and 
access to health care resources may further explain the lower SMR in the 
cohort presented here. Long term follow-up of patients participating in the 
RULJLQDO LQWHUIHURQ ȕ FOLQLFDO WULDO KDV VKRZQ WKDW H[SRVXUH WR WUHDWPHQW PD\
decrease risk of premature death in MS patients (Goodin, Reder et al. 2012). 
This may explain some of the differences seen between our reported SMR and 
those reported previously. While 57%  of the patients in the French study 
(Leray, Morrissey et al. 2007) and 42% of our cohort have been exposed to 
treatment, the majority of the patients in British Columbia (Kingwell, van der 
Kop et al. 2012) were never exposed to treatment and the follow-up time in the 




treatment. Nevertheless, the potential influence of treatment intervention in MS 
on mortality deserves further investigation. In the UK, it has been suggested 
that current smokers with MS have 6.7-fold increased mortality rate compared 
with the sex- and age-matched counterparts without MS (Lalmohamed, 
Bazelier et al. 2012). Our results confirm a higher mortality rate in smokers 
than non-smokers with MS, but with a lower hazard rate of 2.7.  Short patient 
follow-up time and the use of the General Practice Research Database and 
Hospital Episode Statistics may explain the higher hazard rate in the study by 
Lalmohamed and colleagues by capturing the more severe cases of MS. Our 
study offers longer duration of follow-up in a homogeneous cohort of MS 
patients with detailed clinical data. All the patients in this report have the 
diagnosis of clinically definite MS made by MS specialist neurologists. In 
addition our cohort has a population based characteristics and wide spectrum 
in terms of factors such as disease type and disability score. Our study also had 
some limitations.  It is possible that our study has missed some of the patients 
with severe disease who have died before the data collection. Despite these 
limitations our overall cohort characteristics such as gender, MS type ratio (RR 
vs. PP), onset age, etc. were similar to those reported from other MS cohorts 
(Weinshenker, Bass et al. 1989; Confavreux, Vukusic et al. 2003).  
During the past fifty years prevalence of tobacco smoking has decreased in the 
UK general population. This along with advances in medical sciences was 
associated with an increase in general life expectancy and a significant 
decrease in smoking attributable deaths (Thun and Jemal 2006). Despite this, 
we observed a steady increase in the proportion of ever-smokers in our MS 




with women. To the best of our knowledge, this is the first study investigating 
the impact of smoking on life expectancy in patients with MS. Here we have 
presented data from a cohort of MS patients in the UK, but the relevance of 
this study is worldwide. As shown here smoking is a significant risk factor for 
all cause and MS-related death, causing almost 10 years loss of life expectancy 
in patients with MS. In contrast, mortality among non-smokers was only 
modestly and not statistically significantly increased relative to the general 
population.  
On the basis of our findings there is a strong association between tobacco 
smoking and premature mortality in patients with MS. Reduced risk of death 
amongst former smokers calls for effective cessation strategies. Our data 
suggest that reduction in prevalence of tobacco smoking in people with MS 
can potentially eliminate or decrease the excess mortality rates seen in MS 
patients.  Tools and information to help smokers with MS stop smoking and 
non-smokers to never start smoking should be routinely provided to all patients 
with MS. 
 
5.6 Conclusion  
Smoking is an important factor for death due to all cause and MS-related death 
in patients with MS. The higher mortality rates in our cohort could be 
DWWULEXWHG WR SDWLHQWV¶ VPRNLQJ KDELWV 3DWLHQWV ZKR JDYH XS VPRNLQJ KDG D
considerably lower risk of death compared with those who continued to smoke. 
We propose that premature death due to MS disability can be considered as 
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6.1 Summary of the chapter 
Tobacco smoking is a complex multi-dimensional environmental factor 
implicated in a large number of diseases. Measuring the precise influence of 
tobacco smoking on any outcome requires careful modelling of smoking 
specific to the characteristics of that disease. In this chapter we explored some 
simple strategies for modelling smoking in MS. We would try to investigate 
the performance of different modelling approaches and possibly recommend 
the most comprehensive model for use in the future studies. 
The next section 6.2 will offer some key ideas and assumptions on some of the 
most commonly used and new approaches in modelling of smoking. 
Section 6.3 will cover our methodology.  
Our results are presented in Section 6.4 and Section 6.5 discusses our findings, 
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6.2 Background  
Epidemiologic studies of the impact of tobacco smoking on many diseases 
encounter several difficulties in terms of proper and appropriate modelling of 
smoking as a time varying multi-dimensional variable.  Among the dimensions 
of smoking are intensity or the number of cigarette smoked, duration of 
smoking, age at smoking initiation and time since smoking cessation in ex-
smokers. Although widely used, multivariable modelling of separate effects of 
several smoking factors such as intensity, duration and time since cessation is 
not favourable and can reduce statistical power because of the increase in 
variance inflation and multicollinearity of the statistical model. The majority of 
the studies evaluating the impact of smoking on MS has focused on a 
simplified analysis and one aspect of smoking only or were at best limited to 
calculating pack years smoked. However, we believe that ignoring any of these 
factors may result in over or under estimation of the influence of smoking and 
can potentially include confounding, especially in a disease as chronic as MS 
in which duration and intensity of exposure can change overtime. 
The main objective of this chapter was to make a comparison of different 
approaches to modelling of smoking in MS. Of the most commonly used 
smoking indexes in MS are conventional non- ex- and current smoking 
categories and pack-years smoked. Here we compared the performances of 
these conventional approaches together. We also investigated the performance 
of these models to those of more advance indexes to identify a relatively easy, 
widespread approach to model smoking in MS. 
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Comprehensive indexes such as body mass index (BMI) have been widely 
used in epidemiologic studies for evaluating the overall burden of various 
dimensions of one ULVNIDFWRURQ LQGLYLGXDOV¶KHDOWK6HYHUDOVPRNLQJUHODWHG
indexes have been proposed for modelling of smoking in epidemiologic 
studies. A Comprehensive Smoking Index (CSI) (Equation 1) was first used 
for modelling smoking history in the context of periodontal diseases by 
Dietrich and Hoffmann (Dietrich and Hoffmann 2004).  Since then, the 
developed version of the CSI has been used in several diseases such as lung 
cancer and systemic sclerosis with some promising results (Leffondre, 
Abrahamowicz et al. 2006; Dietrich, Garcia et al. 2007; Hudson, Lo et al. 
2011). CSI is a multi-dimensional mathematical representation of LQGLYLGXDOV¶ 
smoking history and works as a single aggregate measure of smoking exposure 
that integrates three the main factors of smoking history; intensity, duration 
and time since cessation based on a series of assumptions. The original CSI 
was developed based on the assumption of an exponential decline of the effect 
of past smoking over time.  
 
൬ ? െ  ?Ǥ ?ቀௗ௨௥ఛ ቁ൰ ൬ ?Ǥ ?ቀ௧௦௖ఛ ቁ൰ ݅݊ݐ 
Equation 1: dur; duration of smoking, tsc: time since cessation, int: average number of 
cigarette smoked per day, Ĳ: the half-life parameter 
 
In 2006, Leffondre and colleagues (Leffondre, Abrahamowicz et al. 2006) 
developed a new version of the CSI (Equation 2) to account for a lag between 
µFDXVDO DFWLRQ¶ DQG GLVHDVH GHWHFWLRQ į DQG JLYHQ WKH IDFW WKDW VPRNLQJ
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intensity has some non-linear effect which showed better results in the context 
of lung cancer. The assumption of non-linear effects of smoking intensity fits 
our data as well (Figure 4-7 in chapter 4).The new CSI by Leffordre was 
developed based on the removal of the exponential decline and suggested that 
WKH LPSDFW RI VPRNLQJ RQ LQGLYLGXDO¶V KHDOWK gradually increases over time 
which seems more appropriate for using in studies of MS.  
 
൬ ? െ  ?Ǥ ?ቀௗ௨௥כఛ ቁ൰ ൬ ?Ǥ ?ቀ௧௦௖כఛ ቁ൰ ሺ݅݊ݐ ൅  ?ሻ 
࢚࢙ࢉ כൌ  ሺݐݏܿ െ ߜǡ  ?ሻࢊ࢛࢘ כൌ  ሺ݀ݑݎ ൅ ݐݏܿ െ ߜǡ  ?ሻ െ ݐݏܿ כ 
Equation 2: dur; duration of smoking, tsc: time since cessation, int: average number 
of cigarette smoked per day, Ĳ: the half-life parameterįthe lag-time (the length of 
delay between initiation of smoking and the first neurological MS related symptom). 
 
The implementation of the new CSI requires the estimation of two parameters: 
įthe length of delay between the initiation of smoking and the first symptom 
DQGĲ the rate at which the health impact of smoking decays over time. This 
can be fixed prior to the analysis if known (e.g. from biological experiments) 
or can be estimated by maximising the goodness-of-fit statistics from the data 
at hand. The estimation of these parameters is also of interest in itself since 
they may give insights into the form of the dose±response rate between the 
outcome and smoking. Better understanding of the formal property of the new 
CSI requires some levels of visualisation which are presented here. Figure 6-1 
shows the estimated CSI in hypothetical ex-smokers (tsc = 20 years & int=30 / 
day) IRU VHOHFWHG FRPELQDWLRQV RI į DQG Ĳ The estimated CSI in current 
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VPRNHUV IRU VHOHFWHG FRPELQDWLRQV RI į DQG Ĳ DUH JUDSKLFDOO\ SUHVHQWHG LQ
Figure 6-2. Figure 6-3 demonstrates how the CSI behaves in ex-smokers 
following smoking cessation for the selected FRPELQDWLRQV RI į DQG Ĳ As 
shown in the figuresDVKRUWHUĲ\LHOGVORZHU&6,GXHWRIDVWHUOHYHOOLQJ-off of 
WKHLPSDFWRIVPRNLQJDQGWKHORQJHUĲZRXOGNHHSWKHULVNRIWKDWSDUWLFXODU
outcome high for a longer time as it will take longer for the effects of smoking 
to level off. ,QWKHLPSURYHG&6,įZRXOGUHSUHVHQWVthe lag-time after smoking 
cessation and also after smoking initiation.  
 
 
Figure 6-1: The CSI of hypothetical Ex-smokers by duration of smoking for selected 
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Figure 6-2: The CSI of current smokers (tsc=0 & int=30/day) by duration of smoking 




Figure 6-3: The CSI of ex-smokers (dur=20 & int=30/day) by time since smoking 
cessation for selected FRPELQDWLRQVRIĲDQGį 
 
Alongside all the advantages of using indexes for measuring the influence of 
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restricting in terms of interpretation of the effects of smoking.  Hence, the 
objective of this study is to present an index to measure the cumulative burden 
of smoking while covering its various dimensions. This would come handy 
when one needs to evaluate the cumulative effects of smoking on an outcome 
such as risk of developing MS or risk of having progressive MS at the disease 
onset or just need to control for smoking in a study such as a clinical trial. 
 
6.3 Methodology  
One of the difficulties in the implementation of CSI is the estimations RIįDQG
Ĳ  ,QRXU VWXG\ į DQG Ĳ were estimated using nested loops search algorithm 
from the data at hand as no previous study had looked at the biology of 
smoking in MS,QWKHSUHVHQWVWXG\ĲLVDOORZHGWRUDQJHIURPWR\HDUV 
with 1-year incrementsZKLOHį is allowed to range from 0 to 20 years in 0.1 
increments. Then, the CSI was computed (for all patients), for each possible 
FRPELQDWLRQ RI YDOXHV RI Ĳ DQG į LQ WKH UDQJH VSHFLILHG DQG WKH Akaike 
information criterion (AIC, measure of goodness of fit statistics) of the 
regression model in the presence of the CSI and all the confounders including 
onset age, sex, initial disease phenotype, use of treatment and disease duration 
was determined. AIC is a statistical method of selecting the best fitted model 
from a series of models. The chosen model will be the model that has a good 
fit to the truth but few parameters. 
The CSI equals zero for never-smokers but would not necessary be higher for 
current smokers compared with ex-smokers as both duration and time since 
cessation are taken into account. With the range specified above we fitted 51 × 
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210 = 10710 models for each outcome. 7KHµRSWLPDO¶YDOXHVRIĲDQGįZHUH
identified as that corresponding to the minimum regression model AIC value 
which consequently would be that corresponding to the best fitted model. We 
also implemented the models by maximising the R-squared to define the 
goodness of fit statistics when obtaining AIC was more time consuming. When 
WKHRSWLPXPYDOXHVRIįDQGĲwere obtained from the search algorithm, they 
were fixed for all individuals and overall burden of the smoking on the risk of 
progressive onset MS, risk of reaching EDSS score milestone 6, average 
MSSS and PDDS score were estimated. 9DOXHV RI į and Ĳ ZHUH estimated 
separately for each outcome. We then compared the AIC, Bayesian 
information criterion (BIC) and degree of multicollinearity of models with 
conventional smoking modelling and the CSI to find the best method of 
modelling smoking in MS. AIC and BIC are both penalised-likelihood criteria 
used for choosing best predictor subsets in regression models. A lower AIC 
means a model is considered to be closer to the truth and a lower BIC means 
that a model is considered to be more likely to be the true model. Their only 
difference is the size of the penalty for model complexity which weighs more 
heavily in BIC. For the comparison of the performance of the models we 
employed the models listed in Table 6-1. 
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Table 6-1: list of the models with different modelling of smoking which were 
compared in our analyses 
Model 1 Ever vs. never smoked 
Model 2 
Non / Ex / Current 
Model 3 (pack-years) dur * (int / 20) 
Model 4 
Int & dur & tsc 
Model 5 






Table 6-2 shows the estimated values RIįDQGĲIURPWKHUHJUHVVLRQPRGHOVIRU
RXWFRPHV XVHG LQ RXU VWXG\  :KHQ WKH RSWLPXP YDOXHV RI į DQG Ĳ ZHUH
obtained, the CSI was calculated for each outcome and all patients. Regression 
analyses were performed in the presence of CSI which integrated smoking 




 Statistical model Ĳorg Ĳ į 
Risk of PP MS at onset Logistic regression 50 2 19.8 
PDDS Linear regression 28 1 18.8 
MSSS Linear regression 50 50 0 
Hazard ratio of reaching 
EDSS score 6 Cox  regression 3 1 3 
EDSS: expanded disability scale status 
PDDS: patient determined disease steps 
MSSS: multiple sclerosis severity score 
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6.4.1 Risk of progressive onset MS 
The first outcome used was the risk of progressive onset MS. Our logistic 
regression model in the presence of the CSI, sex and onset age, failed to show 
any evidence of an influence of tobacco smoking before the onset of the 
disease on the risk of progressive onset MS. Similar to the model with the 
conventional smoking modelling of ever- and never-smoked, in the model 
older age at the onset of the disease and being male were significantly 
associated with progressive onset MS. The two logistic regression models here 
(with and without the CSI) yielded similar results, however, the CSI integrated 
some important features of smoking which were missing when conventional 
modelling was used. Table 6-3 shows the results from conventional modelling 
and the model with CSI with reports of AIC and BIC of each model. No 
evidence of any influence of any smoking factors on the risk of progressive 
onset was seen in any of the models. As seen in the table, the model with the 
pack-years smoked has the lowest BIC and AIC which indicate that it fits our 
data best relative to the other methods used. The model with the original CSI 
showed a better fit to our data than the improved CSI. 
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Table 6-3: Comparison of the fitness of Models for the risk of progressive onset MS 
 OR (95%CI) P-value AIC BIC 
Ever vs. never 
smoked 





0.84 (0.44 to 1.61) 





Pack-years smoked 0.99 (0.98 to 1.01) 1.00 275.21 292.70 
Int  
& dur  
& tsc 
0.99 (0.96 to 1.03) 
1.00 (0.96 to 1.04) 





Log (int + 1) * dur   
& tsc 
1.0 (0.99 to 1.00) 




Original CSI 0.99 (0.94 to 1.05) 0.88 303.84 321.57 
The CSI 1.16 (0.88 to 1.51) 0.8 314.36 332.19 
All models were controlled for onset age and gender. 
$,&$NDLNH¶VLQIRUPDWLRQFULWHULRQZLWKORZHU$,&LQGLFDWLQJWKHEHVWILWWRGDWD 
BIC:  Bayesian information criterion with lower BIC indicating the best fit to data. 
dur: duration of smoking before MS onset.  
Int: intensity of smoking.  
OR: odds ratio 
tsc: time since smoking cessation if gave up smoking before onset of MS. 
 
 
6.4.2 Time to EDSS score milestone 6 
Summaries of the findings from different approaches for modelling of smoking 
and the risk of reaching EDSS score milestone 6 using Cox proportional 
hazard regression models is presented in Table 6-4. As seen, the binary 
modelling of smoking, model 1, has the highest AIC and no influence of 
smoking has been detected using this approach. Model 2, which contains 
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smoking variables categorised as non- ex- and current smokers showed the 
second highest AIC and the highest BIC and revealed the influence of current 
smoking status on the risk of reaching EDSS score 6 but no influence of 
smoking in former smokers. Although the model dismisses some important 
features of smoking such as duration and intensity, it is relatively informative 
when the effects of smoking cessation and current smoking are of interest and 
data at hand is limited to simple categorical status. The next model containing 
the pack year smoked showed relatively high AIC and BIC compared to the 
rest of the models and surprisingly was not sensitive enough to detect any 
influence of smoking on the risk of reaching EDSS score 6. In addition the 
model was not proportional thus its result is not reliable. The best model with 
the lowest AIC and BIC was the model which included the time since 
cessation, intensity and duration of smoking. Treating duration of smoking as a 
time varying covariate increased the AIC and BIC of the model very 
marginally but the model was still very informative. The product of the log 
transformation of intensity and duration of smoking together with time since 
cessation showed relatively good AIC and BIC but could not detect any 
influence of intensity and duration of smoking on the risk of reaching EDSS 
score 6. The CSI showed an average performance when used with the Cox 
regression model and was able to detect the influence of smoking on the risk of 
reaching EDSS score 6. 
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Table 6-4: Comparison of the fitness of Models for the hazard ratio of reaching EDSS 
score 6.  
 HR (95%CI) P-value AIC BIC 





0.9 (0.68 to 1.20) 





Pack-years VPRNHG 1.00 (0.99 to 1.01) 0.29 2685 2707 
Int  
& dur  
& tsc 
1.02 (1.01 to 1.04) 
0.98 (0.97 to 1.00) 








1.02 (1.01 to 1.04) 
0.97 (0.96 to 0.98) 





Log (int + 1) * dur   
& tsc 
1.00 (0.99 to 1.00) 




Original CSI 1.02 (1.01 to 1.03) < 0.001 2506 2528 
7KH&6, 1.27 (1.16 to 1.40) < 0.001 2701 2723 
§ dur modelled as time varying covariate.  
PRGHOZDVQRWSURSRUWLRQDO 
All models controlled for onset age, gender, duration of treatment and the disease 
LQLWLDOSKHQRW\SH$,&$NDLNH¶VLQIRUPDWLRQFULWHULRQZLWKORZHU$,&LQGLFDWLQJWKH
best fit to data.  
BIC:  Bayesian information criterion with lower BIC indicating the best fit to data.  
dur: duration of smoking before EDSS score 6.  
HR: hazard ratio 
int: intensity of smoking.  
tsc: time since smoking cessation if gave up smoking before EDSS score 6.  
 
 
6.4.3 Effects on PDDS score and MSSS  
Linear regression models were used with PDDS and MSSS as outcomes. Thus, 
the reported coefficient here will be adjusted for onset age, initial clinical 
course of the disease, use of treatment, gender and disease duration (in PDDS 
only). The reported regression coefficients in Table 6-5 were obtained from 
various approaches for modelling smoking. Like the findings from the 
previous outcomes, presented above, the binary categorisation of smoking 
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yielded the highest AIC for both outcomes and was the least informative 
approach. Despite having the second highest AIC, model 2 was relatively 
informative as it showed beneficial effects of smoking cessation in former 
smokers. Pack-years smoked showed average AIC in both outcomes. The 
original CSI showed the lowest AIC and BIC, however, like the pack-years 
smoked and model 5 the interpretations of the coefficients were somehow 
difficult and restricted as the effects of smoking cessation could not be 
evaluated. The model with the separate variables of smoking showed the 
highest variance inflation factor (VIF) and no effects of time since smoking 
cessation and duration were evident. 
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Table 6-5: Comparison of the fitness of the Models for MSSS and PDDS score  
 
Regression coefficient AIC 
Mean  variance inflation 
factor (VIF) 
MSSS (P) PDDS (P) MSSS PDDS MSSS PDDS 










2956 2682 1.14 1.23 
Pack-years smoked 0.01 (< 0.001) 0.01 (< 0.001) 2803 2526 1.12 1.22 
int  






< -0.001 (0.96) 
-0.01 (0.15) 
2807 2568 1.51 1.57 
Log (int + 1) * dur  
& tsc 
0.007 (0.001) 
< 0.001 (0.99) 
0.006 (0.001) 
-0.003 (0.5) 
2807 2512 1.11 1.23 
Original CSI 0.09 (0.004) 0.05 (< 0.001) 2499 2526 1.11 1.22 
The CSI 0.64 (0.001) 0.23 (< 0.001) 2863 2530 1.12 1.23 
All models are controlled for onset age, gender, duration of treatment and the disease initial phenotype  
$,&$NDLNH¶VLQIRUPDWLRQFULWHULon with lower AIC indicating the best fit to data.  
IVF:  Variance inflation factor.  
tsc: time since smoking cessation if gave up smoking before the study date. dur: duration of smoking . int: intensity of smoking.  
MSSS: multiple sclerosis severity score. PDDS: patient determined disease steps. 
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6.5 Discussion  
Here we evaluated the performance of different approaches for modelling 
smoking in MS. We examined a range of approaches from a simple binary to 
more complex models with interesting promises. Modelling smoking in MS is 
complex and requires clear definition of the level of information required in 
the study. For example, if the main purpose of the study is just to control the 
cumulative effect of various dimensions of smoking on the risk of a particular 
outcome, the CSI used here showed a good sensitivity to detect any effects of 
smoking and offered an interesting approach. The only inconvenience of the 
CSI is the HVWLPDWLRQRIĲDQGį+RZHYHUWKHLQWHUSUHWDWLRQRIĲDQGįFDQEH
interesting in itself. Except in MSSS, oXUHVWLPDWHGYDOXHVRIĲZHUHrelatively 
short.  
7KHVKRUWĲmeans that the effect of smoking decays relatively rapidly in MS. 
However, in MS, the interpretation of Ĳ is ambiguous since each component of 
tobacco smoke may have different rates of decay and subsequently different 
half-lives. The very long įLQ3''6DQGULVNRISURJUHVVLYHRQVHW06DOPRVW
20 years) means that there is a relatively long delay between the biological 
effects of smoking and its clinical presentation. Hence, there may be a 
significant delay of up to 20 years between initiation of smoking and its 
manifestation on PDDS score and risk of progressive onset MS.  
In addition, thiVORQJįZRXOGFDXVHWKHHIIHFWVRIVPRNLQJto remain high even 
after smoking cessation in former smokers. ,QFRQWUDVW WKHVKRUWįRI ULVNRI
reaching EDSS score 6 indicates that the effects of smoking on this outcome 
can be observed shortly after smoking initiation and can also disappear shortly 
after smoking cessation.  
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For illustration purposes the CSIs for all the four outcomes with their estimated 
YDOXHV RI į DQG Ĳ Table 6-2) for a hypothetical patient with smoking 
component values of 30 years duration of smoking, one year since smoking 
cessation and 20 cigarettes per day are plotted in Figure 6-4, Figure 6-5, Figure 
6-6 and Figure 6-7.  
 




   
Figure 6-4: the CSI in PDDS plotted against A, time since cessation of smoking, B, duration of smoking, and C, intensity of smoking 
 
   
Figure 6-5: the CSI in risk of progressive onset MS plotted against A, time since cessation of smoking, B, duration of smoking, and C, 








































































   
Figure 6-6: the CSI in MSSS plotted against A, time since cessation of smoking, B, duration of smoking, and C, intensity of smoking 
 
   
Figure 6-7: the CSI in the risk of reaching EDSS score 6 plotted against A, time since cessation of smoking, B, duration of smoking, and C, 
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As seen in Figure 6-7 A, about 10 years after smoking cessation the effects of 
smoking on the risk of reaching EDSS score 6 disappears. However, three 
years after smoking cessation the impact of smoking on the risk of reaching 
EDSS score 6 still remains at a high level. Figure 6-7 B, plots CSI against 
duration of smoking. As seen, the effect of smoking on the risk of reaching 
EDSS score 6 increases very rapidly after smoking initiation and after about 8 
years of continuous smoking the CSI reaches a plateau with no further increase 
in the risk of reaching EDSS score 6 upon continuation of smoking. This might 
be the reason for the poor performance of pack-years smoked in our analysis. 
Our study has some limitations. One of the limitations of our work is that we 
compared a limited number of modelling approaches. However, the selected 
approaches here were the ones that have been commonly used in the studies of 
smoking and MS. The other limitation is that we ignored some aspects of 
smoking history such as depth of inhalation. Nevertheless, our results offer 
new insights to the effects of smoking on MS but require further investigations 
possibly in different populations and study designs. 
Overall, both versions of the CSI which were used in the current work showed 
average performance with some very interesting information on the magnitude 
of various effects of smoking. The final decision on the best model to be used 
in the studies of MS depends very much on the availability of data and more 











7. Chapter seven: Conclusion and 
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7.1  Summary of the thesis 
Each of the chapters of this thesis was dedicated to investigating the impact of 
tobacco smoking on a specific stage of MS clinical course. The introduction at 
the beginning of this thesis briefly summarised our current understanding of 
the epidemiology and natural history of MS. This was followed by series of 
specified introductions and systematic review of the effect of tobacco smoking 
on the occurrence of MS, risk of progression of disability and risk of premature 
death at the beginning of each chapter. Chapter 2 described our study 
procedure and gives a descriptive summary of the general and clinical features 
of our sample population. Chapters 3 to 5 were dedicated to describing the 
findings from a matched case-control study of the effects of tobacco smoking 
on the occurrence of MS (chapter 3), a cohort study of the influence of tobacco 
smoking on the risk of progression of disability (chapter 4) and another cohort 
study of the impact of tobacco smoking on the risk of premature death and life 
expectancy (chapter 5). A comparison of the different approaches for 
modelling smoking in MS was made in chapter 6.  
In summary, this study found that tobacco smoking is associated with a 
significantly higher risk of occurrence of MS, higher levels of disease severity 
and disability and higher risk of mortality. Here we performed the most 
comprehensive study of the impact of tobacco smoking on MS to date. Our 
study gives a new insight on the magnitude of the effects of different smoking 
factors. On the basis of our findings there is a strong association between 
tobacco smoking and inverse clinical outcomes in patients with MS.  
Reduced risk of disability progression and death amongst former smokers with 
MS observed in our study, point toward the beneficial effect of smoking 
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cessation. Our data suggest that reduction in prevalence of tobacco smoking 
can potentially decrease the risk of occurrence of MS, risk of disability 
progression and excess mortality rates seen in patients with MS.   
 
7.2  Strengths and limitations of the study 
Our study has several strengths. Firstly, unlike previous studies examining the 
influence of smoking on one aspect of the disease only, our study employed a 
wide variety of outcomes. This enabled us to comment on the magnitude of the 
effects of tobacco smoking not only on one aspect of the disease but on its 
whole natural history, from development to mortality. 
Secondly, we used prospectively collected clinical data from a large population 
based cohort with a very long duration of follow-up. Our methodology and the 
statistical methods employed were robust and were adjusted for important 
prognostic variables. An example of that is time to EDSS score milestones 4 
and 6, which is a robust outcome with many advantages. This has reduced the 
potential for confounding.  
Finally, when appropriate, we used relative rates with age and sex matched 
controls to minimise the risk of any misinterpretation of the results.  
Our study also had some limitations. First, our research had a response rate of 
almost 50%. A potential bias could rise from the half of the patients who did 
not respond to our questionnaire. Generally, the low response rate bias will 
occur when the non-respondents are not a random subset of the whole 
population with respect to the variable being measured in the research. So if 
the two populations are similar in the variable in question, increasing response 
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rate will only increases the cost of a survey without increasing the data quality. 
In order to measure the effect of non-respondents on our results, we made a 
demographic and clinical comparison between respondents and non-
respondents, the result of which is presented in the second chapter. With regard 
to the gender, age distribution and disease phenotype the two groups were 
identical. However, disease duration, percentage of patients who received 
treatment, economic status and disability score were significantly different 
between the two groups. We do not think that the differences in the clinical 
features will have a significant influence on the prevalence of smoking in the 
two groups as smoking is more closely related to demographics than clinical 
features. However, the non-respondents were from more deprived areas which 
are often associated with higher smoking prevalence. Nevertheless, it is 
unlikely that this has influenced our results very dramatically. Even, in theory, 
this should increase the risk estimate of occurrence of MS as the number of 
smokers is going to be increased in MS cases. 
Secondly, despite our efforts to cover a wide spectrum of disabilities caused by 
the disease, still some aspects of the disease such as cognitive impairments 
were not assessed in our research. We acknowledge the importance of this but 
it was practically beyond the scope and ability of this PhD research to conduct 
a project of that size.  
 
7.3 Generalisability of the results 
I think this research has made a considerable contribution to knowledge in the 
field and has identified important factors to be considered for increasing 
SDWLHQWV¶TXDOLW\RIOLIH. Here we presented data from a population based cohort 
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of patients with MS in the UK but I believe the relevance of our findings is 
worldwide. Our research was carried out in the UK with a predominantly white 
Caucasian population but we see no reason that the results are not applicable in 
other populations as the demographic and clinical characteristics of our sample 
population were similar to those reported from other MS cohorts.  
 
7.4 Practical implications and applicability  
This study found that smoking cessation is associated with a significantly 
lower risk of progression of disability. In our findings each year since 
cessation of smoking was associated with 3% to 5% reduction in the risk of 
disability progression. This represents the first positive results with regard to 
the beneficial effect of smoking cessation in patients with MS. 
The study also found a significantly reduced risk of premature mortality due to 
MS-related and non-MS-related deaths amongst ex-smokers compared with 
those who continued smoking. In our sample population life expectancy was 
decreased by 3 and 10 years in former and current smokers compared with 
never-smokers. The other significant finding was the contributory role of 
smoking to the excess mortality rates in MS patients. We observed that never-
smokers with MS in our cohort could live as long as their age and sex matched 
counterparts in the England general population.  
Our findings, presented here, have some significant clinical importance to the 
clinicians and health professionals involved in MS care and management. We 
EHOLHYH WKDW SDWLHQWV¶ TXDOLW\ RI OLIH DQG OLIH H[SHFWDQF\ FDQ EH VLJQLILFDQWO\
improved in a very cost-effective manner if advice on smoking prevention and 
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cessation has been extensively available at the time of the disease onset and/or 
diagnosis. Tools and information to help smokers with MS to stop smoking 
and non-smokers to never start smoking should be routinely provided to all 
patients with MS. 
Assessing applicability and external validity is difficult but it is essential for 
developing guidelines and it is extremely helpful to grade the strength of 
recommendations. Applicability of smoking cessation strategies has been 
extensively discussed before but not in the context of MS. Although smoking 
cessation help kits are readily available to all patients under NHS cessation 
programs for free, no data is available with respect to the extent to which 
patients with MS benefit from these programs. Many of patients with MS live 
with permanent and restricting disabilities. This potentially limit their access to 
the NHS smoking cessation services. Hence, cessation interventions in patients 
with MS require careful planning, shaped according to SDWLHQWV¶SK\VLFDODQG
psychological restrictions, especially at the time of the diagnosis when the 
cessation will have its highest influence. This should be feasible if types of 
cessation interventions and their effectiveness are known.  
  
7.5 Future direction 
Our findings from this large cohort study call for a multi-centre randomised 
control trial of smoking cessation in patients with MS. Unfortunately, this was 
not feasible during my PhD due to our limited time and lack of pilot data on 
the clinical effectiveness of different types of smoking cessation strategies in 
patients with MS. Until then, rDLVLQJSDWLHQWV¶DZDUHQHVV on the adverse health 
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<RX DUH EHLQJ LQYLWHG WR WDNH SDUW LQ WKH DERYH UHVHDUFK VWXG\ %HIRUH \RX
GHFLGHLWLVLPSRUWDQWIRU\RXWRXQGHUVWDQGZK\WKHUHVHDUFKLVEHLQJGRQHDQG
ZKDW LWZLOO LQYROYH3OHDVH WDNH WLPH WR UHDG WKH HQFORVHG LQIRUPDWLRQ VKHHW
FDUHIXOO\ 7DON WR RWKHUV DERXW WKH VWXG\ LI \RX ZLVK 7KLV VWXG\ ZLOO EH
LQYHVWLJDWLQJ WKH HIIHFWV RI VPRNLQJ RQ 0XOWLSOH 6FOHURVLV 06 06 LV D
GLVHDVHFDXVHGE\PLVGLUHFWHGLPPXQHV\VWHP6RPHUHVHDUFKKDVVKRZQWKDW
WKHVPRNLQJPDQLSXODWHVWKHLPPXQHV\VWHP7KHVWXG\KDVEHHQDSSURYHGE\
1RWWLQJKDP (WKLFV &RPPLWWHH DQG LV EHLQJ FDUULHG RXW LQ WKH 'LYLVLRQ RI
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Patient Information Sheet 
 
Study: EXPOSURE TO TOBACCO SMOKE IN PATIENTS WITH 
MULTIPLE 
            SCLEROSIS, AN EPIDEMIOLOGICAL EVALUATION 
 
Chief Investigator:             Professor Cris S Constantinescu;  
Sponsor:                             University of Nottingham 
 
You are being invited to take part in a research study. Before you decide 
whether or not to take part it is important for you to understand why the 
research is being done and what it will involve. Please take time to read the 
following information carefully. Talk to others about the study if you wish. 
Ask us if anything is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
We are interested in the clinical consequences (disease progression and 
worsening of symptoms) of tobacco smoke and respiratory diseases such as 
asthma on Multiple Sclerosis (MS). Although the increasing importance of MS 
has prompted a surge in research into the disease, there are still many gaps in 
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our knowledge and understanding of MS. Little is known about its 
physiopathology, epidemiology, genetic and environmental factors including 
the effect on stress levels, smoking status, quality of life and level of disability. 
Since the frequency of adverse behaviors is high among many chronic 
disorders (such as cancer, heart diseases, diabetes and etc), environmental 
factors may be identified via the frequency of abnormal or adverse behaviors 
in MS patients. Smoking shares many of the pathological consequences of 
chronic inflammatory conditions. For the first time we may be able to identify 
an environmental factor which can contribute to the development and 
progression of vascular complications in MS. 
This study will provide important information to the health professionals 
aiming to develop effective interventions to prevent further progression and 
treat MS by advancing our understanding of the cause and care of MS. We 
believe that there is a need to determine the smoking levels in our patient 
population in order to develop and target future interventions appropriately to 
improve MS management as well as MS prevention in at risk populations.  
We aim first to identify the frequency of smoking amongst MS population and 
VHFRQG WR LGHQWLI\ D OLQNEHWZHHQGLVHDVHSURJUHVVLRQDQGSDWLHQWV¶ VPRNLQJ
status. We intend to examine if smoking can be recognized as a factor, which 
can speed up the process of transition to Secondary Progressive MS over 
shorter period. This will allow for the development of a broad understanding of 
the disease and its co-morbidities across a large sample of individuals. We aim 
to identify target areas where new preventative interventions and treatment 
interventions could be developed and implemented to significantly improve 
patient quality of life. 
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We need to collect data from our MS population to allow us to compare the 
results with healthy population in order to identify the scale of the problem in 
MS patients and develop effective awareness and screening strategies. 
 
Why have I been chosen? 
We are looking to recruit 1500 people with MS. Participants will be recruited 
from Nottingham University Hospital MS clinic those enrolled in the Queen's 
Medical Centre MS clinic registry. You must have a diagnosis of MS made by 
the referring neurologist and be over 18 years of age. 
 
Do I have to take part? 
No. It is up to you to decide whether to take part. If you do, you will keep this 
information sheet and be asked to sign a consent form. You are still free to 
withdraw at any time and without giving a reason, without this affecting your 
future medical care.  
 
What will happen to me if I take part? 
This research just involves completing selected questions from four 
standardized questionnaires assessing your lifetime smoking history, asthma, 
allergy and levels of your disability due to the disease. You also need to sign 
the consent form to allow us to review your medical notes in order to estimate 
your level of disability based on neurological examination by neurologist. We 
also need to collect some MS related information about the results of your 
medical examinations such as your MRI report, Lumbar Puncture (if you had), 
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immunological tests and to see whether if you have ever received any 
treatment for MS.  
 
What do I have to do? 
Should you wish to take part in the study you will need to sign the consent 
form and complete the questionnaires and return them to the research team by 
the prepaid envelop provided. 
 
What are the possible benefits of taking part? 
The information we get might help improve the treatment of people with MS. 
More information on the relationship between smoking and the development 
and progression of MS, particularly in the UK setting, is vital to better 
understand the area for the development of preventative and treatment 
interventions. Because of the severe consequences of disease progression for 
individuals and the relatively high prevalence of disease transition from RRMS 
to SPMS in our MS population, it is important for us to characterize this 
condition in our patients and use this information to develop interventions 
specific to our population to improve their MS care and quality of life. 
 
What happens after the research study stops? 
After analysing the data, we will let you know the major findings if you wish.  
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  




If you have a concern about any aspect of this study, you should ask to speak 
with the researchers who will do their best to answer your questions (Mr Ali 
Manouchehrinia or Professor Cris Constantinescu on 0115 87 54597). If you 
wish to complain formally, you can do this through the normal NHS 
complaints procedure. Details can be obtained from the hospital. 
Harm 
In the event that something does go wrong and you are harmed during the 
study, there are no special compensation arrangements. If you are harmed and 
WKLVLVGXHWRVRPHRQH¶VQHJOLJHQFH\RXPD\KDYHJURXQGVIRUOHJDODFWLRQIRU
compensation but you may still have to pay legal costs. The normal NHS 
complaints mechanisms will still be available to you. 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you 
will be handled in confidence. If you join the study, some parts of the data 
collected for the study will be looked at by authorised persons from the 
University of Nottingham who is organising the research. They may also be 
looked at by authorised people to check that the study is being carried out 
correctly. All will have a duty of confidentiality to you as a research 
participant and we will do our best to meet this duty.  
During the study your data will be assigned a study identity code number, for 
use on study documents and the electronic database. Your data will be 
anonymized after data collection. Data will contain minimum identifying 
details sufficient to trace participants for audit purposes only. 
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All information that is collected about you during the course of the research 
will be kept strictly confidential, stored in a secure and locked office, and on 
a password protected database.  All research data will be kept securely for 7 
years.  After this time your data will be disposed of securely.  During this time 
all precautions will be taken by all those involved to maintain your 




You can withdraw from the study at any time if you wish. Information 
collected up to the point of your withdrawal cannot be erased and with your 
consent may still be used. Any paper or electronic data that can still be 
identified as yours will be destroyed. 
What will happen to the results of the research study? 
Data will be analysed, written up and sent for publication in medical journals 
or international conferences. Some part of this study will be written up as part 
of a PhD thesis. We will also inform you by letter of any significant findings if 
you wish, and we can send you copies of the published papers at your request. 
 
Who is organising and funding the research? 
The Division of Clinical Neurology, C Floor, Medical School, University of 
1RWWLQJKDP4XHHQ¶V0HGLFDO&HQWUH1RWWLQJKDP1*8+ 
 
Who has reviewed the study?  
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All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been 




If you have any queries about the study, please contact Mr Ali Manouchehrinia 
or Prof Cris Constantinescu, Division of Clinical Neurology, C Floor, Medical 





Thank you for taking the time to read this leaflet and considering taking 
part in this study. 
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Appendix 4; Consent form 
 
CONSENT FORM 
(Final version 1.0: 15/04/2011) 
 
Title of Study: EXPOSURE TO TOBACCO SMOKE IN PATIENTS 




REC ref: 11/EM/0158   
 
Name of Researcher: Professor Cris Constantinescu           
Name of Participant: 
 
1. I confirm that I have read and understand the information sheet version 
QXPEHU««««GDWHG.............. for the above study and have had the 
opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, and without my medical care 
or legal rights being affected. I understand that should I withdraw then the 
information collected so far cannot be erased and that this information may 
still be used in the project analysis. 
 
3. I understand that relevant sections of my medical notes and data collected in 
the study may be looked at by authorised individuals from the University of 
Nottingham, the research group and regulatory authorities where it is relevant 
to my taking part in this study. I give permission for these individuals to have 
access to these records and to collect, store, analyse and publish information 
obtained from my participation in this study. I understand that my personal 
details will be kept confidential. 
 
4. I agree to take part in the above study. 
 
______________________ ______________     ____________________ 
Name of Participant   Date          Signature 
 
________________________    ______________             _______________ 
Name of Person taking consent      Date          Signature 
(if different from Principal Investigator) 
 
______________________      ______________     ____________________   
Name of Principal Investigator Date          Signature 
 
 
3 copies: 1 for participant, 1 for the project notes and 1 for the medical notes 
Please initial box 
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'HDU0DGDPRU6LU 
:HZRXOGOLNHWRUHPLQG\RXRIRXULQYLWDWLRQUHJDUGLQJ\RXUSDUWLFLSDWLRQLQ
WKHDERYHVWXG\$QLQYLWDWLRQZDVPDLOHGWR\RXVHYHUDOZHHNVDJRDQGVRIDU
ZHKDYHKHDUGQRWKLQJIURP\RX 
,I\RXKDYHDOUHDG\VHQWWKHSDFNDJHEDFNWRXVSOHDVHGLVUHJDUGWKLVQRWLFH,I
\RXKDYHQRWUHFHLYHGRXULQYLWDWLRQDQG\RXZLVKWRWDNHSDUWLQWKHVWXG\
SOHDVHFRQWDFWXV,I\RXKDYHUHFHLYHGRXULQYLWDWLRQDQG\RXKDYHQRWKDG
WLPHWRJRWKURXJKLWSOHDVHWDNHWLPHDQGUHDGWKHLQIRUPDWLRQVKHHWFDUHIXOO\
,I\RXZLVKWRWDNHSDUWLQWKHVWXG\SOHDVHVLJQWKHFRQVHQWIURPILOOLQWKH
TXHVWLRQQDLUHDQGUHWXUQWKHPE\WKHSUHSDLGHQYHORSHSURYLGHG 
7KDQN\RXLQDGYDQFHIRU\RXUFRRSHUDWLRQLQWKLVPDWWHU 
&RQWDFW'HWDLOV 
3URIHVVRU&ULV&RQVWDQWLQHVFXRU0U$OL0DQRXFKHKULQLD 
'LYLVLRQRI&OLQLFDO1HXURORJ\&)ORRU6RXWK%ORFN4XHHQ¶V0HGLFDO
&HQWUH1RWWLQJKDP1*8+ 
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